rosiglitazone has been researched along with thiazoles in 533 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 104 (19.51) | 18.2507 |
| 2000's | 415 (77.86) | 29.6817 |
| 2010's | 11 (2.06) | 24.3611 |
| 2020's | 3 (0.56) | 2.80 |
| Authors | Studies |
|---|---|
| Amri, EZ; Gaillard, D; Grimaldi, PA; Inadera, H; Staccini, L; Teboul, L | 1 |
| Cawthorne, MA; Coyle, PJ; Holder, JC; Holman, GD; Kirkham, DM; Kozka, IJ; Lister, CA; Smith, SA; Young, PW | 1 |
| Buckingham, RE; Cawthorne, MA; Clark, MG; Colquhoun, EQ; Eldershaw, TP; Rattigan, S | 1 |
| Kliewer, SA; Lehmann, JM; Moore, LB; Smith-Oliver, TA; Wilkison, WO; Willson, TM | 1 |
| Ailhaud, G; Amri, EZ; Cawthorne, MA; Gaillard, D; Grimaldi, PA; Ibrahimi, A; Teboul, L; Young, P | 1 |
| Chisholm, DJ; Jenkins, AB; Kennedy, CJ; Kraegen, EW; Laybutt, DR; Oakes, ND | 1 |
| Brun, RP; Chen, J; Evans, RM; Forman, BM; Spiegelman, BM; Tontonoz, P | 1 |
| Kliewer, SA; Lehmann, JM; Lenhard, JM; Morris, DC; Patel, I; Willson, TM | 1 |
| Kallen, CB; Lazar, MA | 1 |
| Boam, DS; Dickson, AJ; Sidaway, JE; Smith, SA | 2 |
| Berger, J; Chen, Y; Cullinan, CA; Elbrecht, A; Hayes, N; Leibowitz, Md; Moller, DE | 1 |
| Auwerx, J; Briggs, MR; De Vos, P; Guerre-Millo, M; Hamann, LG; Lefebvre, AM; Miller, SG; Saladin, R; Staels, B; Wong, K | 1 |
| Bolton, GC; East, PD; Hollis, FJ; Keogh, JP; Shore, AD | 1 |
| Auwerx, J; Briggs, M; Deeb, S; Heyman, RA; Lefebvre, AM; Peinado-Onsurbe, J; Schoonjans, K; Staels, B | 1 |
| Brown, HR; Brown, KK; Graves, RA; Jennermann, C; Kliewer, SA; Lehmann, JM; MacGinnitie, MA; Morris, DC; Oliver, BB; Tai, TA; Wilkison, WO | 1 |
| Gimble, JM; McAveney, KM; Yu-Lee, L | 1 |
| Cawthorne, MA; Clapham, JC; Dunmore, SJ; Holmes, SD; Moore, GB; Pearson, SL; Smith, SA; Tadayyon, M | 1 |
| Chen, J; Evans, RM; Forman, BM | 1 |
| Kliewer, SA; Lehmann, JM; Willson, TM | 1 |
| Wolf, G | 1 |
| Bischoff, ED; Boehm, MF; Cesario, RM; Crombie, DL; Davies, PJ; Hamann, LG; Heyman, RA; Jow, L; Mondon, CE; Mukherjee, R; Nadzan, AM; Paterniti, JR | 1 |
| Connor, SC; Hughes, MG; Lister, CA; Moore, G; Smith, SA | 1 |
| Camilleri, S; Chisholm, DJ; Furler, SM; Kraegen, EW; Oakes, ND | 1 |
| Lazar, MA; Shao, D | 1 |
| Ailhaud, G; Aubert, J; Champigny, O; Collins, S; Negrel, R; Ricquier, D; Saint-Marc, P | 1 |
| Jain, S; Qi, C; Rao, MS; Reddy, JK; Zhu, Y | 1 |
| Auwerx, J; Briggs, MR; Fievet, C; Fruchart, JC; Lefebvre, AM; Leitersdorf, I; Paterniti, JR; Peinado-Onsurbe, J; Staels, B | 1 |
| Auwerx, J; Lefebvre, AM; Martin, G; Schoonjans, K; Staels, B | 1 |
| Biden, TJ; Browne, CL; Kraegen, EW; Oakes, ND; Schmitz-Peiffer, C | 1 |
| Boss, O; Burger, AG; Chin, WW; Cusin, I; Juge-Aubry, CE; Meier, CA; Pauli, V; Pernin, A; Rohner-Jeanrenaud, F; Siegrist-Kaiser, CA; Zapf, J | 1 |
| Adams, M; Chatterjee, VK; Digby, JE; Holder, JC; Lazar, MA; Montague, CT; O'Rahilly, S; Prins, JB; Sanders, L; Sewter, CP; Smith, SA | 1 |
| Bing, C; Buckingham, R; Dryden, S; Frankish, HM; Hopkins, D; Pickavance, L; Wang, Q; Williams, G | 1 |
| Digby, JE; Montague, CT; O'Rahilly, S; Prins, JB; Sanders, L; Sewter, CP; Wilkison, WO | 1 |
| Akatsuka, H; Arakawa, K; Homma, K; Iijima, I; Inamasu, M; Kawanami, S; Matsumoto, M; Okumura, K; Ozeki, M; Saiga, Y; Watanabe, A; Yasuda, K | 1 |
| Buckle, DR; Cantello, BC; Chapman, H; Clapham, JC; Coyle, PJ; Haigh, D; Hindley, RM; Holder, JC; Kallender, H; Latter, AJ; Lawrie, KW; Mossakowska, D; Murphy, GJ; Roxbee Cox, L; Smith, SA; Young, PW | 1 |
| Blanchard, SG; Consler, TG; Nichols, JS; Parks, DJ | 1 |
| Forest, C; Franckhauser-Vogel, S; Glorian, M; Robin, D; Robin, P | 1 |
| Kim, JB; Spiegelman, BM; Wright, HM; Wright, M | 1 |
| Ciletti, N; Deplewski, D; Kentsis, A; Rosenfield, RL | 1 |
| Franciosa, MD; Greenberg, AS; Lien, P; Souza, SC; Yamamoto, MT | 1 |
| Alvarez, JG; Evans, RM; Nagy, L; Thomazy, VA; Tontonoz, P | 1 |
| Bhushan, V; Chakrabarti, R; Jajoo, HK; Lohray, BB; Madhavan, GR; Mamidi, RN; Murali, N; Rajagopalan, R; Rajesh, BM; Rao, BP; Rao, KN; Reddy, AK; Reddy, PG; Subramaniam, S; Vikramadithyan, RK | 1 |
| Buckingham, RE; Chattington, PD; Naderali, EK; Walker, AB; Williams, G | 1 |
| Carlberg, C; Chiesi, M; Missbach, M; Pignat, W; Spanka, C; Wiesenberg, I | 1 |
| Albrektsen, T; Gustafsson, JA; Johansson, L; Leers, J; Treuter, E | 1 |
| Chinetti, G; Delerive, P; Fadel, A; Fruchart, JC; Habib, A; Koenig, W; Lebret, M; Maclouf, J; Merval, R; Najib, J; Staels, B; Tedgui, A; Torra, IP | 1 |
| Al-Barazanji, KA; Bond, B; Buckingham, RE; Clapham, JC; Connor, SC; Slaughter, M; Toseland, CD; Turner, NC; West, A | 1 |
| Greenberg, AS; Rosenbaum, SE | 1 |
| Baldursson, T; Gram, C; Helledie, T; Knudsen, J; Kristiansen, K; Mandrup, S; Nohr, J; Sorensen, RV | 1 |
| Seed, B | 1 |
| Auwerx, J; Briggs, M; Chen, I; Desreumaux, P; Fruchart, JC; Geboes, K; Heyman, R; Lefebvre, AM; Najib, J | 1 |
| Ailhaud, G; Aubert, J; Negrel, R; Safonova, I | 1 |
| Cobb, JE; Glass, CK; Kurokawa, R; Lambert, MH; Milburn, MV; Nolte, RT; Rosenfeld, MG; Westin, S; Willson, TM; Wisely, GB | 1 |
| Antonucci, M; Chapman, J; Chinetti, G; Delerive, P; Fruchart, JC; Griglio, S; Majd, Z; Najib, J; Staels, B; Torra, IP | 1 |
| Kern, PA; Ranganathan, S | 1 |
| Cummings, R; Elbrecht, A; Hermes, JD; Li, Y; Mitra, S; Moller, DE; Schaeffer, JM; Smith, RG; Wilkinson, HA; Zhou, G | 1 |
| Brockman, JA; Dubois, RN; Gupta, RA | 1 |
| Auwerx, J; Fajas, L; Fruchart, JC | 1 |
| Akanuma, Y; Ide, T; Kadowaki, T; Mochizuki, T; Murakami, K; Ohashi, M; Tobe, K; Yazaki, Y | 1 |
| Bailey, ST; Krakow, SL; Lazar, MA; Rangwala, SM; Reginato, MJ; Shao, D | 1 |
| Andersson, Y; Fruchart, JC; Kosykh, V; Lefebvre, AM; Majd, Z; Martin, G; Najib, J; Sechkin, AV; Staels, B | 1 |
| Blanchard, SG; Parks, DJ; Tomkinson, NC; Villeneuve, MS; Willson, TM | 1 |
| Dandine, M; Dauzats, M; Daviaud, D; Langin, D; Saulnier-Blache, JS; Viguerie-Bascands, N | 1 |
| Auwerx, J; Fajas, L; Fruchart, JC; Gelman, L; Raspé, E; Zhou, G | 1 |
| Burris, TP; Cryan, E; Demarest, KT; Osborne, MC; Pelton, PD; Zhou, L | 1 |
| Gerritsen, ME; Kowalski, J; Xin, X; Yang, S | 1 |
| Aaronson, PI; Knock, GA; Mishra, SK | 1 |
| Kadowaki, T | 1 |
| Allen, A; DiCicco, RA; Freed, MI; Jorkasky, DK | 1 |
| Fleck, E; Goetze, S; Gotlibowski, T; Hsueh, WA; Kawano, H; Law, RE; Xi, XP | 1 |
| Hwang, CS; Lane, MD | 1 |
| Finley, E; Lee, HJ; Lee, SC; Soret, B; Vernon, RG | 1 |
| Blanchard, SG; Cobb, JE; Collins, JL; Cooper, JP; Goreham, DM; Holmes, CP; Hull-Ryde, EA; Kliewer, SA; Lehmann, JM; Lenhard, JM; Milburn, MV; Miller, AB; Mohr, CP; Moore, LB; Oberfield, JL; Parks, DJ; Plunket, K; Willson, TM | 1 |
| Brun, S; Carmona, MC; Giralt, M; Iglesias, R; Mampel, T; Villarroya, F; Viñas, O | 1 |
| Eriksson, P; Hamsten, A; Nilsson, L; Takemura, T | 1 |
| Buckingham, RE; Chattington, PD; Walker, AB; Williams, G | 1 |
| Alexandersson, M; Bamberg, K; Bergström, M; Dahllöf, B; Edvardsson, U; Ljung, B | 1 |
| Aaltonen, LA; de la Chapelle, A; Eng, C; Kum, JB; Mueller, E; Sarraf, P; Smith, WM; Spiegelman, BM; Wright, HM | 1 |
| Balfour, JA; Plosker, GL | 1 |
| Gubrij, I; Jilka, RL; Kajkenova, O; Lecka-Czernik, B; Lipschitz, DA; Manolagas, SC; Moerman, EJ | 1 |
| Burris, TP; Demarest, KT; Pelton, PD; Zhou, L | 1 |
| Bailey, ST; Flanigan, A; Jiang, W; Keilbaugh, SA; Lazar, MA; Murthy, S; Rangwala, SM; Su, CG; Wen, X; Wu, GD | 1 |
| Hull-Ryde, EA; Sigel, CS; Su, JL; Winegar, DA; Wisely, GB | 1 |
| Aviram, M; Bisgaier, CL; Newton, RS; Zhu, L | 1 |
| Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N | 1 |
| Henney, JE | 1 |
| Baugé, E; Chinetti, G; Clavey, V; Copin, C; Dallongeville, J; Fruchart, J; Fruchart, JC; Mariotte, MC; Staels, B | 1 |
| Baldwin, SJ; Chenery, RJ; Clarke, SE | 1 |
| Clapham, JC; Smith, SA; Teruel, T | 1 |
| Fujita, T; Fukumoto, S; Miyamoto, M; Okazaki, R; Takeuchi, Y; Tanaka, K; Toriumi, M | 1 |
| Auwerx, J; Rieusset, J; Vidal, H | 1 |
| Oberpichler-Schwenk, H | 1 |
| Finnerty, D; Freed, MI; Harris, RZ; Inglis, AM; Jorkasky, DK; Miller, AK; Patterson, S; Thompson, KA | 1 |
| Buckingham, RE; Pickavance, LC; Tadayyon, M; Widdowson, PS; Wilding, JP | 1 |
| Aaronson, PI; Mishra, SK | 1 |
| Berger, J; Cai, TQ; Li, Y; Shu, H; Wong, B; Woods, JW; Wright, SD; Zhou, G | 1 |
| Clish, CB; Hauser, S; Hiramatsu, R; Mikami, T; Serhan, CN; Spiegelman, BM; Wright, HM; Yanagi, K | 1 |
| Diamond, RH; Forman, LM; Simmons, DA | 1 |
| Al-Salman, J; Arjomand, H; Kemp, DG; Mittal, M | 1 |
| Boscia, J; Everitt, D; Freid, J | 1 |
| Kuritzky, L; Quillen, DM; Samraj, GP | 1 |
| Nakajima, M; Shimada, N; Suzuki, M; Tane, K; Yamazaki, H; Yokoi, T | 1 |
| Adams, M; Agostini, M; Browne, PO; Burris, TP; Chatterjee, VK; Collingwood, TN; Gurnell, M; Lazar, MA; Provenzano, C; Rajanayagam, O; Schwabe, JW; Wentworth, JM | 1 |
| Miller, JL | 1 |
| Gomis, R; Jones, NP; Patwardhan, RN; Squatrito, S; Wolffenbuttel, BH | 1 |
| Kuzuya, T | 1 |
| Shimizu, N | 1 |
| Kameda, N; Oka, Y; Okuya, S | 1 |
| Ailhaud, G; Aubert, J; Belmonte, N; Dani, C; Négrel, R; Saint-Marc, P | 1 |
| Kalus, AM; Rubin, GL; Simpson, ER; Zhao, Y | 1 |
| Fonseca, V; Patwardhan, R; Rosenstock, J; Salzman, A | 1 |
| Cole, ST; Freed, MI; Patwardhan, R; Rappaport, EB; Raskin, P; Yan, Y | 1 |
| Horikoshi, H; Yachi, M | 1 |
| Chaput, E; Edgar, AD; Saladin, R; Silvestre, M | 1 |
| Arch, JR; Buckingham, RE; Cai, XJ; Lister, CA; Pickavance, L; Wilding, J; Williams, G; Wilson, S | 1 |
| Brown, MN | 1 |
| Deacon, LF; Jones, NP; Nolan, JJ; Patwardhan, R | 1 |
| Glass, CK; Li, M; Pascual, G | 1 |
| Crowley, VE; Digby, JE; O'Rahilly, S; Prins, JB; Sewter, CP; Whitehead, JP | 1 |
| King, AB | 1 |
| Cowley, H; Cox, PJ; Harris, AM; Hollis, FJ; Miller, AK; Ryan, DA; Vousden, M | 1 |
| Reddy, SS | 1 |
| Seuwen, K; Sottile, V | 2 |
| Camp, HS; Frankowski, CL; Hong, YH; Leff, T; Li, O; Shen, X; Vanbogelen, R; Wise, SC | 1 |
| Chapman, H; Gould, GW; Lister, CA; Maier, VH; Melvin, DR; Murphy, GJ | 1 |
| Clapham, JC; Peterson, J; Smith, SA; Teruel, T | 1 |
| DeFronzo, RA | 1 |
| Bledsoe, RK; Gampe, RT; Kliewer, SA; Lambert, MH; Milburn, MV; Miller, AB; Montana, VG; Willson, TM; Xu, HE | 1 |
| Bakris, G | 1 |
| Hangai, M; He, S; Hinton, DR; Hsueh, WA; Ishibashi, T; Kim, S; Law, RE; Murata, T; Ryan, SJ; Xi, XP | 1 |
| de Abrew, K; Mylvaganam, S; Samarasekera, MS | 1 |
| Krische, D | 1 |
| Böhm, S | 1 |
| Hisatome, I; Ogino, K; Shigemasa, C; Shimoyama, M; Uchida, K | 1 |
| Bailey, CJ; Krentz, AJ; Melander, A | 1 |
| Kitahara, M; Naitoh, T; Tsuruzoe, N | 1 |
| Füchtenbusch, M; Schatz, H; Standl, E | 1 |
| Chandraratna, RA; Fleck, E; Goetze, S; Graf, K; Hsueh, WA; Kim, S; Kintscher, U; Law, RE; Nagpal, S; Wakino, S | 1 |
| Hishinuma, T; Mizugaki, M; Yamazaki, T | 1 |
| Baum, U | 1 |
| Cawthorne, MA; Crombie, DL; Heyman, RA; Hislop, DC; Liu, YL; Sennitt, MV | 1 |
| Brown, KK; Glass, CK; Li, AC; Palinski, W; Silvestre, MJ; Willson, TM | 1 |
| Goldstein, BJ | 1 |
| Fujita, T; Fujiwara, T; Honma, H; Horikoshi, H; Kaneko, T; Oguchi, M; Ohsumi, J; Sakakibara, S; Serizawa, N; Tanaka, A; Wada, K | 1 |
| Ludvik, B | 1 |
| Barbehenn, E; Lurie, P; Sasich, LD; Wolfe, SM | 1 |
| Anania, FA; Miyahara, T; Motomura, K; Rippe, R; Schrum, L; Tsukamoto, H; Willson, TM; Xiong, S; Yee, HF | 1 |
| Bilakovics, J; Croston, GE; Faulkner, A; Hoener, PA; Jow, L; Klausing, K; Mais, DE; Mukherjee, R; Paterniti, JR | 1 |
| Isley, WL; Oki, JC | 1 |
| Boullier, A; Chang, MK; Glass, CK; Green, SR; Han, KH; Li, A; Quehenberger, O | 1 |
| Blanchard, SG; Furfine, ES; Ittoop, O; Jain, RG; Lenhard, JM; Orband-Miller, LA; Paulik, MA; Weiel, JE | 1 |
| Asakawa, M; Komuro, I; Masuda, Y; Nagai, T; Oka, T; Saito, T; Takano, H; Toyozaki, T | 1 |
| Nori, U; Ravinuthala, RS | 1 |
| Stiefelhagen, P | 1 |
| Blanchard, SG; Gribble, GW; Honda, T; Leesnitzer, LM; Mangelsdorf, DJ; Plunket, KD; Porter, WW; Sporn, MB; Suh, N; Wang, Y; Willson, TM | 1 |
| Filz, HP | 1 |
| Force, RW; Hachey, DM; O'Neil, MP | 1 |
| Allen, A; Carr, A; Di Cicco, RA; Fowles, S; Freed, MI; Jorkasky, DK | 1 |
| Arioglu, E; Chao, L; Gavrilova, O; Marcus-Samuels, B; Mason, MM; Moitra, J; Reitman, ML; Vinson, C | 1 |
| Kimura, H; Momose, Y; Moriyama, S; Odaka, H; Sakamoto, J; Sawada, H; Sugiyama, Y | 1 |
| Chen, L; Cohen, SE; Kahn, CR | 1 |
| Bolesta, S; Malinowski, JM | 1 |
| Kenyon, CJ; Livingstone, DE; Walker, BR | 1 |
| Angeli, V; Capron, M; Chinetti, G; Delerive, P; Faveeuw, C; Fontaine, J; Fougeray, S; Gosset, P; Maliszewski, C; Moser, M; Staels, B; Trottein, F | 1 |
| Bryan, J | 1 |
| Blumenthal, RS; Nass, CM | 1 |
| Cawthorne, MA; Emilsson, V; Heyman, R; Liu, YL; O'Dowd, J; Sennitt, M; Wang, S | 1 |
| Brüne, B; Von Knethen A, A | 1 |
| Benbow, A; Stewart, M; Yeoman, G | 1 |
| Person, EC; Scanlan, TS; Taylor, RN; Waite, LL | 1 |
| Blumberg, RS; Kadowaki, T; Kubota, N; Matsuhashi, N; Miki, H; Nagai, R; Nakajima, A; Nakajima, N; Ohnishi, S; Saubermann, LJ; Terauchi, Y; Wada, K | 1 |
| Henry, RR; Mudaliar, S | 1 |
| Albrektsen, T; Fleckner, J | 1 |
| Di Cicco, RA; Freed, MI; Miller, AK; Patterson, S | 1 |
| Meneilly, GS; Tessier, D | 1 |
| Funk, WB; Lenhard, MJ | 1 |
| Daubresse, JC | 1 |
| Lloyd, SJ; Thomas, ML | 1 |
| Ahima, RS; Bailey, ST; Banerjee, RR; Bhat, S; Brown, EJ; Lazar, MA; Patel, HR; Steppan, CM; Wright, CM | 1 |
| Boeglin, WE; Brash, AR; Case, T; Dubois, RN; Gupta, RA; Jack, GS; Manning, S; Matusik, RJ; Price, J; Schneider, C; Shappell, SB; Wheeler, TM; Whitehead, R | 1 |
| Grunberger, G; Miller, E; Patwardhan, R; Phillips, LS; Rappaport, EB; Salzman, A | 1 |
| Berthold, HK; Gouni-Berthold, I; Ko, Y; Sachinidis, A; Seul, C; Vetter, H; Weber, AA | 1 |
| Anderson, RJ; Patel, J; Rappaport, EB | 1 |
| Robinson, S; Schachter, M; Valabhji, J | 1 |
| Buckingham, RE; Lister, CA; Smith, SA; Toseland, CD | 1 |
| Collins, AR; Hsueh, WA; Kawano, Y; Nicholas, SB; Wakino, S | 1 |
| Collins, AR; Hsueh, WA; Jackson, S; Kintscher, U; Law, RE; Meehan, WP; Noh, G; Palinski, W; Wakino, S | 1 |
| Dole, JF; Freed, MI; Lebovitz, HE; Patwardhan, R; Rappaport, EB | 1 |
| Dharmalingam, M; Kumar, P | 1 |
| Banerji, MA; Lebovitz, HE | 1 |
| Braun, M; Brenner, RE; Debatin, KM; Hauner, H; Heinze, E; Melzner, I; Möller, P; Wabitsch, M | 1 |
| Cai, TQ; Gan, X; Wong, B; Wright, SD | 1 |
| Bandyopadhyay, G; Farese, RV; Kanoh, Y; Sajan, MP; Standaert, ML | 2 |
| Fowles, S; Muxlow, AM; Russell, P | 1 |
| Boehm, M; Crombie, DL; Davies, PJ; Depre, C; Heyman, RA; Leibowitz, MD; Liu, S; Nagy, L; Singh Ahuja, H; Tontonoz, P | 1 |
| Matthews, DR | 2 |
| Berger, J; Elbrecht, A; Hermanowski-Vosatka, A; Moller, DE; Tanen, M; Thieringer, R; Wright, SD | 1 |
| Davies, SS; Harrison, KA; Hilaire, AS; Hinshaw, JC; Marathe, GK; McIntyre, TM; Murphy, RC; Pontsler, AV; Prescott, SM; Prestwich, GD; Zimmerman, GA | 1 |
| Auwerx, J; Chambon, P; Colombel, JF; Derijard, B; Desreumaux, P; Desvergne, B; Dubuquoy, L; Englaro, W; Leibowitz, MD; Nutten, S; Peuchmaur, M; Schoonjans, K; Wahli, W | 1 |
| Porterfield, LM | 1 |
| Cheatham, WW; Glazer, NB | 1 |
| Bond, R; Cook, J; Gilkeson, G; Guyton, K; Halushka, P; Reilly, C | 1 |
| Janka, HU | 1 |
| Buckingham, RE; Finegood, DT; Kojwang, D; Leonard, T; McArthur, MD; Thomas, MJ; Topp, BG | 1 |
| Hayashi, T; Hosoda, K; Inoue, G; Inoue, R; Masuzaki, H; Nakao, K; Nishimura, H; Ogawa, Y; Shintani, M; Yamamoto, Y; Yonemitsu, S | 1 |
| Jacinto, SM; Ljung, B; Oakes, ND; Thalén, PG | 1 |
| Huijberts, MS; Sels, JP; Wolffenbuttel, BH | 1 |
| Liang, YC; Lin, JK; Lin-Shiau, SY; Tsai, DC; Tsai, SH | 1 |
| Eriksson, U; Hansson, GK; Romert, A; Sirsjö, A; Törmä, H; Wuttge, DM | 1 |
| Endo, T; Haraguchi, K; Hershman, JM; Ohta, K; Onaya, T | 1 |
| Hata, Y; Hinton, DR; Hsueh, WA; Ishibashi, T; Kim, S; Law, RE; Murata, T | 1 |
| Bragg, T | 1 |
| Brown, KK; Görgün, CZ; Harrington, WW; Hotamisligil, GS; Kliewer, SA; Oliver, WR; Tong, Q; Uysal, KT; Way, JM; Willson, TM | 1 |
| Auclair, M; Capeau, J; Caron, M; Forest, C; Glorian, M; Vigouroux, C | 1 |
| Coxon, P; Downes, CP; Macphee, CH; Pass, I; Patel, L; Smith, SA | 1 |
| Auwerx, J; Bouzakri, K; Chambrier, C; Dusserre, E; Laville, M; Rieusset, J; Riou, JP; Vidal, H | 1 |
| DuBois, RN; Gupta, RA; Israel, DA; Krishna, U; Peek, RM; Polk, DB; Yan, F | 1 |
| Culkin, KT; Finnerty, D; Freed, MI; Inglis, AM; Jorkasky, DK; Miller, AK; Patterson, SD | 1 |
| Bateman, R; Eckers, C; Giles, K; Sage, AB; Wolff, JC | 1 |
| Arima, S; Ikeda, Y; Ito, S; Kudo, M; Sato, K; Sugawara, A; Takeuchi, K; Taniyama, Y; Uruno, A | 1 |
| Gale, EA | 1 |
| Baek, SJ; Eling, TE; Hsi, LC; Ikawa, H; Kameda, H; Kamitani, H; Nixon, JB | 1 |
| Bugelski, PJ; Campbell, S; Francis, I; Mehdi, N; Toseland, CD | 1 |
| Buckingham, RE; Pickavance, LC; Wilding, JP | 1 |
| Culkin, KT; Freed, MI; Inglis, AM; Jorkasky, DK; Miller, AK | 1 |
| Honda, K; Imagawa, M; Nishihara, T; Nishizuka, M; Tsuchiya, T | 1 |
| Dole, JF; Freed, MI; Raskin, P; Rendell, M; Riddle, MC; Rosenstock, J | 1 |
| Abe, I; Eto, K; Fujishima, M; Nakamura, Y; Ohya, Y | 1 |
| Boscá, L; Castrillo, A; Hortelano, S; Mojena, M | 1 |
| Hupfeld, CJ; Weiss, RH | 1 |
| Blicklé, JF | 2 |
| Berthold, HK; Gouni-Berthold, I; Sachinidis, A; Seul, C; Vetter, H; Weber, AA | 1 |
| Burge, MR; Colleran, K; Sood, V | 1 |
| McMorran, M; Vu, D | 1 |
| Wood, I | 1 |
| Blumentrath, J; Neye, H; Verspohl, EJ | 1 |
| Csermely, P; Jermendy, G | 1 |
| Atzpodien, E; Bedoucha, M; Boelsterli, UA | 1 |
| Blumberg, RS; Nakajima, A; Wada, K | 1 |
| Chapman, H; Clapham, JC; Holder, JC; Lister, CA; Moore, GB; Piercy, V; Smith, SA | 1 |
| Algenstaedt, P; Hamann, A | 1 |
| Jazet, IM; Meinders, AE | 1 |
| Brown, JM; Geigerman, C; Halvorsen, YD; Lea-Currie, YR; McIntosh, M | 1 |
| Iwata, Y; Kasuya, A; Miyamoto, S; Takamura, M; Yanagisawa, H | 1 |
| Travaglini, MT; Werner, AL | 1 |
| Chatterjee, VK; Nugent, C; O'Rahilly, S; Prins, JB; Savage, D; Wentworth, JM; Whitehead, JP | 1 |
| Akanuma, Y; Ezaki, O; Fukayama, M; Hori, W; Ide, T; Itai, A; Kadowaki, T; Kagechika, H; Kamon, J; Kato, S; Kimura, S; Komeda, K; Kubota, N; Miki, H; Motojima, K; Murakami, K; Nagai, R; Shudo, K; Terauchi, Y; Tobe, K; Tsuboyama-Kasaoka, N; Tsuchida, A; Waki, H; Yamauchi, N; Yamauchi, T | 1 |
| Amri, EZ; Cabane, C; Dani, C; Dérijard, B; Phillips, B; Yeow, K | 1 |
| Charbonnier, AS; Delerive, P; Fontaine, J; Gosset, P; Pestel, J; Staels, B; Tonnel, AB; Trottein, F | 1 |
| Hsueh, WA; Kim, S; Kintscher, U; Kuroki, T; Law, RE; Liu, Z; Ohba, M; Schönthal, AH; Wakino, S; Yin, F | 1 |
| Birkeland, KI | 1 |
| Chang, JC; Chang, TJ; Chuang, LM; Hsu, WH; Liu, MW; Tai, TY; Yang, C | 1 |
| Auwerx, J; Bac, P; Blanchard, SG; Champy, MF; Desreumaux, P; Dubuquoy, L; Gelman, L; Leesnitzer, LM; Moras, D; Picard, F; Plunket, KD; Potier, N; Renaud, JP; Rocchi, S; Vamecq, J; Zeyer, D | 1 |
| Finegood, DT; Topp, BG | 1 |
| Zinman, B | 1 |
| Adler, A; Bush, E; Kramer, D; Rondinone, CM; Shapiro, R | 1 |
| Abbasi, F; Cataldo, NA; Lamendola, C; McLaughlin, TL; Reaven, GM | 1 |
| Cohen, RI; Gouda, HE; Khan, A; Schwartz, J | 1 |
| Collins, AR; Fleck, E; Goetze, S; Hsueh, WA; Kaneshiro, K; Kim, S; Kintscher, U; Law, RE; Meehan, WP | 1 |
| Oka, Y; Yonezawa, N | 1 |
| Bao, W; Boyce, R; Bril, A; Buckingham, RE; Chen, J; Gu, JL; Hart, TK; Jiang, W; Lysko, PG; Narayanan, PK; Ohlstein, EH; Yue Tl, TL; Zimmerman, DM | 1 |
| Pospísilová, Y | 1 |
| Isley, WL | 1 |
| Beale, EG; Duplus, E; Forest, C; Glorian, M; Granner, DK; Scott, DK | 1 |
| Quesada-Gómez, JM; Serrano-Alferez, I | 1 |
| Scheen, AJ | 2 |
| Hsueh, WA; Law, RE | 1 |
| Hiraoka, S; Kitamura, S; Kiyohara, T; Matsuzawa, Y; Miyazaki, Y; Nagasawa, Y; Shinomura, Y; Takakura, R; Toyota, M | 1 |
| Brunmair, B; Fürnsinn, C; Gras, F; Nowotny, P; Roden, M; Vierhapper, H; Waldhäusl, W | 1 |
| Adamson, DJ; Frew, D; Palmer, CN; Tatoud, R; Wolf, CR | 1 |
| Ailhaud, G; Amri, EZ; Belmonte, N; Dani, C; Iehlé, C; Milstone, DS; Mortensen, RM; O'Donnell, PE; Phillips, B; Vernochet, C; Villageois, P; Wdziekonski, B | 1 |
| Demissie, EJ; Deren, JJ; Fogt, F; Furth, EE; Hurd, LB; Judge, TA; Keilbaugh, SA; Lazar, MA; Lewis, JD; Lichtenstein, GR; Stein, RB; Su, CG; Wu, GD | 1 |
| Berry, E; Gilmour, R; Helliwell, R; Keelan, J; Marvin, K; Mitchell, M; Nijmeijer, B; Sato, T | 1 |
| Charlton, SJ; Clapham, JC; Coxon, P; Macphee, CH; Marshall, IC; Moore, GB; Moores, K; Newman, SJ; Patel, L; Smith, SA | 1 |
| Bell, A; Gagnon, A; Koumas, L; Phipps, RP; Sempowski, GD; Smith, TJ; Sorisky, A | 1 |
| Cusi, K; DeFronzo, RA; Glass, L; Mahankali, A; Mahankali, S; Mandarino, LJ; Matsuda, M; Miyazaki, Y; Triplitt, C | 1 |
| Nakajima, M; Yamamoto, Y; Yamazaki, H; Yokoi, T | 1 |
| Hop, CE; Romanyshyn, L; Tiller, PR | 1 |
| Marathe, GK; McIntyre, TM; Pontsler, AV; St Hilaire, A; Zimmerman, GA | 1 |
| Chen, CL; Chuang, LM; Funahashi, T; Jeng, CY; Matsuzawa, Y; Tai, TY; Tanaka, S; Wang, JP; Wu, TJ; Yang, WS | 1 |
| Wooltorton, E | 1 |
| Andersen, AS; Brand, CL; Bury, PS; Fleckner, J; Jeppesen, L; Lehmann, SV; Mogensen, JP; Mortensen, SB; Panajotova, V; Pettersson, I; Polivka, Z; Rasmussen, HB; Sauerberg, P; Sindelar, K; Sturis, J; Svensson, LA; Wassermann, K; Wöldike, HF; Wulff, EM; Ynddal, L | 1 |
| Berg, AH; Berger, J; Charron, MJ; Chatterjee, K; Combs, TP; Doebber, T; Gertz, BJ; Gottesdiener, KM; Larson, PJ; Moller, DE; O'Rahilly, S; Savage, DB; Scherer, PE; Tanen, M; Wagner, JA; Wang, WJ; Weiss, S; Zhang, BB | 1 |
| Lotz, N | 1 |
| Cheung, HS; Di Battista, JA; Fahmi, H; Fernandes, JC; Martel-Pelletier, J; Pelletier, JP | 1 |
| Blows, F; O'Rahilly, S; Sewter, CP; Vidal-Puig, A | 1 |
| Befroy, D; Cline, GW; Dufour, S; Enocksson, S; Hundal, RS; Inzucchi, SE; Lebon, V; Mayerson, AB; Petersen, KF; Shulman, GI | 1 |
| Groop, L; Ridderstråle, M | 1 |
| Lund, S; Pedersen, O; Vestergaard, H | 1 |
| Asakawa, M; Hasegawa, H; Kadowaki, T; Komuro, I; Kubota, N; Masuda, Y; Nagai, T; Saito, T; Takano, H; Uozumi, H | 1 |
| Dalal, CK; Hartman, HB; Hu, X; Lazar, MA; Tyler, KX | 1 |
| Abbasi, F; Chu, JW; Cooke, JP; Lamendola, C; McLaughlin, TL; Reaven, GM; Stühlinger, MC; Tsao, PS | 1 |
| Albrektsen, T; Boel, E; Fleckner, J; Frederiksen, KS; Holmes, WE; Taylor, K | 1 |
| Ardecky, RJ; Bean, JS; Bensch, WR; Bilakovics, JM; Broderick, CL; Brooks, DA; Brozinick, JT; Dana, SL; Etgen, GJ; Johnson, WT; Kauffman, RF; Liu, S; McCarthy, JR; Misener, EA; Montrose, CR; Ogilvie, KM; Oldham, BA; Paterniti, JR; Rito, CJ; Shuker, AJ; Tyhonas, JS | 1 |
| Buckingham, RE; Clarke, K; Cole, MA; Desrois, M; Draper, NJ; Sidell, RJ | 1 |
| Khan, MA; St Peter, JV; Xue, JL | 1 |
| Pritts, EA; Ricke, E; Taylor, RN; Waite, L; Zhao, D | 1 |
| Grüb, M; Hombach, V; Kehrle, B; Koenig, W; Kohlhammer, K; Libby, P; Marx, N; Plutzky, J | 1 |
| Boyle, PJ; King, AB; Lau, H; Magar, R; Marchetti, A; Martin, J; Olansky, L | 1 |
| Anderson, LA; Barnett, AH; Eggo, MC; Green, A; Harte, AL; Holder, JC; Kumar, S; McTernan, PG; Smith, SA | 1 |
| Berrebi-Bertrand, I; Bril, A; Buckingham, RE; Delerive, P; Khandoudi, N; Staels, B | 1 |
| Freed, MI; Kreider, M; Lebovitz, HE | 1 |
| Lazar, MA; Li, Y | 1 |
| Lawrence, IG | 1 |
| Carling, D; Fryer, LG; Parbu-Patel, A | 1 |
| Bahn, RS; Dutton, CM; Harteneck, DA; Valyasevi, RW | 1 |
| Bindl, L; Debatin, KM; Fischer, P; Melzner, I; Möller, P; Tornqvist, H; Wabitsch, M | 1 |
| Greenberg, AS; Pittas, AG | 1 |
| Amiri, F; Cohn, JS; Diep, QN; El Mabrouk, M; Endemann, D; Neves, MF; Schiffrin, EL; Virdis, A | 1 |
| Albrektsen, T; Boysen, MS; Fleckner, J; Grøntved, L; Helledie, T; Jensen, SS; Kiilerich, P; Kristiansen, K; Larsen, LK; Mandrup, S; Nøhr, J; Rietveld, L; Stunnenberg, HG | 1 |
| Bagchi, A; Berger, J; Doebber, TW; Elbrecht, A; Fridman, A; Gerhold, DL; Holder, DJ; Jiang, G; Li, Z; Liu, F; Lu, M; Moller, DE; Sachs, JR; Xu, J; Zhang, BB | 1 |
| DuBois, RN; Shao, J; Sheng, H | 1 |
| Valensi, P | 1 |
| O'Moore-Sullivan, TM; Prins, JB | 1 |
| Babu, AP; Katneni, K; Mullangi, R; Naidu, MU; Rajagopalan, R; Rani, UP; Rao, MN; Ravikanth, B; Srinivas, NR | 1 |
| Adeli, K; Buckingham, R; Carpentier, A; Leung, N; Lewis, GF; Szeto, L; Taghibiglou, C; Uffelman, KD; Van Iderstine, SC | 1 |
| Dransfield, I; Farrow, SN; Haslett, C; Murray, J; Rossi, AG; Ward, C | 1 |
| Casini, A; Ceni, E; Crabb, DW; Galli, A; Mello, T; Ridolfi, F; Salzano, R; Surrenti, C; Svegliati-Baroni, G; Trozzi, L | 1 |
| Frauwirth, KA; Lazar, MA; Rangwala, SM; Thompson, CB; Wang, YL | 1 |
| Arner, P; Dicker, A; Hauner, H; Lönnqvist, F; Näslund, E; Rydén, M; van Harmelen, V | 1 |
| Chun, D; Cobitz, AR; Davis, HM; Haimbach, RE; Jucker, BM; Mayer, M; McIntosh, TS; Ohlstein, DH; Sarkar, SK; Schaeffer, TR; Smith, SA | 1 |
| Kiayias, JA; Lakka-Papadodima, E; Theodosopoulou, E; Vlachou, ED | 1 |
| Chatterjee, PK; Cuzzocrea, S; Hattori, Y; McDonald, MC; Mota-Filipe, H; Pisano, B; Thiemermann, C; Wayman, NS | 1 |
| Radhakrishna, T; Satyanarayana, A; Satyanarayana, J | 1 |
| Akarca, C; Barton, DM; Baskar, V; Buch, HN; Kamalakannan, D; Singh, BM | 1 |
| Anderson, JW; Frederich, RC; Konz, EC; Reynolds, LR | 1 |
| Chayama, K; Fujimoto, Y; Kawasaki, Y; Kuwada, Y; Sasaki, T; Tsuchida, A | 1 |
| Li, M; Lin, Y; Ma, Y; Zheng, Z | 1 |
| Azar, R; Banner, B; Bird, S; Bonkovsky, HL; Szabo, G | 1 |
| Braddon, J; Phillips, P | 1 |
| Berger, J; Dallas-Yang, Q; Doebber, T; Jiang, G; Li, Z; Liu, F; Moller, DE; Shen, X; Szalkowski, D; Wu, M; Zhang, BB; Zhou, G | 1 |
| Goa, KL; Wagstaff, AJ | 1 |
| Chicheportiche, R; Dayer, JM; Dreyer, MG; Juge-Aubry, CE; Meier, CA | 1 |
| Caron, A; Darteil, R; Latta-Mahieu, M; Mahfoudi, A; Staels, B; Thuillier, V; Wang, M | 1 |
| Chen, H; Freed, MI; Greenberg, AS; Haffner, SM; Weston, WM; Williams, K | 1 |
| Mohan, V; Vidhya, S | 1 |
| Bishop-Bailey, D; Hla, T; Warner, TD | 1 |
| Häring, HU; Stumvoll, M | 1 |
| DiCicco, RA; Freed, MI; Miller, AK | 1 |
| Babu, AP; Benjamin, B; Bhanduri, J; Chaluvadi, MR; Katneni, K; Mamidi, RN; Rajagopalan, R; Ramesh, M; Rao, NM | 1 |
| Battarbee, H; Coates, G; Nissim, I; Welbourne, T | 1 |
| Füzesi, L; Krüger, U; Middel, P; Mössner, R; Neumann, C; Reich, K; Schinner, S; Schulz, U | 1 |
| Cawthorne, MA; Converset, V; Heller, M; Hochstrasser, DF; Nolan, A; Sanchez, JC; Schmid, G; Sennitt, MV; Wang, S | 1 |
| Heise, M; Kreider, M | 1 |
| Berry, RA; Freed, MI; Greene, DA; Haffner, SM; Heise, MA; Herman, WH; Holman, RR; Jones, NP; Kahn, SE; Lachin, JM; Levy, D; Viberti, G; Zinman, B | 1 |
| Greenberg, AS; Mathys, JM; Rabbi, MF; Skolnik, PR | 1 |
| Herrmann, A; Hesselbarth, N; Hippius, M; Hoffmann, A; Kuschel, U | 1 |
| Biswas, N; Carey, DG; Cowin, GJ; Doddrell, DM; Galloway, GJ; Jones, NP; Richards, JC | 1 |
| Yamanouchi, T | 1 |
| Oka, Y | 1 |
| Chen, CY; Chen, HL; Hsu, SC; Lu, SC; Shieh, WY | 1 |
| Brathwaite, CE; Brebbia, JS; Fuhrer, J; Gelato, MC; McNurlan, MA; Mynarcik, DC; Quick, JL; Steigbigel, RT; Wax, MR | 1 |
| Aleksunes, LM; Reagan, LA; Vergara, CM; Wang, F | 1 |
| Biswas, N; Brunzell, JD; Cohen, BR; Freed, MI; Kreider, MM; Marcovina, SM; Ratner, R | 1 |
| Fackett, A; Hayden, MJ; Hewitt, NJ; Li, AP; Lloyd, S; Sakai, Y; Silber, PM | 1 |
| Dandona, P; Dole, JF; Freed, M; Murphy, K; Patel, J; Patwardhan, R; Rendell, M; St John Sutton, M | 1 |
| German, JB; Leiter, EH; Pan, HJ; Reifsnyder, PR; Watkins, SM | 1 |
| Desvergne, B; Escher, P; Michalik, L; Niesor, E; Rieusset, J; Touri, F; Wahli, W | 1 |
| Bradley, C | 1 |
| Benito, M; Hernandez, R; Lorenzo, M; Teruel, T | 1 |
| Göke, B; Parhofer, KG | 1 |
| Kazdova, L; Kren, V; Krenova, D; Seda, O | 2 |
| LaCivita, KA; Villarreal, G | 1 |
| Hällsten, K; Knuuti, J; Lönnqvist, F; Nuutila, P; Oksanen, A; Rönnemaa, T; Sipilä, H; Viikari, J; Viljanen, T; Virtanen, KA | 1 |
| Domann, FE; Girnun, GD; Moore, SA; Robbins, ME | 1 |
| Barbot, DJ; Goldstein, BJ; Hardy, VE; Motoshima, H; Rosato, EL; Rosato, FE; Sinha, MK; Wu, X | 1 |
| Craft, S; Watson, GS | 1 |
| Brockman, JA; DuBois, RN; Gupta, RA; Raftery, LA; Sarraf, P; Shappell, SB; Willson, TM | 1 |
| Banday, AA; Hussain, T; Lokhandwala, MF; Umrani, DN | 1 |
| Andersen, B; Brand, CL; Fleckner, J; Fledelius, C; Gotfredsen, CF; Hansen, BF; Sauerberg, P; Sturis, J; Wassermann, K; Ye, JM | 1 |
| Aburatani, H; Blumberg, RS; Kadowaki, T; Matsuhashi, N; Nagai, R; Nakajima, A; Saubermann, LJ; Terauchi, Y; Wada, K; Zhao, S | 1 |
| Auwerx, J; Debril, MB; Egler, V; Fajas, L; Hansen, J; Kristiansen, K; Miard, S; Reiter, R | 1 |
| Eggo, MC; Holder, JC; Kumar, S; Patel, NG; Smith, SA | 1 |
| Belz, U; Herling, AW; Juretschke, HP; Kalisch, J; Kleinschmidt, E; Kramer, W; Kuhlmann, J; Neumann-Haefelin, C; Stein, M | 1 |
| Bekins, SA; Raji, A; Seely, EW; Simonson, DC; Williams, GH | 1 |
| Buckels, AC; Holbrook, JD; Kinghorn, IJ; Macphee, CH; Murdock, PR; Patel, L; Plumpton, C; Smith, SA | 1 |
| Dey, CS; Kumar, N | 1 |
| Amiri, F; Diep, QN; Iglarz, M; Lavoie, MF; Schiffrin, EL; Touyz, RM | 1 |
| Kaplowitz, N; Lewis, JH; Watkins, PB | 1 |
| Anglard, P; Bonnafous, S; Chavey, C; Mari, B; Monthouel, MN; Tartare-Deckert, S; Van Obberghen, E | 1 |
| Bell, G; Burkart, A; Corvera, S; Czech, M; Leszyk, J; Mendelson, K; Nicoloro, S; Wilson-Fritch, L | 1 |
| Cleasby, ME; Livingstone, DE; Nyirenda, MJ; Seckl, JR; Walker, BR | 1 |
| Hällsten, K; Huupponen, R; Janatuinen, T; Knuuti, J; Lönnqvist, F; Lönnroth, P; Nuutila, P; Parkkola, R; Rönnemaa, T; Viljanen, T; Virtanen, KA | 1 |
| Cohen, H; Dvir, A; Gerber, Y; Harats, D; Levi, Z; Levkovitz, H; Ravid, M; Rhachmani, R; Shaish, A; Trestman, S; Yacov, N | 1 |
| Benoist, F; Gauthier, A; McPherson, R; Vassiliou, G | 1 |
| Cooney, GJ; Ellis, B; Iglesias, MA; Jensen, PB; Kraegen, EW; Larsen, PJ; Sørensen, RV; Wassermann, K; Watson, DG; Wood, L; Ye, JM | 1 |
| Fujisawa, N; Ishimine, S; Kadowaki, T; Kawamori, T; Matsuhashi, N; Nakagama, H; Nakajima, A; Ochiai, M; Osawa, E; Sekihara, H; Wada, K | 1 |
| Ben Khalifa, F; Chow, WH; Menon, PS; Quimpo, JA; Vongthavaravat, V; Waitman, JN; Wajchenberg, BL | 1 |
| Flodgren, E; Kotarsky, K; Nilsson, NE; Olde, B; Owman, C | 1 |
| Blau, N; Keller, U; Linscheid, P; Müller, B; Schaer, DJ | 1 |
| Grossman, E | 1 |
| Bakris, G; Freed, MI; Heise, M; Porter, LE; Viberti, G; Weston, WM | 1 |
| Joe, EH; Jou, I; Park, EJ; Park, SY | 1 |
| Camirand, A; López-Solache, I; Marie, V; Silva, JE; Vignault, E | 1 |
| Froehlich, J; Hombach, V; Ittner, J; Koenig, W; Marx, N; Scharnagl, H; Schmidt, A; Siam, L; Wierse, G | 1 |
| Shaarawy, M; Shobokshi, A | 1 |
| Bae, MA; Rhee, H; Song, BJ | 1 |
| Kirschfink, M; Peter, HH; Walker, UA | 1 |
| Apolito, RA | 1 |
| Cobitz, AR; Haimbach, RE; Jucker, BM; Mayer, ME; Ohlstein, DH; Sarkar, SK; Schaeffer, TR; Smith, SA | 1 |
| Nowotny, P; Vierhapper, H; Waldhäusl, W | 1 |
| Adams, AD; Berger, JP; Doebber, TW; Hu, Z; Jones, AB; MacNaul, KL; Moller, DE; Santini, C; Yuen, W | 1 |
| Brewer, B; Gavrilova, O; Gonzalez, FJ; Haluzik, M; Lambert, G; Matsusue, K; Reitman, ML; Ward, JM; Yim, SH | 1 |
| Bryer-Ash, M; Ghazeeri, G; Haas, D; Ke, RW; Kutteh, WH | 1 |
| Ida, M; Kurosaki, E; Nakano, R; Shibasaki, M; Shikama, H; Shimaya, A; Suzuki, T; Yoshida, S | 1 |
| Costello, A; Donnelly, R; Gray, S | 1 |
| Plosker, SM | 1 |
| Blum, R; Chapelsky, MC; Freed, MI; Miller, AK; Sack, M; Thompson-Culkin, K | 1 |
| Antoine, B; Beale, EG; Chauvet, G; Forest, C; Quette, J; Tordjman, J | 1 |
| Berger, GD; Berger, J; Doebber, T; Han, W; MacNaul, K; Moller, DE; Mosley, R; Sahoo, SP; Santini, C; Tolman, RL; Wu, M | 1 |
| Ehrenborg, E; Hall, K; Hilding, A; Lewitt, MS; Skogsberg, J | 1 |
| Viberti, GC | 1 |
| Acerini, CL; Agostini, M; Bell, JD; Boiani, R; Chatterjee, VK; Cinti, S; Dixon, AK; Dunne, F; Gurnell, M; Jebb, SA; Karpe, F; O'Rahilly, S; Savage, DB; Tan, GD; Thomas, EL; Umpleby, AM; Vidal-Puig, A; Williams, RL | 1 |
| Fischer, S; Hanefeld, M | 1 |
| Baker, SF; Brown, J; Davis, B; Hong, G; Khatoon, N | 1 |
| Kuenzli, S; Saurat, JH | 1 |
| Jones, NP; Jones, TA; Sautter, M; Van Gaal, LF | 1 |
| Froehlich, J; Hombach, V; Imhof, A; Ittner, J; Koenig, W; Maerz, W; Marx, N; Schmidt, A; Siam, L; Wierse, G | 1 |
| Carter, L; Ciaraldi, TP; Henry, RR; Mudaliar, SR; Reehman, N; Wilmsen, HM | 1 |
| Moses, R | 1 |
| Herbert, BS; Hynan, LS; Kopelovich, L; LaRue, DM; Pearce, VP; Shay, JW; Wright, WE | 1 |
| Bierhaus, A; Brodbeck, K; Häring, HU; Schleicher, ED; Weigert, C | 1 |
| Tuepker, J | 1 |
| Chow, WH; Davies, C; Jiang, J; Li, GW; Pan, CY; Shi, HL; Sun, XC; Tian, H; Yang, WY; Zhu, XX | 1 |
| Bolusu, G; Chakrabarti, R; Gershome, C; Hiriyan, J; Juluri, S; Kashireddy, P; Misra, P; Qi, C; Rajjak, A; Ramanujam, R; Rao, MS; Reddy, JK; Surapureddi, S; Vikramadithyan, RK; Yu, S; Zhu, YJ | 1 |
| Angeli, V; Capron, M; Hammad, H; Lambrecht, BN; Staels, B; Trottein, F | 1 |
| An, HX; Chen, LL; Deng, XL; Li, ZY; Yang, L | 1 |
| Bruemmer, D; de Dios, ST; Dilley, RJ; Ivey, ME; Jennings, GL; Law, RE; Little, PJ | 1 |
| Barnett, AH; Grant, PJ; Hitman, GA; Mather, H; Pawa, M; Robertson, L; Trelfa, A | 1 |
| Berg, T; Gjøen, T; Juvet, LK; Malerød, L; Mousavi, A; Sporstøl, M | 1 |
| Chao, L; Chen, Y; Choi, H; Fillmore, JJ; Gavrilova, O; Haluzik, M; Higashimori, T; Kim, HJ; Kim, JK; Qu, X; Reitman, ML; Shulman, GI; Yu, C | 1 |
| Iyengar, S; Peehl, DM; Roberts, RL; Shappell, SB; Xu, Y | 1 |
| Armoni, M; Bar-Yoseph, F; Chen, H; Harel, C; Karnieli, E; Kritz, N; Quon, MJ | 1 |
| Bell, DS; Braunstein, S; Drexler, AJ; Miller, JL; Nuckolls, JG; Wyne, KL | 1 |
| Birmingham, J; Buckingham, RE; Changani, KK; Hockings, PD; O'Brien, P; Osborne, J; Reid, DG; Saeed, N; Toseland, CN | 1 |
| Ahn, YB; Cha, BY; Kang, SK; Ko, SH; Lee, KW; Son, HS; Son, HY; Song, KH; Yoo, SJ; Yoon, KH | 1 |
| Chen, H; Cobitz, AR; Goldstein, BJ; Hand, LM | 1 |
| Cutson, JJ; Dietz, KR; Gavrilova, O; Gonzalez, FJ; Haluzik, M; Johnson, L; Matsusue, K; Nicol, CJ; Reitman, ML; Vinson, C | 1 |
| Rochester, CD; Samuel, J | 1 |
| Delouis, C; Evain-Brion, D; Fournier, T; Hermouet, A; Pavan, L; Tarrade, A; Thérond, P; Titeux, M; Vidaud, M | 1 |
| Burgermeister, E; Liscovitch, M; Tencer, L | 1 |
| Görtz, A; Lander, T; Reblin, T; Seidel, D; Stein, D | 1 |
| Cameron, DP; Herington, AC; Hutley, LJ; Joyner, JM; Newell, FM; Prins, JB; Suchting, SJ | 1 |
| Diamant, M; Heine, RJ | 1 |
| Auwerx, J; Egler, V; Fajas, L; Lefebvre, AM; Miard, S; Reiter, R | 1 |
| Debard, C; Frayn, KN; Humphreys, SM; Karpe, F; Langin, D; Tan, GD; Tiraby, C; Vidal, H | 1 |
| Ballary, C; Desai, A | 1 |
| Bell, CF; Botteman, MF; Braunstein, SN; Devine, ST; Ramsdell, JW; Stephens, JM | 1 |
| Amiri, F; Diep, QN; Iglarz, M; Paradis, P; Schiffrin, EL; Touyz, RM; Viel, EC | 1 |
| Chen, J; Di, F; He, R; Wang, D; Wang, Y; Yang, J; Yang, M; Yuan, S; Zhu, X | 1 |
| Chandramouli, J; Tolman, KG | 1 |
| Berger, JP; Blaschke, F; Bruemmer, D; Fleck, E; Forman, BM; Law, RE; Liu, J; Sakai, T; Van Herle, AJ; Yin, F | 1 |
| Bandyopadhyay, G; Beeson, M; Dizon, M; Farese, RV; Gomez-Daspet, J; Grebenev, D; Kanoh, Y; Miura, A; Powe, J; Sajan, MP; Standaert, ML | 1 |
| DeFronzo, RA; He, H; Mandarino, LJ; Miyazaki, Y | 1 |
| Bishop-Bailey, D; Warner, TD | 1 |
| Cheng, J; Dey, D; Gowri, M; Gross, C; Medicherla, S; Nag, B; Neogi, P; Reaven, GM; Sharma, SD | 1 |
| Havekes, LM; Mensink, RP; Muurling, M; Pijl, H; Romijn, JA; Voshol, PJ | 1 |
| Auwerx, J; Capron, M; Dombrowicz, D; Honda, K; Loyens, M; Papin, JP; Staels, B; Woerly, G | 1 |
| Chao, VA; Pritts, EA; Sohn, SH; Taylor, RN; Waite, LL; Zhao, D | 1 |
| Hollingdal, M; Juhl, CB; Lönnqvist, F; Prange, A; Pørksen, N; Schmitz, O | 1 |
| Albanese, C; Brownlee, M; Donehower, LA; Fu, M; Harris, EL; Hulit, J; Johns, DC; Jones, JG; Li, Z; Neumeister, P; Novikoff, PM; Pattabiraman, N; Pestell, RG; Rohan, T; Sakamaki, T; Scherer, PE; Wang, C; Whitney, KD; Wu, K; Zhou, JN | 1 |
| Flight, IH; Lord, JM; Norman, RJ | 1 |
| Gardner, DG; Liang, F; Wang, F; Zhang, S | 1 |
| Cocca, C; Perez-Castillo, A; Pignatelli, M; Santos, A | 1 |
| Buse, JB | 1 |
| Kim, HS; Kim, MS; Koh, EH; Lee, KU; Park, HS; Park, JY; Youn, JH; Youn, JY | 1 |
| Bach, H; Grüb, M; Hetzel, M; Hombach, V; Marx, N; Walcher, D | 1 |
| Evers, BM; Farrow, B; Hashimoto, K; Iwamura, T; O'Connor, KL | 1 |
| Ardecky, RJ; Boehm, MF; Chen, JH; D'Arrigo, J; Grese, TA; Karanewsky, DS; Leibowitz, MD; Liu, S; Mais, DA; Mapes, CM; Michellys, PY; Montrose-Rafizadeh, C; Ogilvie, KM; Reifel-Miller, A; Rungta, D; Thompson, AW; Tyhonas, JS | 1 |
| Abe, S; Ando, K; Kuwahara, S; Magae, J; Nishimura, T; Ozawa, S; Tamura, G; Togashi, M; Tsuruga, M; Ubukata, M | 1 |
| Bacon, BR; Brunt, EM; Neuschwander-Tetri, BA; Oliver, D; Wehmeier, KR | 1 |
| Barringhaus, KG; Chen, M; Czarnik, AC; Hesselbacher, S; Ley, K; Nadler, J; Phillips, JW; Sanders, JM; Sarembock, IJ; Yang, Z | 1 |
| Narce, M; Poisson, JP | 1 |
| Avery, MA; Benson, SC; Chittiboyina, A; Desai, P; Ho, CI; Kurtz, TW; Pershadsingh, HA; Pravenec, M; Qi, N; Wang, J | 1 |
| Del Prato, S; Volpe, L | 1 |
| Kaya, T; Sheu, SH; Vajda, S; Waxman, DJ | 1 |
| Arch, JR; Augstein, P; Cawthorne, MA; Demuth, HU; Heinke, P; Hoffmann, T; Meyer, A; Sennitt, MV; Stocker, C; Subramanian, A; Wargent, E | 1 |
| Balaguer, P; Carlavan, I; Lemaire, G; Nicolas, JC; Perrin, A; Pillon, A; Seimandi, M; Vignon, F; Voegel, JJ | 1 |
| Brüne, B; Loitsch, S; Stein, J; Ulrich, S; von Knethen, A; Wächtershäuser, A | 1 |
| Lazarenko, OP; Lecka-Czernik, B; Rzonca, SO; Suva, LJ | 1 |
| Johnson, TE; Shi, S; Umbenhauer, DR; Zhang, X | 1 |
| Brunskill, NJ; Chana, RS | 1 |
| Biswas, N; Chou, H; Cobitz, A; Garber, A; Rood, J; Rosenstock, J | 1 |
| Kanna, B; Pokharna, H | 1 |
| De Windt, LJ; Smeets, PJ; Teunissen, BE; Van Bilsen, M; Van der Vusse, GJ; Willemsen, PH | 1 |
| Garber, A | 1 |
| Bronfman, M; Leisewitz, AV; Loyola, G; Martinez, GR; Urrutia, CR | 1 |
| Binfaré, RW; García, AG; Kaster, MP; López, MG; Martín-Aparicio, E; Martinez, A; Medina, M; Morales, S; Navarro-Rico, ML; Rodrigues, AL; Rosa, AO | 1 |
| Feng, SD; Hu, B; Liao, DF; Ling, HY; Ou, HS; Wang, BX; Zhou, SH; Zu, XY | 1 |
| Balabolkin, MI; Klebanova, EM; Kreminskaia, VM; Kuzin, AG; Mamaeva, GG; Tel'nova, ME | 1 |
| Gosker, HR; Langen, RC; Remels, AH; Russell, AP; Schols, AM; Schrauwen, P; Spaapen, F; Voncken, JW | 1 |
| Karpushev, AV; Levchenko, V; Pavlov, TS; Staruschenko, A; Vandewalle, A | 1 |
| Onal, A | 1 |
| Artis, DR; Bollag, G; Erbe, DV; Gareski, T; Gartrell, K; Harding, K; Ibrahim, PN; Jalenak, M; Kubasiak, D; Lin, JJ; Mansour, TS; Panza, D; Perreault, M; Saiah, E; Tobin, JF; Vlasuk, GP; Wang, S; Will, S; Womack, P | 1 |
| Chen, R; Ding, G; Huang, S; Yuan, Y; Zhang, A | 1 |
| Decsi, T; Liebisch, G; Marosvölgyi, T; Mihály, J; Rühl, R; Schmitz, G; Weiss, K | 1 |
| Doubova, SV; Flores-Hernández, S; Mino-León, D; Reyes-Morales, H | 1 |
| McLean, L; Naik, H; Palmer, R; Wu, JT | 1 |
| Dyer, C | 1 |
| Cui, N; Jiang, C; Jin, X; Wang, Y; Yu, L; Zhu, D | 1 |
| Danhof, M; DeJongh, J; Scott, G; Stringer, F | 1 |
| Baatjes, AJ; Campbell, H; Dua, B; Gauvreau, GM; Hill, M; Howie, K; Oliveria, JP; Sehmi, R; Smith, SG; Watson, BM; Watson, RM | 1 |
| Andrisani, OM; Bi, P; Bidwell, CA; Castro, B; Durkes, A; Elzey, BD; Freeman, JL; Karki, A; Konieczny, SF; Kuang, S; Wang, C; Wirbisky, SE; Yue, F | 1 |
| Agarwal, AK; Garg, A; Sankella, S | 1 |
| Chandran, A; Drews, K; El Ghormli, L; Sylvetsky, AC; Talegawkar, SA; Welsh, JA | 1 |
| Mourad, AAE; Mourad, MAE | 1 |
| Astakhova, AA; Chistyakov, DV; Goriainov, SV; Sergeeva, MG | 1 |
60 review(s) available for rosiglitazone and thiazoles
| Article | Year |
|---|---|
The peroxisome proliferator-activated receptors: ligands and activators.
Topics: Animals; Fatty Acids; Gene Expression Regulation, Enzymologic; Ligands; Mice; Microbodies; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Transcription Factors | 1996 |
Adipocyte differentiation is regulated by a prostaglandin liganded to the nuclear peroxisome proliferator-activated receptor.
Topics: Adipocytes; Animals; Cell Differentiation; Cell Line; Fibroblasts; Glucose; Homeostasis; Humans; Hypoglycemic Agents; Nuclear Proteins; Prostaglandins; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 1996 |
[Insulin-sensitizing agents].
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Humans; Hypoglycemic Agents; Isoxazoles; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
Rosiglitazone.
Topics: Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Polypharmacy; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs].
Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lactones; Lipase; Metformin; Orlistat; Peroxisome Proliferators; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Improving management of type 2 diabetes mellitus: 5. Thiazolidinediones.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Combinations; Drug Interactions; Drug Monitoring; Humans; Hypoglycemic Agents; Liver Function Tests; Patient Selection; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Failure; Troglitazone | 2000 |
[The development of thiazolidinedione drugs as anti-diabetic agents].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Mice; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Proper usage of thiazolidinediones].
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Liver Failure, Acute; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
[Rosiglitazone (BRL-49653)].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2000 |
[PPAR gamma and thiozolidinedione derivatives as an antidiabetic drug for treating insuline resistance].
Topics: Animals; Chromans; Drug Design; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2000 |
The thiazolidinediones or "glitazones" a treatment option for type 2 diabetes mellitus.
Topics: Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Synergism; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2000 |
The glitazones: proceed with caution.
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Evaluation; Humans; Hypoglycemic Agents; Liver; Pioglitazone; Prognosis; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Troglitazone; Weight Gain | 2000 |
Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review.
Topics: Aged; Area Under Curve; Biological Availability; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2001 |
Diabetes in elderly adults.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diet Therapy; Exercise; Female; Glyburide; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2001 |
[The importance of syndrome X in daily practice].
Topics: Anthropometry; Cardiovascular Diseases; Diet, Reducing; Exercise; Humans; Hyperinsulinism; Hypertension; Hypertriglyceridemia; Hypoglycemic Agents; Insulin Resistance; Lipoproteins, HDL; Lipoproteins, LDL; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
New pharmacological development (alpha glucosidase inhibitors, amylin analogues, GLP-1, thiozolidinediones, short acting insulin analogues).
Topics: Amyloid; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Islet Amyloid Polypeptide; Peptide Fragments; Protein Precursors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Insulin resistance and its treatment by thiazolidinediones.
Topics: Adipose Tissue; Binding Sites; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dimerization; Drug Interactions; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Models, Biological; Muscle, Smooth; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sex Factors; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
[Glitazones. Profile of a new class of substances].
Topics: Albuminuria; Animals; Anticholesteremic Agents; Chromans; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Germany; Humans; Hypoglycemic Agents; Isoenzymes; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2001 |
Rosiglitazone.
Topics: Animals; Blood Pressure; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Lessons from the glitazones: a story of drug development.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Drug Approval; Drug Therapy, Combination; Europe; Humans; Hypoglycemic Agents; Liver Failure; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2001 |
[Thiazolidinediones: clinical data and perspectives].
Topics: Animals; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Thiazolidinediones: a comparative review of approved uses.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gene Expression Regulation; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 2000 |
[Thiazolidinediones--a new class of oral antidiabetic drugs].
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
[Glitazone--a new class of drugs for the treatment of type 2 diabetes].
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
[The thiazolidinedione derivates: a new class of oral blood glucose lowering agents].
Topics: Administration, Oral; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
A review of rosiglitazone in type 2 diabetes mellitus.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Pioglitazone and rosiglitazone for diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Beta-cell deterioration--prospects for reversal or prevention.
Topics: Animals; Blood Glucose; Cell Death; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Islets of Langerhans; Lipids; Rats; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Insulin resistance and beta-cell function--a clinical perspective.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[Rosiglitazone(BRL-49653)].
Topics: Animals; Controlled Clinical Trials as Topic; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Lipid Metabolism; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
[News in oral antidiabetic therapy].
Topics: Administration, Oral; Carbamates; Diabetes Mellitus; Humans; Hypoglycemic Agents; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Hepatotoxicity with thiazolidinediones: is it a class effect?
Topics: Aged; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
PPARgamma and atherosclerosis: effects on cell growth and movement.
Topics: Animals; Arteriosclerosis; Cell Division; Cell Movement; Endothelium, Vascular; Humans; Metabolic Syndrome; Muscle, Smooth, Vascular; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Thiazolidinediones in the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
[Rosiglitazone: clinical data].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2002 |
[Rosiglitazone: a clinical development focused on cardio-vascular prevention].
Topics: Albuminuria; Animals; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Hypoglycemic Agents; Plasminogen Activator Inhibitor 1; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Thiazolidinediones and type 2 diabetes: new drugs for an old disease.
Topics: Adult; Aged; Australia; Clinical Trials as Topic; Contraindications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
[Medication of the month. Rosiglitazone (Avandia)].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Prognosis; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Gain | 2002 |
Oral hypoglycaemics. When not to use what.
Topics: Acarbose; Acidosis, Lactic; Aged; Contraindications; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Pioglitazone; Renal Insufficiency; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.
Topics: Administration, Oral; Aged; Area Under Curve; Diabetes Mellitus, Type 2; Drug Interactions; Half-Life; Humans; Hypoglycemic Agents; Intestinal Absorption; Liver; Middle Aged; Randomized Controlled Trials as Topic; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Glitazones: clinical effects and molecular mechanisms.
Topics: Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
[Insulin sensitizer drugs--review].
Topics: Adipose Tissue; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
[Rosiglitazone (BRL-49653)].
Topics: Animals; Carbohydrate Metabolism; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Treatment Outcome | 2002 |
Management of rosiglitazone-induced edema: two case reports and a review of the literature.
Topics: Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diuresis; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
The glitazones: a new treatment for type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dosage Forms; Drug Monitoring; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United Kingdom | 2002 |
The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.
Topics: Alzheimer Disease; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al.
Topics: Albuminuria; Blood Pressure Determination; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Prognosis; Risk Assessment; Risk Factors; Rosiglitazone; Sensitivity and Specificity; Thiazoles; Thiazolidinediones | 2003 |
Polycystic ovary syndrome and insulin resistance.
Topics: Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Polycystic Ovary Syndrome; Prevalence; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; Women's Health | 2003 |
Rosiglitazone: potential beneficial impact on cardiovascular disease.
Topics: Albuminuria; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Male; Metformin; Middle Aged; Obesity; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Repaglinide in combination therapy.
Topics: Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Pioglitazone; Piperidines; Postprandial Period; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome; Troglitazone | 2002 |
Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones.
Topics: Administration, Oral; Algorithms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Combination agents for diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Hepatotoxicity of the thiazolidinediones.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Humans; Hypoglycemic Agents; Liver Failure, Acute; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration | 2003 |
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.
Topics: Anovulation; Chromans; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Ovulation Induction; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Rosiglitazone plus metformin: combination therapy for Type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2004 |
59 trial(s) available for rosiglitazone and thiazoles
| Article | Year |
|---|---|
Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro.
Topics: Adipose Tissue; Animals; Arteries; Chromans; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Hypoglycemic Agents; Male; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 1998 |
Systemic exposure to rosiglitazone is unaltered by food.
Topics: Adolescent; Adult; Cross-Over Studies; Dietary Fats; Fasting; Food-Drug Interactions; Humans; Hypoglycemic Agents; Male; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics.
Topics: Adolescent; Adult; Calcium Channel Blockers; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Male; Nifedipine; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors | 1999 |
Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Fructosamine; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Triglycerides | 2000 |
Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Eating; Fasting; Female; Fructosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors | 2000 |
Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Europe; Female; Fructosamine; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors | 2000 |
A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
Topics: Body Weight; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2000 |
Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans.
Topics: Adult; Aged; Biological Availability; Chromatography, High Pressure Liquid; Cross-Over Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Rosiglitazone does not alter the pharmacokinetics of metformin.
Topics: Acidosis, Lactic; Adult; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin.
Topics: Adolescent; Adult; Cardiotonic Agents; Cross-Over Studies; Digoxin; Drug Interactions; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fructosamine; Glycated Hemoglobin; Humans; Insulin; Lipids; Male; Middle Aged; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Islets of Langerhans; Male; Middle Aged; Rosiglitazone; Single-Blind Method; Thiazoles; Thiazolidinediones | 2001 |
Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Contraceptives, Oral, Combined; Contraceptives, Oral, Synthetic; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Interactions; Estradiol Congeners; Ethinyl Estradiol; Female; Humans; Hypoglycemic Agents; Norethindrone; Oxidoreductases, N-Demethylating; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
The effect of acarbose on the pharmacokinetics of rosiglitazone.
Topics: Acarbose; Adult; Analysis of Variance; Area Under Curve; Cross-Over Studies; Drug Interactions; Female; Half-Life; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ethnicity; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Placebos; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Triglycerides; United States | 2001 |
Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Osmolar Concentration; Oxidation-Reduction; Regression Analysis; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients.
Topics: Adiponectin; Adipose Tissue; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Multivariate Analysis; Proteins; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization.
Topics: 3T3 Cells; Adipocytes; Adiponectin; Animals; Blood Proteins; Cross-Over Studies; Diabetes Mellitus, Type 2; Electrophoresis, Polyacrylamide Gel; Hypoglycemic Agents; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Metformin; Mice; Mice, Inbred C57BL; Pilot Projects; Proteins; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metformin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2002 |
Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Liver Failure; Liver Function Tests; Male; Metformin; Middle Aged; Reference Values; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone.
Topics: Administration, Oral; Adult; Cross-Over Studies; Drug Interactions; Humans; Hypoglycemic Agents; Intestinal Absorption; Male; Rosiglitazone; Sucralfate; Thiazoles; Thiazolidinediones | 2002 |
Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2002 |
Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus.
Topics: Biomarkers; Blood Pressure; Body Constitution; Body Mass Index; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Life Style; Obesity; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Weight Loss | 2002 |
[Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome].
Topics: Administration, Oral; Adult; Androstenedione; Blood Glucose; Body Weight; Female; Follicle Stimulating Hormone; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Lipids; Luteinizing Hormone; Menstruation; Neuropeptide Y; Ovulation; Polycystic Ovary Syndrome; Rosiglitazone; Testosterone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Biomarkers; Body Weight; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Interleukin-6; Leukocyte Count; Male; Matrix Metalloproteinase 9; Middle Aged; Receptors, Cytoplasmic and Nuclear; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers.
Topics: Administration, Oral; Adult; Anti-Ulcer Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Histamine H2 Antagonists; Humans; Hypoglycemic Agents; Injections, Intravenous; Male; Ranitidine; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
HPLC method for the determination of rosiglitazone in human plasma and its application in a clinical pharmacokinetic study.
Topics: Adult; Chromatography, High Pressure Liquid; Humans; Hypoglycemic Agents; Male; Reference Standards; Reproducibility of Results; Rosiglitazone; Spectrometry, Fluorescence; Thiazoles; Thiazolidinediones | 2002 |
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
Topics: Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Double-Blind Method; Glyburide; Humans; Hypoglycemic Agents; Metformin; Research Design; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Time Factors; Treatment Failure; Treatment Outcome | 2002 |
Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Composition; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipoproteins; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2002 |
Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study.
Topics: Adipose Tissue; Adult; Blood Glucose; Body Composition; Female; Glucose; Glucose Clamp Technique; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Pilot Projects; Radiography; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; North America; Pyrroles; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Time Factors; Treatment Outcome | 2002 |
A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Physiological Phenomena; Cardiovascular System; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin; Hemodynamics; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Racial Groups; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Time Factors; Ventricular Function, Left | 2002 |
Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Exercise; Fasting; Female; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Leg; Male; Metformin; Middle Aged; Muscle, Skeletal; Oxygen Consumption; Radionuclide Imaging; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients.
Topics: Aged; Blood Glucose; Blood Pressure; Female; Humans; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
Topics: Adipose Tissue; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Fluorodeoxyglucose F18; Glucose; Humans; Hypoglycemic Agents; Insulin; Kinetics; Lactates; Lipids; Male; Metformin; Middle Aged; Placebos; Radiopharmaceuticals; Rosiglitazone; Thiazoles; Thiazolidinediones; Tomography, Emission-Computed; Weight Loss | 2003 |
An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Developing Countries; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
Topics: Administration, Oral; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Kidney Function Tests; Male; Middle Aged; Reference Values; Rosiglitazone; Sensitivity and Specificity; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease.
Topics: Adult; Aged; Anti-Inflammatory Agents; Apolipoproteins; Biomarkers; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 8; Matrix Metalloproteinase 9; Middle Aged; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Serum Amyloid A Protein; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2003 |
Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy.
Topics: Adult; Area Under Curve; Clomiphene; Drug Therapy, Combination; Estrogen Antagonists; Female; Follicle Stimulating Hormone; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Luteinizing Hormone; Menstruation; Polycystic Ovary Syndrome; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Clomiphene; Deamino Arginine Vasopressin; Dehydroepiandrosterone Sulfate; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Ovulation Induction; Placebos; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Outcome; Rosiglitazone; Sex Hormone-Binding Globulin; Testosterone; Thiazoles; Thiazolidinediones | 2003 |
Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency.
Topics: Administration, Oral; Adolescent; Adult; Aged; Area Under Curve; Creatinine; Female; Half-Life; Humans; Hypoglycemic Agents; Male; Middle Aged; Renal Insufficiency; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Effect of topical PPARbeta/delta and PPARgamma agonists on plaque psoriasis. A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Female; Free Radical Scavengers; Humans; Male; Middle Aged; Pilot Projects; Psoriasis; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sulfides; Thiazoles; Thiazolidinediones; Transcription Factors; Treatment Outcome; Vasodilator Agents | 2003 |
Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease.
Topics: Adult; Aged; Biomarkers; Blood Glucose; CD40 Ligand; Coronary Artery Disease; Diabetes Mellitus, Type 2; E-Selectin; Female; Fibrinolytic Agents; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Receptors, Interleukin-2; Reference Values; Rosiglitazone; Solubility; Thiazoles; Thiazolidinediones; Time; Transcription Factors; Treatment Outcome; Vasodilator Agents | 2003 |
Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C.
Topics: Adult; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Environmental Exposure; Female; Gliclazide; Glyburide; Glycated Hemoglobin; Hepatitis B; Hepatitis C; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2003 |
The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus.
Topics: Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Korea; Lipids; Lipoprotein(a); Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
A "futile cycle" induced by thiazolidinediones in human adipose tissue?
Topics: Adipocytes; Adipose Tissue; Animals; Blood Glucose; Carrier Proteins; Cells, Cultured; Diabetes Mellitus, Type 2; Enzyme Activation; Fasting; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids, Nonesterified; Glycerol; Glycerol Kinase; Humans; Hypoglycemic Agents; Insulin; Mice; Middle Aged; Neoplasm Proteins; Nerve Tissue Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Tumor Suppressor Proteins | 2003 |
Efficacy and safety of a combination of metformin and rosiglitaone in patients with type 2 diabetes mellitus--a postmarketing study.
Topics: Adult; Aged; Analysis of Variance; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
Efffect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 2003 |
Activation of protein kinase C-zeta by insulin and phosphatidylinositol-3,4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Exercise; Fatty Acids, Nonesterified; Female; Glucose Intolerance; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Isoenzymes; Male; Middle Aged; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Phosphatidylinositol 3-Kinases; Phosphatidylinositol Phosphates; Phosphoproteins; Phosphorylation; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones | 2003 |
Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
Topics: Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose Clamp Technique; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Secretion; Male; Middle Aged; Muscle, Skeletal; Phosphoproteins; Phosphorylation; Receptor, Insulin; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Tyrosine | 2003 |
Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility.
Topics: Arginine; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Entropy; Female; Glucose; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Middle Aged; Rosiglitazone; Stimulation, Chemical; Thiazoles; Thiazolidinediones | 2003 |
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
Topics: Adult; Aged; Alanine Transaminase; Biopsy; Fatty Liver; Female; Humans; Insulin Resistance; Liver; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2006 |
The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.
Topics: Administration, Oral; Adolescent; Adult; Analysis of Variance; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Biotransformation; Cross-Over Studies; Cytochrome P-450 CYP2C8; Double-Blind Method; Drug Interactions; Febuxostat; Female; Gout Suppressants; Half-Life; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Rosiglitazone; Substrate Specificity; Thiazoles; Thiazolidinediones; Young Adult | 2012 |
A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Genotype; Glucuronosyltransferase; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Peroxisome Proliferator-Activated Receptors; Polymorphism, Genetic; Propionates; Rosiglitazone; Thiazoles; Thiazolidinediones | 2014 |
Consumption of Beverages Containing Low-Calorie Sweeteners, Diet, and Cardiometabolic Health in Youth With Type 2 Diabetes.
Topics: Adolescent; Beverages; Body Mass Index; Cardiometabolic Risk Factors; Child; Diabetes Mellitus, Type 2; Diet; Diet Records; Dietary Sugars; Drug Combinations; Energy Intake; Female; Humans; Life Style; Longitudinal Studies; Male; Metformin; Rosiglitazone; Surveys and Questionnaires; Sweetening Agents; Thiazoles | 2020 |
414 other study(ies) available for rosiglitazone and thiazoles
| Article | Year |
|---|---|
Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Actins; Adipose Tissue; Animals; Biomarkers; Carrier Proteins; Cell Differentiation; Cell Division; Chromans; Clone Cells; Creatine Kinase; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids, Nonesterified; Gene Expression; Glycerolphosphate Dehydrogenase; Hypoglycemic Agents; Linoleic Acid; Linoleic Acids; Mice; Muscles; Myelin P2 Protein; Myogenin; Neoplasm Proteins; Nerve Tissue Proteins; Palmitic Acid; Palmitic Acids; Phenotype; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1995 |
Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling.
Topics: Adipocytes; Adipose Tissue; Affinity Labels; Animals; Azides; Blood Glucose; Cell Membrane; Cholesterol; Diabetes Mellitus, Type 2; Diet; Disaccharides; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Epididymis; Fatty Acids, Nonesterified; Glucose; Glucose Tolerance Test; Glucose Transporter Type 4; Glycosides; Hypoglycemic Agents; Insulin; Kinetics; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Monosaccharide Transport Proteins; Muscle Proteins; Propylamines; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 1995 |
Treatment with the thiazolidinedione (BRL 49653) decreases insulin resistance in obese Zucker hindlimb.
Topics: Adipose Tissue; Animals; Hindlimb; Insulin Resistance; Male; Muscle, Skeletal; Perfusion; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones | 1995 |
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).
Topics: Adipocytes; Animals; Cell Differentiation; Cell Line; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Ligands; Mice; Mice, Inbred C3H; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Stem Cells; Thiazoles; Thiazolidinediones; Transcription Factors | 1995 |
Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells.
Topics: 3T3 Cells; Adipose Tissue; Animals; Carrier Proteins; Cells, Cultured; Diabetes Mellitus; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Gene Expression Regulation; Hypoglycemic Agents; Kinetics; Mice; Neoplasm Proteins; Nerve Tissue Proteins; Palmitates; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones | 1994 |
A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Adipose Tissue, Brown; Animals; Biological Availability; Blood Glucose; Dietary Carbohydrates; Dietary Fats; Fatty Acids, Nonesterified; Glucose; Glucose Clamp Technique; Glycerol; Heart; Hydroxybutyrates; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Liver Glycogen; Male; Muscles; Myocardium; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 1994 |
15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma.
Topics: 3T3 Cells; Adipocytes; Animals; Base Sequence; Carrier Proteins; Cell Differentiation; Complement Factor D; DNA-Binding Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fibroblasts; Hypoglycemic Agents; Ligands; Mice; Molecular Sequence Data; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Pioglitazone; Prostaglandin D2; Prostaglandins; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Serine Endopeptidases; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transcriptional Activation | 1995 |
A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.
Topics: Adipocytes; Animals; Binding, Competitive; Cell Differentiation; Cells, Cultured; Fibroblasts; Hypoglycemic Agents; Ligands; Mice; Microbodies; Prostaglandin D2; Prostaglandins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation | 1995 |
Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes.
Topics: 3T3 Cells; Adipocytes; Animals; Base Sequence; Gene Expression Regulation; Hypoglycemic Agents; Leptin; Mice; Molecular Sequence Data; Obesity; Oligodeoxyribonucleotides; Protein Binding; Proteins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 1996 |
Effect of the thiazolidinedione BRL49653 and genetic obesity on hepatic gene expression in the Zucker rat.
Topics: Animals; Cell Line; Gene Expression; Hypoglycemic Agents; Liver; Obesity; Phosphoenolpyruvate Carboxykinase (GTP); Rats; Rats, Zucker; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones | 1995 |
Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2.
Topics: Amino Acid Sequence; Animals; Base Sequence; Blotting, Northern; Cell Line; Chlorocebus aethiops; Cloning, Molecular; DNA Primers; DNA, Complementary; Gene Expression; Humans; Kinetics; Molecular Sequence Data; Polymerase Chain Reaction; Protein Conformation; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Transfection | 1996 |
Effect of the thiazolidinedione antihyperglycaemic agent BRL 49653 on liver fatty acid binding protein gene expression.
Topics: Animals; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Hypoglycemic Agents; Liver; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Oligonucleotide Probes; Rats; Rats, Zucker; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription, Genetic | 1996 |
Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma.
Topics: Adipocytes; Adipose Tissue; Animals; Base Sequence; DNA Primers; Enzyme Activation; Gene Expression; Humans; Leptin; Liver; Molecular Sequence Data; Organ Size; Pioglitazone; Promoter Regions, Genetic; Proteins; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 1996 |
The fate of a thiazolidinedione antidiabetic agent in rat and dog.
Topics: Animals; Carbon Radioisotopes; Dogs; Feces; Glucuronates; Hydroxylation; Hypoglycemic Agents; Male; Rats; Rats, Sprague-Dawley; Rosiglitazone; Sulfates; Thiazoles; Thiazolidinediones | 1996 |
PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene.
Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Animals; Cell Line; Dimerization; DNA; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipoprotein Lipase; Liver; Mice; Mice, Inbred C57BL; Myocardium; Organ Specificity; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation | 1996 |
Activation of the nuclear receptor peroxisome proliferator-activated receptor gamma promotes brown adipocyte differentiation.
Topics: Adipocytes; Adipose Tissue, Brown; Carrier Proteins; Cell Differentiation; Cell Line; Gene Expression Regulation; Hyperplasia; Hypoglycemic Agents; Ion Channels; Membrane Proteins; Mitochondrial Proteins; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Uncoupling Protein 1 | 1996 |
Prolactin receptor expression during adipocyte differentiation of bone marrow stroma.
Topics: Adipocytes; Animals; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Mice; Pioglitazone; Receptors, Prolactin; Rosiglitazone; Stem Cells; Stromal Cells; Thiazoles; Thiazolidinediones | 1996 |
The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPAR-gamma and aP2 in adipose tissue of high-fat-fed rats.
Topics: Adipose Tissue; Animals; Carrier Proteins; Dietary Fats; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Hypoglycemic Agents; Male; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 1996 |
Discovery of ligands for the nuclear peroxisome proliferator-activated receptors.
Topics: Animals; Cell Nucleus; Hypoglycemic Agents; Ligands; Mice; Nuclear Proteins; Prostaglandins; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 1996 |
Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists.
Topics: Animals; Bexarotene; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Insulin Resistance; Ligands; Mice; Mice, Inbred C57BL; Mice, Obese; Nicotinic Acids; Obesity; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection | 1997 |
Antidiabetic efficacy of BRL 49653, a potent orally active insulin sensitizing agent, assessed in the C57BL/KsJ db/db diabetic mouse by non-invasive 1H NMR studies of urine.
Topics: Administration, Oral; Aging; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycosuria; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred C57BL; Protons; Rosiglitazone; Thiazoles; Thiazolidinediones | 1997 |
The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat.
Topics: Analysis of Variance; Animals; Diglycerides; Fatty Acids; Fatty Acids, Nonesterified; Hypoglycemic Agents; Lipid Metabolism; Liver; Male; Muscles; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 1997 |
Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation.
Topics: 3T3 Cells; Adipocytes; Animals; Blotting, Western; CCAAT-Enhancer-Binding Proteins; Cell Cycle; Cell Differentiation; DNA-Binding Proteins; Mice; Nuclear Proteins; Receptors, Cytoplasmic and Nuclear; Retinoblastoma Protein; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tretinoin | 1997 |
Up-regulation of UCP-2 gene expression by PPAR agonists in preadipose and adipose cells.
Topics: Adipocytes; Animals; Cell Differentiation; Cell Line; Epoprostenol; Gene Expression Regulation; Mice; Mitochondria; Palmitates; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Uncoupling Agents | 1997 |
Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor.
Topics: Amino Acid Sequence; Animals; Base Sequence; Blotting, Northern; Carrier Proteins; DNA-Binding Proteins; DNA, Complementary; Fungal Proteins; In Situ Hybridization; Male; Mediator Complex Subunit 1; Mice; Molecular Sequence Data; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Testis; Thiazoles; Thiazolidinediones; Transcription Factors | 1997 |
Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates.
Topics: Adipose Tissue; Animals; Apolipoproteins; Drug Combinations; Fenofibrate; Gene Expression; Hypolipidemic Agents; Lipoprotein Lipase; Lipoproteins; Lipoproteins, VLDL; Liver; Male; Osmolar Concentration; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 1997 |
Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators.
Topics: 3T3 Cells; Adipose Tissue; Animals; Carrier Proteins; Coenzyme A Ligases; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Liver; Male; Mice; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Nuclear Proteins; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Cells, Cultured | 1997 |
Reversal of chronic alterations of skeletal muscle protein kinase C from fat-fed rats by BRL-49653.
Topics: Animals; Cytosol; Dietary Carbohydrates; Dietary Fats; Gene Expression Regulation, Enzymologic; Hypoglycemic Agents; Isoenzymes; Male; Muscle Fibers, Fast-Twitch; Muscle, Skeletal; Protein Kinase C; Protein Kinase C-epsilon; Protein Kinase C-theta; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones | 1997 |
Direct effects of leptin on brown and white adipose tissue.
Topics: Adipocytes; Adipose Tissue; Adipose Tissue, Brown; Animals; Carrier Proteins; Cell Nucleus; Cells, Cultured; DNA-Binding Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Gene Expression; Glucose; Hypoglycemic Agents; Janus Kinase 1; Leptin; Lipoprotein Lipase; Malate Dehydrogenase; Male; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Protein-Tyrosine Kinases; Proteins; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptors, Cell Surface; Receptors, Leptin; Rosiglitazone; STAT1 Transcription Factor; Thiazoles; Thiazolidinediones; Trans-Activators | 1997 |
Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.
Topics: Adipocytes; Animals; Cell Differentiation; Cells, Cultured; Chromans; Humans; Mice; Microbodies; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Stem Cells; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Troglitazone | 1997 |
Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y.
Topics: Animals; Appetite Stimulants; Body Weight; Eating; Hyperphagia; Hypoglycemic Agents; Hypothalamus; Leptin; Male; Neuropeptide Y; Proteins; Rats; Rats, Wistar; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones | 1997 |
Thiazolidinedione exposure increases the expression of uncoupling protein 1 in cultured human preadipocytes.
Topics: Adipocytes; Base Sequence; Carrier Proteins; Cells, Cultured; DNA Primers; Female; Gene Expression Regulation; Humans; Hypoglycemic Agents; Ion Channels; Male; Membrane Proteins; Mitochondrial Proteins; Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Stem Cells; Thiazoles; Thiazolidinediones; Transcription Factors; Uncoupling Protein 1 | 1998 |
Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships.
Topics: Animals; Benzopyrans; Benzoxazoles; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Male; Mice; Obesity; Pioglitazone; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Troglitazone | 1997 |
Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma.
Topics: 3T3 Cells; Adipocytes; Animals; Benzoxazoles; Female; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Phenylpropionates; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Transcription Factors | 1998 |
Development of a scintillation proximity assay for peroxisome proliferator-activated receptor gamma ligand binding domain.
Topics: Amino Acid Sequence; Biotinylation; Chromatography, Gel; Humans; Ligands; Molecular Sequence Data; Radioligand Assay; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Scintillation Counting; Streptavidin; Thiazoles; Thiazolidinediones; Transcription Factors | 1998 |
Glucocorticoids repress induction by thiazolidinediones, fibrates, and fatty acids of phosphoenolpyruvate carboxykinase gene expression in adipocytes.
Topics: 3T3 Cells; Adipocytes; Adrenergic beta-Agonists; Animals; Clofibrate; Dexamethasone; Enzyme Induction; Fatty Acids; Gene Expression Regulation, Enzymologic; Genes; Glucocorticoids; Hypoglycemic Agents; Isoproterenol; Male; Mice; Phosphoenolpyruvate Carboxykinase (GTP); Protein Biosynthesis; Proteins; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Regulatory Sequences, Nucleic Acid; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Trans-Activators; Transcription Factors | 1998 |
ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand.
Topics: 3T3 Cells; Adipose Tissue; Animals; Binding, Competitive; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Kinetics; Ligands; Mice; Nuclear Proteins; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection | 1998 |
Mechanisms of androgen induction of sebocyte differentiation.
Topics: Androgens; Animals; Cell Differentiation; Cells, Cultured; Dihydrotestosterone; Linoleic Acid; Lipids; Pyrimidines; Rats; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sebaceous Glands; Thiazoles; Thiazolidinediones; Transcription Factors | 1998 |
BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones.
Topics: 3T3 Cells; Adipocytes; Animals; Carrier Proteins; Fatty Acids, Nonesterified; Glycerol; Hypoglycemic Agents; Insulin Resistance; Lipolysis; Mice; Perilipin-1; Phosphoproteins; Prostaglandin D2; Rosiglitazone; Sterol Esterase; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 1998 |
PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL.
Topics: Alitretinoin; Animals; Arteriosclerosis; CD36 Antigens; Cell Differentiation; Dimerization; Foam Cells; HL-60 Cells; Humans; Ligands; Lipoproteins, LDL; Macrophages; Membrane Proteins; Mice; Mice, Transgenic; Monocytes; Promoter Regions, Genetic; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Receptors, Immunologic; Receptors, Lipoprotein; Receptors, Retinoic Acid; Receptors, Scavenger; Retinoid X Receptors; Rosiglitazone; Scavenger Receptors, Class B; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Tretinoin | 1998 |
Novel euglycemic and hypolipidemic agents. 1.
Topics: Animals; Blood Glucose; Drug Evaluation, Preclinical; Hypoglycemic Agents; Hypolipidemic Agents; Indoles; Male; Mice; Mice, Inbred C57BL; Rats; Rats, Wistar; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Tissue Distribution; Triglycerides | 1998 |
Specific activation of the nuclear receptors PPARgamma and RORA by the antidiabetic thiazolidinedione BRL 49653 and the antiarthritic thiazolidinedione derivative CGP 52608.
Topics: 3T3 Cells; Animals; Arthritis, Experimental; Cell Nucleus; Dexamethasone; Hypoglycemic Agents; Insulin Resistance; Leptin; Male; Mice; Proteins; Rats; Rats, Inbred Lew; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiosemicarbazones; Transcription Factors; Triglycerides | 1998 |
A regulatory role for RIP140 in nuclear receptor activation.
Topics: Adaptor Proteins, Signal Transducing; Alitretinoin; Amino Acid Sequence; Animals; Binding, Competitive; Cell Nucleus; Cloning, Molecular; Dimerization; DNA-Binding Proteins; Fatty Acids; Gene Expression Regulation; Gene Library; Histone Acetyltransferases; Humans; Macromolecular Substances; Molecular Sequence Data; Nuclear Proteins; Nuclear Receptor Co-Repressor 1; Nuclear Receptor Coactivator 1; Nuclear Receptor Coactivators; Nuclear Receptor Interacting Protein 1; Oncogene Proteins; Pyrimidines; Rabbits; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Receptors, Thyroid Hormone; Recombinant Fusion Proteins; Repressor Proteins; Retinoid X Receptors; Rosiglitazone; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Thiazoles; Thiazolidinediones; Trans-Activators; Transcription Factors; Transcription, Genetic; Transfection; Tretinoin; Zinc Fingers | 1998 |
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators.
Topics: Acute-Phase Proteins; Animals; Anti-Inflammatory Agents; Aorta; Coronary Disease; COS Cells; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Fenofibrate; Gemfibrozil; Gene Expression Regulation, Enzymologic; Humans; Hyperlipidemias; Hypolipidemic Agents; Inflammation; Interleukin-1; Interleukin-6; Isoenzymes; Membrane Proteins; Muscle, Smooth, Vascular; NF-kappa B; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic | 1998 |
Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats.
Topics: Acetylglucosaminidase; Albuminuria; Animals; Blood Pressure; Body Weight; Histocytochemistry; Hypoglycemic Agents; Immunohistochemistry; Islets of Langerhans; Kidney; Kidney Diseases; Male; Obesity; Pancreas; Pancreatic Diseases; Proteinuria; Rats; Rats, Zucker; Rosiglitazone; Systole; Thiazoles; Thiazolidinediones | 1998 |
The short- and long-term effects of tumor necrosis factor-alpha and BRL 49653 on peroxisome proliferator-activated receptor (PPAR)gamma2 gene expression and other adipocyte genes.
Topics: Adipocytes; Animals; Carrier Proteins; Cell Differentiation; Down-Regulation; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Gene Expression Regulation; Hypoglycemic Agents; Mice; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Perilipin-1; Phosphoproteins; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sterol Esterase; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Transcription, Genetic; Tumor Necrosis Factor-alpha | 1998 |
Inhibition of 3T3-L1 adipocyte differentiation by expression of acyl-CoA-binding protein antisense RNA.
Topics: 1-Methyl-3-isobutylxanthine; 3T3 Cells; Adipocytes; Animals; Carrier Proteins; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Clone Cells; Dexamethasone; Diazepam Binding Inhibitor; DNA-Binding Proteins; Gene Expression Regulation; Hypoglycemic Agents; Insulin; Mice; Nuclear Proteins; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; RNA, Antisense; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection | 1998 |
PPAR--the good news and the bad.
Topics: Adenomatous Polyposis Coli; Animals; Chromans; Humans; Hypoglycemic Agents; Mice; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1998 |
PPARgamma and colorectal carcinoma: conflicts in a nuclear family.
Topics: Adenomatous Polyposis Coli; Animals; Chromans; Colorectal Neoplasms; Humans; Mice; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1998 |
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice.
Topics: Adenocarcinoma; Animals; beta Catenin; Chromans; Colorectal Neoplasms; Cyclooxygenase 2; Cytoskeletal Proteins; HT29 Cells; Humans; Isoenzymes; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Prostaglandin-Endoperoxide Synthases; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Trans-Activators; Transcription Factors; Troglitazone | 1998 |
Insulin down-regulates angiotensinogen gene expression and angiotensinogen secretion in cultured adipose cells.
Topics: 3T3 Cells; Adipose Tissue; Angiotensinogen; Animals; Cells, Cultured; Down-Regulation; Gene Expression Regulation; Hypoglycemic Agents; Insulin; Mice; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 1998 |
Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma.
Topics: Amino Acid Sequence; Binding Sites; Cloning, Molecular; Conserved Sequence; Crystallography, X-Ray; Escherichia coli; Histone Acetyltransferases; Humans; Hypoglycemic Agents; Ligands; Macromolecular Substances; Molecular Sequence Data; Nuclear Receptor Coactivator 1; Protein Conformation; Protein Structure, Tertiary; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation | 1998 |
Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages.
Topics: Apoptosis; Arteriosclerosis; Caspase 3; Caspases; Cell Differentiation; Humans; Immunohistochemistry; Inflammation; Interferon-gamma; Ligands; Macrophages; NF-kappa B; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection; Tumor Necrosis Factor-alpha | 1998 |
Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes.
Topics: Adipocytes; Animals; Biological Transport; Cell Differentiation; CHO Cells; Chromans; Cricetinae; Enzyme Inhibitors; Gene Expression Regulation; Glucose; Insulin; Insulin Resistance; Lipids; Lipoprotein Lipase; Mice; Protein Biosynthesis; Rats; RNA, Messenger; Rosiglitazone; Stem Cells; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1998 |
Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer.
Topics: Animals; Binding Sites; CREB-Binding Protein; Cricetinae; Energy Transfer; Estrogen Receptor alpha; Histone Acetyltransferases; Nuclear Proteins; Nuclear Receptor Coactivator 1; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Receptors, Estrogen; Rosiglitazone; Spectrometry, Fluorescence; Thiazoles; Thiazolidinediones; Trans-Activators; Transcription Factors | 1998 |
Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells.
Topics: Cell Cycle; Cell Division; Colorectal Neoplasms; G1 Phase; Humans; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Cells, Cultured | 1998 |
PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter.
Topics: 5' Untranslated Regions; Adipose Tissue; Adult; Animals; Base Sequence; Cell Line; Dimerization; Exons; Humans; Intestine, Large; Molecular Sequence Data; Promoter Regions, Genetic; Prostaglandins; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Response Elements; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 1998 |
A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.
Topics: Acyl-CoA Oxidase; Adipose Tissue; Animals; Blood Glucose; Body Weight; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Gene Expression; Hypoglycemic Agents; Insulin; Ligands; Lipid Metabolism; Liver; Male; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Obesity; Organ Size; Oxidoreductases; Radioligand Assay; Rats; Rats, Wistar; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors; Transcriptional Activation; Triglycerides | 1998 |
Interdomain communication regulating ligand binding by PPAR-gamma.
Topics: 3T3 Cells; Adipocytes; Animals; Binding Sites; Calcium-Calmodulin-Dependent Protein Kinases; Cell Differentiation; Histone Acetyltransferases; Ligands; Mice; Nuclear Receptor Coactivator 1; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic | 1998 |
Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation.
Topics: Aging; Animals; Apolipoprotein C-I; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins C; Fenofibrate; Gene Expression Regulation; Gene Expression Regulation, Developmental; Humans; Hypolipidemic Agents; Kinetics; Liver; Male; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 1999 |
Differential activity of rosiglitazone enantiomers at PPAR gamma.
Topics: Hypoglycemic Agents; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Stereoisomerism; Thiazoles; Thiazolidinediones; Transcription Factors | 1998 |
Increase in uncoupling protein-2 mRNA expression by BRL49653 and bromopalmitate in human adipocytes.
Topics: Adipocytes; Adipose Tissue; Adult; Cells, Cultured; Culture Techniques; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Ion Channels; Leptin; Membrane Transport Proteins; Middle Aged; Mitochondrial Proteins; Palmitates; Proteins; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Transcriptional Activation; Tumor Necrosis Factor-alpha; Uncoupling Protein 2 | 1999 |
p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively.
Topics: Cyclic AMP Response Element-Binding Protein; DNA-Binding Proteins; HeLa Cells; Humans; Ligands; Nuclear Proteins; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Trans-Activators; Transcription Factors; Zinc Fingers | 1999 |
A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation.
Topics: Adipocytes; Animals; Base Sequence; Carrier Proteins; Cells, Cultured; Chromans; Diabetes Mellitus; DNA Probes; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Female; Gene Expression Regulation; Genetic Techniques; Humans; Hypoglycemic Agents; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Molecular Sequence Data; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Tretinoin; Troglitazone; Tumor Suppressor Proteins | 1999 |
Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo.
Topics: Animals; Cell Differentiation; Cell Division; Cells, Cultured; Cornea; Eicosanoids; Endothelium, Vascular; Gene Expression Regulation; Humans; Ligands; Neovascularization, Physiologic; Prostaglandin D2; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 1999 |
Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes.
Topics: Animals; Aorta, Thoracic; Chromans; Electric Stimulation; Hypoglycemic Agents; In Vitro Techniques; Ion Channels; Male; Membrane Potentials; Muscle, Smooth, Vascular; Potassium Channels; Pulmonary Artery; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells.
Topics: Animals; Aorta, Thoracic; Calcium-Calmodulin-Dependent Protein Kinases; Cell Movement; Cells, Cultured; Chemotactic Factors; Chromans; Cycloheximide; Dactinomycin; Enzyme Activation; Insulin-Like Growth Factor I; Ligands; Muscle, Smooth, Vascular; Platelet-Derived Growth Factor; Prostaglandin D2; Protein Synthesis Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Thrombin; Transcription Factors; Troglitazone | 1999 |
Up-regulation of uncoupling protein-3 by fatty acid in C2C12 myotubes.
Topics: Animals; Carrier Proteins; Cell Line; Fatty Acids; Ion Channels; Male; Mice; Mice, Inbred C57BL; Mitochondria, Muscle; Mitochondrial Proteins; Muscle, Skeletal; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Uncoupling Protein 3; Up-Regulation | 1999 |
Regulation of differentiation of sheep subcutaneous and abdominal preadipocytes in culture.
Topics: Abdomen; Adipose Tissue; Animals; Animals, Suckling; Cattle; Cell Differentiation; Cells, Cultured; Dexamethasone; Female; Fibroblast Growth Factors; Glucocorticoids; Growth Hormone; Insulin; Male; Pregnancy; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sheep; Thiazoles; Thiazolidinediones; Transcription Factors; Triiodothyronine | 1999 |
A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation.
Topics: Adipocytes; Animals; Binding Sites; Cell Differentiation; Cell Line; Chlorocebus aethiops; Crystallography, X-Ray; Humans; Kinetics; Ligands; Mice; Models, Molecular; Molecular Conformation; Molecular Sequence Data; Nuclear Proteins; Protein Structure, Secondary; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors; Transfection | 1999 |
Activators of peroxisome proliferator-activated receptor-alpha induce the expression of the uncoupling protein-3 gene in skeletal muscle: a potential mechanism for the lipid intake-dependent activation of uncoupling protein-3 gene expression at birth.
Topics: Animals; Bezafibrate; Carrier Proteins; Clofibrate; DNA-Binding Proteins; Eating; Fatty Acids, Nonesterified; Female; Gene Expression Regulation, Developmental; Hypolipidemic Agents; Ion Channels; Leptin; Male; Mice; Mitochondria, Muscle; Mitochondrial Proteins; Muscle Development; Muscle, Skeletal; Peroxisome Proliferators; Proteins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Uncoupling Protein 3 | 1999 |
Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.
Topics: Bezafibrate; Cells, Cultured; Clofibric Acid; Endothelium, Vascular; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Plasminogen Activator Inhibitor 1; Pyrimidines; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription, Genetic | 1999 |
The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.
Topics: Acetylcholine; Animals; Blood Pressure; Endothelium, Vascular; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Vascular Resistance; Vasodilator Agents | 1999 |
Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice.
Topics: Animals; Electrophoresis, Gel, Two-Dimensional; Hypoglycemic Agents; Liver; Male; Mice; Mice, Obese; Obesity; Peroxisome Proliferators; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 1999 |
Loss-of-function mutations in PPAR gamma associated with human colon cancer.
Topics: Amino Acid Substitution; Binding Sites; Chromans; Colorectal Neoplasms; Dimerization; DNA-Binding Proteins; Exons; Genes, Tumor Suppressor; Humans; Hydroxyeicosatetraenoic Acids; Ligands; Linoleic Acids; Linoleic Acids, Conjugated; Mutation; Prostaglandin D2; Protein Binding; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Response Elements; Retinoid X Receptors; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Troglitazone | 1999 |
Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2.
Topics: Adipocytes; Animals; Bone Marrow; Cell Differentiation; Cell Line; Core Binding Factor Alpha 1 Subunit; Gene Expression; Lipoprotein Lipase; Mice; Neoplasm Proteins; Osteoblasts; Phenotype; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection | 1999 |
PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes.
Topics: Adipocytes; Carrier Proteins; Cell Differentiation; Cell Line; Cells, Cultured; Chromans; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Gene Expression; Humans; Kinetics; Monocytes; Myelin P2 Protein; Neoplasm Proteins; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Suppressor Proteins | 1999 |
A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response.
Topics: Animals; Caco-2 Cells; Colitis; Cytokines; DNA-Binding Proteins; Epithelium; Gene Expression; HT29 Cells; Humans; I-kappa B Proteins; Inflammation; Inflammatory Bowel Diseases; Interleukin-8; Ligands; Mice; Microbodies; NF-kappa B; NF-KappaB Inhibitor alpha; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 1999 |
Use of a PPAR gamma-specific monoclonal antibody to demonstrate thiazolidinediones induce PPAR gamma receptor expression in vitro.
Topics: Adipocytes; Alternative Splicing; Animals; Antibodies, Monoclonal; Antibody Specificity; Cell Differentiation; Cell Line; Chromans; Humans; Hybridomas; Hypoglycemic Agents; In Vitro Techniques; Mice; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; Species Specificity; Stem Cells; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1999 |
9-cis retinoic acid induces monocyte chemoattractant protein-1 secretion in human monocytic THP-1 cells.
Topics: Alitretinoin; Blood Cells; Chemokine CCL2; Dose-Response Relationship, Drug; Humans; Monocytes; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Tretinoin; Tumor Cells, Cultured | 1999 |
From the Food and Drug Administration.
Topics: Diabetes Mellitus, Type 2; Endotoxemia; Gentamicins; Humans; Hypoglycemic Agents; Joint Prosthesis; Pioglitazone; Rosiglitazone; Temporomandibular Joint; Temporomandibular Joint Disorders; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 1999 |
Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Blood; Carcinoma, Hepatocellular; Cattle; Culture Media; DNA-Binding Proteins; Fenofibrate; Gemfibrozil; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Kinetics; Liver Neoplasms; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured | 1999 |
Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.
Topics: Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; DNA, Complementary; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Kinetics; Microsomes, Liver; Rosiglitazone; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Thiazoles; Thiazolidinediones; Transfection; Tumor Cells, Cultured | 1999 |
PPARalpha activation by Wy 14643 induces transactivation of the rat UCP-1 promoter without increasing UCP-1 mRNA levels and attenuates PPARgamma-mediated increases in UCP-1 mRNA levels induced by rosiglitazone in fetal rat brown adipocytes.
Topics: Adipose Tissue, Brown; Alitretinoin; Animals; Carrier Proteins; Cells, Cultured; Gene Expression Regulation; Ion Channels; Membrane Proteins; Mitochondrial Proteins; Peroxisome Proliferators; Promoter Regions, Genetic; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transfection; Tretinoin; Uncoupling Protein 1 | 1999 |
Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro.
Topics: Acid Phosphatase; Adipocytes; Animals; Bone Marrow Cells; Bone Resorption; Calcitriol; Cell Differentiation; Cells, Cultured; Chromans; Hypoglycemic Agents; Interleukin-11; Isoenzymes; Mice; Mice, Inbred ICR; Osteoclasts; Parathyroid Hormone; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Tartrate-Resistant Acid Phosphatase; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 1999 |
Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes.
Topics: Adipocytes; Adipose Tissue; Adult; Aged; DNA-Binding Proteins; Female; Gene Expression Regulation; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Ion Channels; Leptin; Male; Membrane Transport Proteins; Middle Aged; Mitochondrial Proteins; Monosaccharide Transport Proteins; Muscle Proteins; Obesity; Phosphatidylinositol 3-Kinases; Proteins; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness; Transcription Factors; Transcription, Genetic; Uncoupling Protein 2 | 1999 |
Rosiglitazone maleate. Ketotifen fumarate.
Topics: Conjunctivitis, Allergic; Diabetes Mellitus; Drug Administration Schedule; Histamine H1 Antagonists; Humans; Hypoglycemic Agents; Ketotifen; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
[Type II diabetes mellitus. Rosiglitazone is effective against insulin resistance].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution.
Topics: Animals; Body Weight; Diet; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Hemodilution; Hemodynamics; Hypoglycemic Agents; Insulin; Leptin; Male; Obesity; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
Rosiglitazone for type 2 diabetes mellitus.
Topics: Administration, Oral; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones | 1999 |
Differential block by troglitazone and rosiglitazone of glibenclamide-sensitive K(+) current in rat aorta myocytes.
Topics: Animals; Aorta, Thoracic; Chromans; Glyburide; Hypoglycemic Agents; In Vitro Techniques; Male; Membrane Potentials; Muscle, Smooth, Vascular; Potassium Channel Blockers; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells.
Topics: Cell Nucleus; Cytosol; DNA-Binding Proteins; Fenofibrate; Gene Expression Regulation; Humans; Interleukin-8; Kinetics; Lipopolysaccharides; Matrix Metalloproteinase 9; Monocytes; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Cells, Cultured | 2000 |
A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation.
Topics: 1-Methyl-3-isobutylxanthine; 3T3 Cells; Adipocytes; Animals; Benzhydryl Compounds; Cell Differentiation; Cell Nucleus; Chromatography, High Pressure Liquid; Dexamethasone; Dose-Response Relationship, Drug; Epoxy Compounds; Gas Chromatography-Mass Spectrometry; Glucocorticoids; Hypoglycemic Agents; Insulin; Ligands; Mice; Phosphodiesterase Inhibitors; Protein Binding; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic | 2000 |
Hepatic failure in a patient taking rosiglitazone.
Topics: Aged; Combined Modality Therapy; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Ischemia; Liver; Liver Failure; Male; Monitoring, Physiologic; Pravastatin; Rosiglitazone; Thiazoles; Thiazolidinediones; Verapamil | 2000 |
Hepatocellular injury in a patient receiving rosiglitazone. A case report.
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Liver; Liver Function Tests; Male; Middle Aged; Monitoring, Physiologic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Rosiglitazone and hepatic failure.
Topics: Coronary Disease; Humans; Hypoglycemic Agents; Ischemia; Liver; Liver Failure; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone.
Topics: Chromans; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Hypoglycemic Agents; In Vitro Techniques; Isoenzymes; Kinetics; Microsomes, Liver; Oxidation-Reduction; Pioglitazone; Recombinant Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Xenobiotics | 2000 |
A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis.
Topics: Adenoviridae; Adipocytes; Cell Line; DNA-Binding Proteins; Dose-Response Relationship, Drug; Genes, Dominant; Genetic Vectors; Humans; Ligands; Models, Biological; Mutation; Nuclear Receptor Co-Repressor 2; Plasmids; Precipitin Tests; Receptors, Cytoplasmic and Nuclear; Repressor Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection | 2000 |
Rosiglitazone approved for treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 1999 |
Prostacyclin IP receptor up-regulates the early expression of C/EBPbeta and C/EBPdelta in preadipose cells.
Topics: 3T3 Cells; Adipocytes; Animals; Carrier Proteins; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Clone Cells; Colforsin; Cyclic AMP; DNA-Binding Proteins; Epoprostenol; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Kinetics; Mice; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Nuclear Proteins; Receptors, Cytoplasmic and Nuclear; Receptors, Epoprostenol; Receptors, Prostaglandin; RNA, Messenger; Rosiglitazone; Signal Transduction; Stem Cells; Thiazoles; Thiazolidinediones; Transcription Factors; Up-Regulation | 2000 |
Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy.
Topics: Adipose Tissue; Animals; Aromatase; Aromatase Inhibitors; Binding, Competitive; Breast; Breast Neoplasms; Cell Line; Cells, Cultured; Chromans; Dose-Response Relationship, Drug; Estrogens; Female; Gene Expression Regulation, Enzymologic; Humans; Ligands; Promoter Regions, Genetic; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Stromal Cells; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone | 2000 |
Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight.
Topics: Acyl-CoA Oxidase; Animals; Apolipoprotein A-I; Apolipoprotein C-III; Apolipoproteins C; Body Weight; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fenofibrate; Hypolipidemic Agents; Male; Mice; Myelin P2 Protein; Neoplasm Proteins; Nerve Tissue Proteins; Oxidoreductases; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Time Factors; Transcription Factors; Triglycerides | 2000 |
Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and zucker diabetic fatty rats and effects of rosiglitazone.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Gene Expression Regulation; Hyperglycemia; Hypoglycemic Agents; Hypothalamus; Insulin; Intracellular Signaling Peptides and Proteins; Leptin; Neuropeptides; Obesity; Orexins; Protein Precursors; Rats; Rats, Zucker; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness; Transcription, Genetic | 2000 |
Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene.
Topics: Animals; Binding Sites; CREB-Binding Protein; Dimerization; DNA-Binding Proteins; Gene Expression Regulation; Histone Acetyltransferases; Macrophages; Mice; Mutation; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nuclear Proteins; Nuclear Receptor Coactivator 1; Phosphorylation; Point Mutation; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Trans-Activators; Transcription Factors | 2000 |
Depot-related and thiazolidinedione-responsive expression of uncoupling protein 2 (UCP2) in human adipocytes.
Topics: Adipocytes; Adult; Animals; Cells, Cultured; CHO Cells; Cricetinae; Female; Humans; Hypoglycemic Agents; Ion Channels; Male; Membrane Transport Proteins; Microscopy, Fluorescence; Middle Aged; Mitochondrial Proteins; Omentum; Polymerase Chain Reaction; Protein Biosynthesis; Proteins; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transfection; Uncoupling Protein 2 | 2000 |
[New antidiabetic in "virtual reality". Eye to eye with insulin resistance].
Topics: Computer Simulation; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; User-Computer Interface | 2000 |
How should patients taking the discontinued diabetes drug troglitazone be managed?
Topics: Alanine Transaminase; Chromans; Diabetes Mellitus; Humans; Hypoglycemic Agents; Liver; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Bone morphogenetic protein-2 stimulates adipogenic differentiation of mesenchymal precursor cells in synergy with BRL 49653 (rosiglitazone).
Topics: Adipocytes; Animals; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Cell Differentiation; Cell Line; Drug Synergism; Hypoglycemic Agents; Mesoderm; Mice; Rats; Rosiglitazone; Thiazoles; Thiazolidinediones; Transforming Growth Factor beta | 2000 |
Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.
Topics: 3T3 Cells; Animals; Cell Line; Chromans; Electrophoresis, Gel, Two-Dimensional; Epithelial Cells; Gene Expression Regulation; Humans; Hypoglycemic Agents; Kidney; Mice; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection; Troglitazone; Trypsin | 2000 |
v- and t-SNARE protein expression in models of insulin resistance: normalization of glycemia by rosiglitazone treatment corrects overexpression of cellubrevin, vesicle-associated membrane protein-2, and syntaxin 4 in skeletal muscle of Zucker diabetic fat
Topics: Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gene Expression; Glucose Transporter Type 4; Hypoglycemic Agents; Immunoblotting; Insulin Resistance; Male; Membrane Proteins; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Obesity; Qa-SNARE Proteins; R-SNARE Proteins; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Vesicle-Associated Membrane Protein 3 | 2000 |
[Tackling insulin resistance. Control of etiology in type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Synergistic activation of UCP-3 expression in cultured fetal rat brown adipocytes by PPARalpha and PPARgamma ligands.
Topics: Adipose Tissue, Brown; Animals; Base Sequence; Carrier Proteins; Cells, Cultured; DNA Primers; Drug Synergism; Gene Expression Regulation; Ion Channels; Ligands; Membrane Proteins; Mitochondrial Proteins; Peroxisome Proliferators; Pyrimidines; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Uncoupling Protein 1; Uncoupling Protein 3 | 2000 |
Pharmacologic therapy for type 2 diabetes mellitus.
Topics: Algorithms; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 2000 |
Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.
Topics: Alitretinoin; Amino Acid Sequence; Binding Sites; Crystallography; Diabetes Mellitus, Type 2; Dimerization; Drug Design; Histone Acetyltransferases; Humans; Ligands; Models, Molecular; Molecular Sequence Data; Nuclear Proteins; Nuclear Receptor Coactivator 1; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Sequence Homology, Amino Acid; Surface Properties; Thiazoles; Thiazolidinediones; Transcription Factors; Tretinoin | 2000 |
Oral antidiabetic agents safe with renal disease?
Topics: Aged; Contraindications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Kidney Diseases; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization.
Topics: Animals; Blotting, Western; Cell Division; Cell Movement; Choroid; Choroidal Neovascularization; Chromans; Dose-Response Relationship, Drug; Endothelial Growth Factors; Endothelium, Vascular; Fluorescein Angiography; Humans; Injections; Laser Coagulation; Ligands; Lymphokines; Macaca fascicularis; Male; Pigment Epithelium of Eye; Rats; Rats, Inbred BN; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
All that glitters in glitazones.
Topics: Antiviral Agents; Chromans; Drug Approval; Drug Prescriptions; Europe; Guanidines; Humans; Hypoglycemic Agents; National Health Programs; Pyrans; Rosiglitazone; Sialic Acids; Sri Lanka; Thiazoles; Thiazolidinediones; Troglitazone; United Kingdom; United States; United States Food and Drug Administration; Zanamivir | 1999 |
[Type 2 diabetes. A new kind of insulin sensitizer at the door].
Topics: Diabetes Mellitus, Type 2; Drugs, Investigational; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazoles; Thiazolidinediones | 1999 |
Correction: Liver injury and rosiglitazone.
Topics: Chemical and Drug Induced Liver Injury; Humans; Hypoglycemic Agents; Indoles; Phenylcarbamates; Rosiglitazone; Sulfonamides; Thiazoles; Thiazolidinediones; Tosyl Compounds | 2000 |
Acute hemodynamic effects of insulin-sensitizing agents in isolated perfused rat hearts.
Topics: Animals; Chromans; Dose-Response Relationship, Drug; Hemodynamics; Hypoglycemic Agents; Indomethacin; Isoxazoles; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Perfusion; Pioglitazone; Prostaglandins; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Vitamin E | 2000 |
Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Topics: Chemical and Drug Induced Liver Injury; Chromans; Contraindications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
The effect of activation of peroxisome proliferator-activated receptor gamma (PPARgamma) on human monocyte function: PPARgamma ligands do not inhibit tumor necrosis factor-alpha release in human monocytic cell line THP-1.
Topics: Antineoplastic Agents; Carcinogens; Cell Survival; Cells, Cultured; Chromans; Humans; Hypoglycemic Agents; Ligands; Monocytes; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha | 2000 |
Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes.
Topics: 5,8,11,14-Eicosatetraynoic Acid; Cell Movement; Chemokine CCL2; Chemotaxis; Chromans; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Flavonoids; Humans; Matrix Metalloproteinase 9; Mitogen-Activated Protein Kinases; Monocytes; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Rosiglitazone; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1; Transcription Factors; Troglitazone; Tumor Cells, Cultured | 2000 |
Troglitazone has a reducing effect on thromboxane production.
Topics: Arachidonic Acid; Blood Platelets; Chromans; Diabetes Mellitus, Type 2; Fibrinolytic Agents; Gas Chromatography-Mass Spectrometry; Humans; Leukemia, Erythroblastic, Acute; Rosiglitazone; Thiazoles; Thiazolidinediones; Thromboxane A2; Troglitazone; Tumor Cells, Cultured; Vitamin E | 2000 |
[Thiazolidinediones in type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats.
Topics: Analysis of Variance; Animals; Blood Glucose; Body Weight; Eating; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Nicotinic Acids; Obesity; Rats; Rats, Zucker; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.
Topics: Animals; Arteriosclerosis; Base Sequence; CD36 Antigens; DNA Primers; Female; Gene Expression; Humans; Insulin Resistance; Ligands; Male; Matrix Metalloproteinase 9; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxazoles; Receptors, Cytoplasmic and Nuclear; Receptors, Immunologic; Receptors, LDL; Receptors, Lipoprotein; Receptors, Scavenger; RNA, Messenger; Rosiglitazone; Scavenger Receptors, Class B; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha; Tyrosine | 2000 |
Rosiglitazone.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Food-Drug Interactions; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2000 |
Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones.
Topics: 3T3 Cells; Adipocytes; Animals; Biological Availability; Cell Differentiation; Diabetes Mellitus; Drug Design; Drug Evaluation, Preclinical; Heart; Hypoglycemic Agents; Imidazoles; Male; Mice; Organ Size; Rats; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones | 2000 |
[Diabetes therapy related to etiology. Indications, uses and side effects of new insulin sensitizers].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Information on thiazolidinediones.
Topics: Chromans; Drug Industry; Humans; Hypoglycemic Agents; Internet; Ligands; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States; United States Food and Drug Administration | 2000 |
Peroxisome proliferator-activated receptors and hepatic stellate cell activation.
Topics: Animals; Cell Size; Cell Survival; Cells, Cultured; Collagen; DNA; Gene Expression Regulation; Liver; Liver Cirrhosis, Biliary; Liver Cirrhosis, Experimental; Male; Promoter Regions, Genetic; Prostaglandin D2; Protein Binding; Protein Isoforms; Pyrimidines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2000 |
A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes.
Topics: 1-Methyl-3-isobutylxanthine; 3T3 Cells; Adipocytes; Animals; Benzoates; Cell Differentiation; Cell Line; Dexamethasone; Glucose; Humans; Hypoglycemic Agents; Insulin; Kinetics; Ligands; Mice; Naphthalenes; Nuclear Proteins; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Recombinant Proteins; Retinoid X Receptors; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection; Triglycerides; Tumor Necrosis Factor-alpha | 2000 |
Rosiglitazone and liver failure.
Topics: Humans; Liver Failure; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma.
Topics: Animals; Apolipoproteins B; Arteriosclerosis; Cells, Cultured; Down-Regulation; Humans; Linoleic Acid; Linoleic Acids; Linoleic Acids, Conjugated; Lipoproteins, LDL; Mice; Monocytes; Muscle, Smooth, Vascular; Phospholipids; Receptors, CCR2; Receptors, Chemokine; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.
Topics: Adipocytes; Animals; Azo Compounds; Bexarotene; Carbamates; Carrier Proteins; Cell Differentiation; Cells, Cultured; Coloring Agents; Fatty Acid-Binding Proteins; Furans; HIV Protease Inhibitors; Indinavir; Insulin; Lipolysis; Lipoprotein Lipase; Nelfinavir; Neoplasm Proteins; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Ritonavir; RNA, Messenger; Rosiglitazone; Saquinavir; Stem Cells; Sulfonamides; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2000 |
Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes.
Topics: Animals; Cell Nucleus; Cells, Cultured; Chromans; Drug Interactions; Gemfibrozil; Hypoglycemic Agents; Lipopolysaccharides; Myocardium; NF-kappa B; Peroxisome Proliferators; Pyrimidines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone; Tumor Necrosis Factor-alpha | 2000 |
[First insulin sensitizer approved in Germany. Insulin resistance in type 2 diabetes can be treated].
Topics: Diabetes Mellitus, Type 2; Drug Approval; Germany; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Rosiglitazone toxicity.
Topics: Chemical and Drug Induced Liver Injury; Female; Humans; Hypoglycemic Agents; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
[New development in diabetes therapy. 35th Annual Meeting of the German Diabetes Society, Munich, May 5-June 3, 2000].
Topics: Chromans; Diabetes Mellitus, Type 2; Germany; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma.
Topics: 3T3 Cells; Adipocytes; Animals; Cell Differentiation; CREB-Binding Protein; Drug Synergism; Ligands; Methylation; Mice; Nicotinic Acids; Nuclear Proteins; Nuclear Receptor Co-Repressor 1; Oleanolic Acid; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Repressor Proteins; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Trans-Activators; Transcription Factors; Transcriptional Activation | 2000 |
[Insulin sensitizer. A new therapy option for type 2 diabetic patients].
Topics: Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Isolated elevation of alkaline phosphatase level associated with rosiglitazone.
Topics: Alkaline Phosphatase; Chemical and Drug Induced Liver Injury; Female; Humans; Hypoglycemic Agents; Middle Aged; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones.
Topics: Adipose Tissue; Animals; Blood Glucose; Chromans; Diabetes Mellitus, Lipoatrophic; Disease Models, Animal; Female; Hypoglycemic Agents; Insulin; Ligands; Liver; Mice; Mice, Inbred C57BL; Mice, Transgenic; Receptors, Cytoplasmic and Nuclear; Respiratory Function Tests; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Troglitazone | 2000 |
Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.
Topics: Animals; Apolipoprotein A-I; Bezafibrate; Chlorocebus aethiops; Chromans; COS Cells; Fenofibrate; Gene Expression Regulation; Humans; Hypoglycemic Agents; Kinetics; Pioglitazone; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Transfection; Troglitazone; Tumor Cells, Cultured | 2000 |
Unraveling the mechanism of action of thiazolidinediones.
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2000 |
Mechanisms of dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Adipose Tissue; Adrenal Glands; Adrenalectomy; Analysis of Variance; Animals; Blood Glucose; Corticosterone; Eating; Hydroxysteroid Dehydrogenases; Hypertrophy; Hypoglycemic Agents; Insulin; Liver; Male; Metformin; Obesity; Omentum; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Gain | 2000 |
Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells.
Topics: Animals; Antigens, CD; CD40 Antigens; Cell Differentiation; Dendritic Cells; Dimethyl Sulfoxide; Interferon-gamma; Interleukin-12; Interleukins; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; T-Lymphocytes; Thiazoles; Thiazolidinediones; Transcription Factors | 2000 |
Diabetes. Type-righting lessons.
Topics: Cost of Illness; Diabetes Mellitus, Type 2; Drug Costs; Humans; Hypoglycemic Agents; Rosiglitazone; State Medicine; Thiazoles; Thiazolidinediones; United Kingdom | 2000 |
[New prospects for the type 2 diabetic patient. Delaying disease progression].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Insulin Resistance; Prognosis; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease.
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipids; Middle Aged; Pioglitazone; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2000 |
[Causal therapy of type 2 diabetes. Determining the cause of insulin resistance early].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |
The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat.
Topics: Adipose Tissue, Brown; Animals; Body Weight; Carrier Proteins; Eating; Ion Channels; Membrane Proteins; Membrane Transport Proteins; Mitochondrial Proteins; Nicotinic Acids; Obesity; Proteins; Rats; Rats, Zucker; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Uncoupling Protein 1; Uncoupling Protein 2; Uncoupling Protein 3; Weight Gain | 2000 |
Delayed activation of PPARgamma by LPS and IFN-gamma attenuates the oxidative burst in macrophages.
Topics: Animals; Cell Line; Cell Survival; Cells, Cultured; Escherichia coli; Genes, Reporter; Humans; Hypoglycemic Agents; Interferon-gamma; Lipopolysaccharides; Luciferases; Macrophages; Mice; Microbodies; Monocytes; NG-Nitroarginine Methyl Ester; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Respiratory Burst; Rosiglitazone; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection | 2001 |
Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure.
Topics: Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Albumin regulates induction of peroxisome proliferator-activated receptor-gamma (PPARgamma) by 15-deoxy-delta(12-14)-prostaglandin J(2) in vitro and may be an important regulator of PPARgamma function in vivo.
Topics: Hot Temperature; Immunologic Factors; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Serum Albumin; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Cells, Cultured | 2001 |
Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury.
Topics: Animals; Cells, Cultured; Colitis; Epithelial Cells; Gastric Mucosa; Gene Expression; Hypoglycemic Agents; In Vitro Techniques; Intercellular Adhesion Molecule-1; Interleukin-8; Intestinal Mucosa; L-Lactate Dehydrogenase; Liver; Mice; Mice, Inbred BALB C; Mice, Knockout; NF-kappa B; Peroxidase; Pneumonia; Receptors, Cytoplasmic and Nuclear; Reperfusion Injury; RNA, Messenger; Rosiglitazone; Stomach; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2001 |
The transcription factor Fos-related antigen 1 is induced by thiazolidinediones during differentiation of 3T3-L1 cells.
Topics: 3T3 Cells; Animals; Cell Differentiation; Cell Nucleus; Chromans; Dimerization; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypoglycemic Agents; Mice; Pioglitazone; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Receptors, Cytoplasmic and Nuclear; RNA Stability; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Troglitazone; Up-Regulation | 2001 |
Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Pulmonary edema associated with rosiglitazone and troglitazone.
Topics: Aged; Chromans; Diabetes Mellitus, Type 2; Humans; Male; Pulmonary Edema; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Vasodilator Agents | 2001 |
The hormone resistin links obesity to diabetes.
Topics: 3T3 Cells; Adipocytes; Amino Acid Sequence; Animals; Base Sequence; Chromosomes, Human, Pair 19; Cloning, Molecular; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet; DNA; Female; Gene Expression Regulation; Glucose Intolerance; Hormones; Hormones, Ectopic; Humans; Hypoglycemic Agents; Insulin Antagonists; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Nerve Growth Factor; Neutralization Tests; Obesity; Proteins; Resistin; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones | 2001 |
15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells.
Topics: Agar; Arachidonate 15-Lipoxygenase; Blotting, Northern; Catalysis; Cell Division; Culture Media; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Hydroxyeicosatetraenoic Acids; Isoenzymes; Luciferases; Male; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured | 2001 |
Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an extracellular signal-regulated kinase-independent pathway.
Topics: Animals; Apoptosis; Cells, Cultured; Chromans; Fibrinolytic Agents; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Rats; Rats, Inbred WKY; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Anticipated US approval for rosiglitazone and pioglitazone.
Topics: Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; United States; United States Food and Drug Administration | 1999 |
Rosiglitazone.
Topics: Humans; Hypoglycemic Agents; Liver; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones | 2000 |
The failings of NICE. NICE's guidance suggests using rosiglitazone in type 2 diabetes later than is ideal.
Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Rosiglitazone; Technology Assessment, Biomedical; Thiazoles; Thiazolidinediones; United Kingdom | 2001 |
Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.
Topics: Aging; Animals; Cataract; Diabetes Mellitus, Type 2; Glucagon; Hyperglycemia; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Pancreas; Proteinuria; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness; Thirst; Time Factors | 2000 |
Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells.
Topics: Animals; Cell Nucleus; Cells, Cultured; Chromans; Cytoplasm; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; DNA; Dose-Response Relationship, Drug; Fibrinolysin; Glomerular Mesangium; Matrix Metalloproteinase Inhibitors; Plasminogen Activator Inhibitor 1; Platelet-Derived Growth Factor; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aorta; Arteriosclerosis; Blood Glucose; Body Weight; Cell Movement; Cells, Cultured; Chemokine CCL2; Chromans; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Endothelium, Vascular; Flavonoids; Fructose; Humans; Insulin; Lipids; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Monocytes; Receptors, LDL; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured; Vasodilator Agents | 2001 |
Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation.
Topics: Adipocytes; Adipose Tissue; Cell Differentiation; Cell Division; Cells, Cultured; Female; Gene Expression; Glypicans; Growth Disorders; Heparan Sulfate Proteoglycans; Humans; Infant; Insulin; Karyotyping; Leptin; Male; Models, Biological; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Syndrome; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Production of matrix metalloproteinase-9 in CaCO-2 cells in response to inflammatory stimuli.
Topics: Caco-2 Cells; Humans; Inflammation Mediators; Inflammatory Bowel Diseases; Interleukin-1; Lipopolysaccharides; Matrix Metalloproteinase 9; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha; Up-Regulation | 2001 |
Rosiglitazone, insulin treatment, and fasting correct defective activation of protein kinase C-zeta/lambda by insulin in vastus lateralis muscles and adipocytes of diabetic rats.
Topics: Adipocytes; Animals; Blotting, Western; Diabetes Mellitus, Type 2; Enzyme Activators; Fasting; Hypoglycemic Agents; Insulin; Isoenzymes; Mice; Muscle, Skeletal; Phosphatidylinositol 3-Kinases; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Automated high-performance liquid chromatography method for the determination of rosiglitazone in human plasma.
Topics: Automation; Chromatography, High Pressure Liquid; Humans; Hypoglycemic Agents; Reference Standards; Reproducibility of Results; Rosiglitazone; Sensitivity and Specificity; Spectrometry, Fluorescence; Thiazoles; Thiazolidinediones | 2001 |
Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.
Topics: Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Experimental; Disease Models, Animal; Gene Expression; Glucose Tolerance Test; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Liver; Male; Muscle, Skeletal; Nicotinic Acids; Obesity; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Guidance on rosiglitazone for type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; England; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Practice Guidelines as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3 Cells; Adipocytes; Animals; Cycloheximide; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Gene Expression Regulation, Enzymologic; Hydroxysteroid Dehydrogenases; Kinetics; Leptin; Ligands; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic | 2001 |
Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists.
Topics: Animals; Binding Sites; Binding, Competitive; CD36 Antigens; Cell Line; DNA-Binding Proteins; Genes, Reporter; Humans; In Vitro Techniques; Kinetics; Ligands; Lipoproteins, LDL; Monocytes; Oxidation-Reduction; Phosphatidylcholines; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection | 2001 |
Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies.
Topics: Animals; Colitis; Dimerization; Drug Synergism; Mice; Mice, Mutant Strains; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Trinitrobenzenesulfonic Acid | 2001 |
What caused this patient's sudden liver dysfunction?
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
A comprehensive review of the antidiabetic agent rosiglitazone.
Topics: Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
Differential effects of 15-deoxy-delta(12,14)-prostaglandin J2 and a peroxisome proliferator-activated receptor gamma agonist on macrophage activation.
Topics: Animals; Cyclopentanes; DNA-Binding Proteins; Enzyme Activation; Epoprostenol; I-kappa B Proteins; Lipopolysaccharides; Macrophage Activation; Macrophages, Peritoneal; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; NF-KappaB Inhibitor alpha; Nitric Oxide; Phosphorylation; Prostaglandin D2; Protein Processing, Post-Translational; Rats; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Thromboxane B2; Transcription Factors; Tumor Necrosis Factor-alpha | 2001 |
Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death.
Topics: Aging; Animals; Blood Glucose; Body Weight; Cell Death; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Obesity; Organ Size; Pancreas; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Troglitazone induces GLUT4 translocation in L6 myotubes.
Topics: Animals; Biological Transport; Cell Line; Cell Membrane; Chromans; Cycloheximide; Deoxyglucose; Gene Expression Regulation; Glucose Transporter Type 1; Glucose Transporter Type 3; Glucose Transporter Type 4; Insulin; Kinetics; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Nerve Tissue Proteins; Protein Transport; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone | 2001 |
Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Fasting; Fatty Acids, Nonesterified; Glucose Clamp Technique; Humans; Hyperinsulinism; Hypertriglyceridemia; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Kinetics; Lipid Mobilization; Lipoproteins, VLDL; Liver; Male; Metabolic Clearance Rate; Muscle, Skeletal; Obesity; Oxidation-Reduction; Polyethylene Glycols; Postprandial Period; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides | 2001 |
Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor-gamma by flavonoids in mouse macrophages.
Topics: Animals; Apigenin; Binding, Competitive; Cell Line; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Flavonoids; Genes, Reporter; Kaempferols; Macrophages; Mice; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Promoter Regions, Genetic; Prostaglandin-Endoperoxide Synthases; Protein Binding; Quercetin; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Induction of CD36 by all-trans retinoic acid: retinoic acid receptor signaling in the pathogenesis of atherosclerosis.
Topics: Arteriosclerosis; CD36 Antigens; Cell Line; Cells, Cultured; Fibrinolytic Agents; Gene Expression Regulation; Humans; Lipoproteins, LDL; Monocytes; Muscle, Smooth, Vascular; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Tretinoin | 2001 |
Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Northern; Carcinoma, Papillary; Cell Division; Chromans; Humans; Male; Mice; Mice, Inbred BALB C; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Thymidine; Thyroid Neoplasms; Transcription Factors; Troglitazone; Tumor Cells, Cultured | 2001 |
Response of experimental retinal neovascularization to thiazolidinediones.
Topics: Animals; Blotting, Western; Cattle; Cell Division; Cell Movement; Chromans; Endothelial Growth Factors; Endothelium, Vascular; Fluorescein Angiography; Hypoglycemic Agents; Immunoenzyme Techniques; Injections; Lymphokines; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Models, Animal; Phosphorylation; Retinal Ganglion Cells; Retinal Neovascularization; Retinal Vessels; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Rosiglitazone and type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
A high-capacity screen for adipogenic differentiation.
Topics: Adipocytes; Cell Differentiation; Cells, Cultured; Glyceraldehyde-3-Phosphate Dehydrogenases; Hypoglycemic Agents; NAD; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Spectrophotometry, Ultraviolet; Thiazoles; Thiazolidinediones; Transcription Factors; Transforming Growth Factor beta; Transforming Growth Factor beta3 | 2001 |
Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists.
Topics: Adipocytes; Animals; Benzophenones; Down-Regulation; Hormones, Ectopic; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Male; Mice; Nerve Growth Factor; Obesity; Proteins; Rats; Receptors, Cytoplasmic and Nuclear; Resistin; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tyrosine | 2001 |
The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance.
Topics: 3T3 Cells; Adipocytes; Animals; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Cell Division; Cell Nucleus; DNA-Binding Proteins; HIV Protease Inhibitors; Indinavir; Insulin; Insulin Resistance; Mice; Rosiglitazone; Stem Cells; Sterol Regulatory Element Binding Protein 1; Thiazoles; Thiazolidinediones; Time Factors; Tissue Distribution; Transcription Factors | 2001 |
Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Genes, Tumor Suppressor; Humans; Phosphoric Monoester Hydrolases; Pioglitazone; PTEN Phosphohydrolase; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins; Up-Regulation | 2001 |
The expression of the p85alpha subunit of phosphatidylinositol 3-kinase is induced by activation of the peroxisome proliferator-activated receptor gamma in human adipocytes.
Topics: Adipocytes; Adipose Tissue; Cells, Cultured; Gene Expression Regulation; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Insulin Receptor Substrate Proteins; Kinetics; Monosaccharide Transport Proteins; Muscle Proteins; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Protein Serine-Threonine Kinases; Protein Subunits; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic | 2001 |
Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells.
Topics: Apoptosis; Cell Line; Cyclooxygenase 2; Gastric Mucosa; Helicobacter pylori; Humans; Isoenzymes; Membrane Proteins; NF-kappa B; Prostaglandin-Endoperoxide Synthases; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Species Specificity; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Accurate mass liquid chromatography/mass spectrometry on quadrupole orthogonal acceleration time-of-flight mass analyzers using switching between separate sample and reference sprays. 2. Applications using the dual-electrospray ion source.
Topics: Calibration; Cimetidine; Indicators and Reagents; Rosiglitazone; Spectrometry, Mass, Electrospray Ionization; Thiazoles; Thiazolidinediones | 2001 |
Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes.
Topics: alpha-Tocopherol; Animals; Cells, Cultured; Chromans; Gene Expression; Hypoglycemic Agents; Muscle, Smooth, Vascular; Pioglitazone; Promoter Regions, Genetic; Rats; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Cytoplasmic and Nuclear; Receptors, Thromboxane; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone | 2001 |
Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells.
Topics: Adenocarcinoma; Colorectal Neoplasms; Cyclooxygenase 2; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Isoenzymes; Ligands; Membrane Proteins; Models, Biological; Prostaglandin-Endoperoxide Synthases; Pyrimidines; Receptor Cross-Talk; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2001 |
Comparison of adipose tissue changes following administration of rosiglitazone in the dog and rat.
Topics: Adipose Tissue; Adipose Tissue, Brown; Animals; Dogs; Dose-Response Relationship, Drug; Female; Hypoglycemic Agents; Intubation, Gastrointestinal; Male; Microscopy, Electron; Rats; Rats, Sprague-Dawley; Rosiglitazone; Sex Factors; Thiazoles; Thiazolidinediones | 2001 |
Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia.
Topics: Animals; Body Weight; Carrier Proteins; Eating; Food Deprivation; Hyperphagia; Hypoglycemic Agents; Hypothalamus; Insulin Resistance; Ion Channels; Leptin; Male; Mitochondrial Proteins; Neuropeptide Y; Obesity; Rats; Rats, Wistar; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Uncoupling Protein 3 | 2001 |
RGS2 promotes adipocyte differentiation in the presence of ligand for peroxisome proliferator-activated receptor gamma.
Topics: 3T3 Cells; Adipocytes; Animals; Blotting, Northern; Cell Differentiation; Ligands; Mice; Plasmids; Receptors, Cytoplasmic and Nuclear; RGS Proteins; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Vasodilator Agents | 2001 |
Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle.
Topics: Analysis of Variance; Animals; Barium; Calcium; Chromans; Dose-Response Relationship, Drug; Electric Stimulation; Female; Guinea Pigs; Humans; Insulin Resistance; Ion Channels; Isoxazoles; Membrane Potentials; Muscle, Smooth, Vascular; Pioglitazone; Potassium Channels; Prostaglandin D2; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Peroxisome proliferator-activated receptor-gamma-independent inhibition of macrophage activation by the non-thiazolidinedione agonist L-796,449. Comparison with the effects of 15-deoxy-delta(12,14)-prostaglandin J(2).
Topics: Anions; Apoptosis; Benzofurans; Blotting, Northern; Blotting, Western; Cell Nucleus; Chloramphenicol O-Acetyltransferase; Cytosol; Dose-Response Relationship, Drug; Flow Cytometry; Genes, Reporter; Glutathione Transferase; I-kappa B Kinase; Immunohistochemistry; Kinetics; Ligands; Macrophage Activation; Macrophages; Microscopy, Confocal; NF-kappa B; Nitric Oxide; Phenylacetates; Plasmids; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Transfection | 2001 |
TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27.
Topics: Animals; Becaplermin; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cell Division; Cells, Cultured; Culture Media, Serum-Free; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; DNA; Enzyme Inhibitors; Muscle, Smooth, Vascular; Oligonucleotides, Antisense; Platelet-Derived Growth Factor; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-sis; Rats; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Suppressor Proteins | 2001 |
Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth.
Topics: Animals; Aorta, Thoracic; Blotting, Western; Cell Division; Chromans; DNA; Enzyme Activation; Hypoglycemic Agents; JNK Mitogen-Activated Protein Kinases; Kinetics; Lipoproteins, LDL; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Inbred WKY; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Troglitazone | 2001 |
Rosiglitazone (Avandia): hepatic, cardiac and hematological reactions.
Topics: Aged; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Female; Hematologic Diseases; Humans; Hypoglycemic Agents; Liver Failure; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Avandia, a leading alternative for Rezulin patients, prescribed to more than 700,000 patients.
Topics: Chromans; Consumer Product Safety; Diabetes Mellitus, Type 2; Drug Industry; Humans; Hypoglycemic Agents; Liver; Liver Function Tests; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; United States | 2000 |
How can anti-diabetics suppress tumours?
Topics: Humans; Hypoglycemic Agents; Neoplasms; Phosphoric Monoester Hydrolases; PTEN Phosphohydrolase; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Suppressor Proteins | 2001 |
Effects of retinoids and thiazolidinediones on proliferation, insulin release, insulin mRNA, GLUT 2 transporter protein and mRNA of INS-1 cells.
Topics: Alitretinoin; Animals; Binding Sites; Blotting, Northern; Blotting, Western; Cell Division; Cell Line; DNA-Binding Proteins; Dose-Response Relationship, Drug; Glucose; Glucose Transporter Type 2; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Monosaccharide Transport Proteins; Proinsulin; Protein Precursors; Receptors, Retinoic Acid; Retinoic Acid Receptor gamma; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Tretinoin | 2001 |
Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.
Topics: Animals; Chromans; Diabetes Mellitus; Fatty Liver; Gene Expression; Hypoglycemic Agents; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Obesity; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Up-Regulation | 2001 |
PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease.
Topics: Animals; Anti-Inflammatory Agents; Chromans; Colitis, Ulcerative; Crohn Disease; Disease Models, Animal; Inflammation; Intestines; Ligands; Mice; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice.
Topics: Adiponectin; Adrenergic beta-Agonists; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Hormones, Ectopic; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Mice; Mice, Obese; Nerve Growth Factor; Phenethylamines; Protein Biosynthesis; Proteins; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Resistin; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2001 |
[ACE inhibitor plus glitazone. Insulin sensitizer, preventing diabetes?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Insulin Resistance; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Trans-10, cis-12, but not cis-9, trans-11, conjugated linoleic acid attenuates lipogenesis in primary cultures of stromal vascular cells from human adipose tissue.
Topics: Adipose Tissue; Blood Vessels; Cells, Cultured; Dose-Response Relationship, Drug; Glucose; Humans; Linoleic Acid; Lipids; Lipolysis; Osmolar Concentration; Rosiglitazone; Stereoisomerism; Stromal Cells; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
Interaction between peroxisome proliferator-activated receptor gamma and its agonists: docking study of oximes having 5-benzyl-2,4-thiazolidinedione.
Topics: Hypoglycemic Agents; Ligands; Models, Molecular; Molecular Conformation; Molecular Structure; Oximes; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation.
Topics: 3T3 Cells; Adenoviridae; Adipocytes; Animals; Benzophenones; Cell Membrane; Drug Synergism; Gene Expression; Glucose; Glucose Transporter Type 1; Glucose Transporter Type 4; Green Fluorescent Proteins; Hypoglycemic Agents; Insulin; Luminescent Proteins; Mice; Monosaccharide Transport Proteins; Muscle Proteins; Mutation; Oxazoles; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection; Tyrosine | 2001 |
Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes.
Topics: 3T3 Cells; Adipose Tissue; Animals; Benzhydryl Compounds; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Epoxy Compounds; Fatty Acids; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Leptin; Mice; Mice, Knockout; Nicotinic Acids; Obesity; Receptors, Adrenergic, beta-3; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Inhibition of myogenesis enables adipogenic trans-differentiation in the C2C12 myogenic cell line.
Topics: Adipocytes; Biomarkers; Cell Differentiation; Cell Line; Chromones; Enzyme Inhibitors; MAP Kinase Kinase 3; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Morpholines; Muscle Development; Muscles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein-Tyrosine Kinases; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Vasodilator Agents | 2001 |
Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells.
Topics: Chemokine CCL4; Chemokine CCL5; Chemokine CXCL10; Chemokines, CXC; Dendritic Cells; Humans; Interleukin-12; Macrophage Inflammatory Proteins; Monocytes; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Th1 Cells; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Peroxisome proliferator-activated receptor gamma ligands inhibit mitogenic induction of p21(Cip1) by modulating the protein kinase Cdelta pathway in vascular smooth muscle cells.
Topics: Acetophenones; Adenoviridae; Animals; Aorta, Thoracic; Apoptosis; Benzopyrans; Blotting, Western; Carbazoles; Cell Division; Cells, Cultured; Chromans; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cycloheximide; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; Hydroquinones; Indoles; Insulin; Isoenzymes; Kinetics; Ligands; Mice; Mitogens; Models, Biological; Muscle, Smooth, Vascular; Phosphorylation; Platelet-Derived Growth Factor; Precipitin Tests; Protein Kinase C; Protein Kinase C-delta; Protein Processing, Post-Translational; Protein Synthesis Inhibitors; Protein Tyrosine Phosphatases; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; RNA; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Troglitazone; Tyrosine; Up-Regulation; Vanadates | 2001 |
[Glitazones--a new therapeutic principle in diabetes].
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Rosiglitazone (BRL 49653) enhances insulin secretory response via phosphatidylinositol 3-kinase pathway.
Topics: Animals; Dose-Response Relationship, Drug; Drug Synergism; Glucose; Hypoglycemic Agents; In Vitro Techniques; Insulin; Insulin Secretion; Male; Phosphatidylinositol 3-Kinases; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity.
Topics: Adipocytes; Amino Acids; Animals; Binding Sites; Blood Glucose; Body Weight; Cell Differentiation; Cell Line; Dose-Response Relationship, Drug; Fluorenes; Gene Expression Regulation; Genes, Reporter; Hypoglycemic Agents; Insulin Resistance; Leucine; Ligands; Male; Mice; Mice, Inbred Strains; Molecular Structure; Protein Binding; Protein Conformation; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Spectrometry, Mass, Electrospray Ionization; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Tyrosine | 2001 |
Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Administration, Oral; Animals; Blood Glucose; Body Weight; Glucose; Glucose Clamp Technique; Glucose Transporter Type 1; Glucose Transporter Type 4; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Thinness | 2001 |
Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Insulin; Ovulation; Polycystic Ovary Syndrome; Pregnancy; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Liver failure in a patient treated with long-term rosiglitazone therapy.
Topics: Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Humans; Hypoglycemic Agents; Liver Failure; Male; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration.
Topics: Animals; Aortic Diseases; Cell Adhesion; Cell Movement; Cell Nucleus; Cells, Cultured; Chromans; Cytosol; Enzyme Inhibitors; Graft Occlusion, Vascular; Ligands; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Proto-Oncogene Protein c-ets-1; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ets; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Troglitazone | 2001 |
In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
Topics: Animals; CD18 Antigens; Cell Adhesion Molecules; Chemokine CCL2; Diabetes Complications; Hypoglycemic Agents; Macrophage-1 Antigen; Macrophages; Male; Monocytes; Myocardial Contraction; Myocardial Infarction; Myocardial Reperfusion Injury; Neutrophil Infiltration; Neutrophils; Rats; Rats, Inbred Lew; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
Glitazones, glycemia, and global health status.
Topics: Blood Glucose; Health Status; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Gain | 2001 |
A single element in the phosphoenolpyruvate carboxykinase gene mediates thiazolidinedione action specifically in adipocytes.
Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Animals; Carcinoma, Hepatocellular; Gene Expression; Hypoglycemic Agents; Male; Mice; Phosphoenolpyruvate Carboxykinase (GTP); Promoter Regions, Genetic; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Repetitive Sequences, Nucleic Acid; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection; Tumor Cells, Cultured | 2001 |
Nonhypoglycemic effects of thiazolidinediones.
Topics: Adipocytes; Humans; Hypoglycemic Agents; Osteogenesis; Osteoporosis; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
PPARgamma agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells.
Topics: Animals; Blotting, Northern; Blotting, Western; Cell Division; Cell Line; Cell Line, Transformed; Cell Nucleus; Chromans; Cyclin D1; DNA, Complementary; Dose-Response Relationship, Drug; Epidermal Growth Factor; Epithelial Cells; Flow Cytometry; Humans; Hypoglycemic Agents; Intestines; Ligands; Luciferases; Plasmids; Promoter Regions, Genetic; ras Proteins; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transfection; Troglitazone | 2001 |
Thiazolidinediones influence plasma steroids of male obese Zucker rats.
Topics: Animals; Blood Glucose; Body Weight; Chromans; Glucose; Hormones; Insulin; Male; Muscle, Skeletal; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling.
Topics: Adipocytes; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Differentiation; Cell Division; COS Cells; Diclofenac; Drug Interactions; Fibrinolytic Agents; Humans; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured | 2002 |
PPARgamma-dependent and PPARgamma-independent effects on the development of adipose cells from embryonic stem cells.
Topics: Adipocytes; Animals; Biomarkers; Cell Differentiation; Cell Lineage; Cells, Cultured; Gene Expression; HMGA2 Protein; Lipoprotein Lipase; Mice; Mice, Inbred C57BL; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Stem Cells; Thiazoles; Thiazolidinediones; Transcription Factors; Tretinoin | 2002 |
[Infarct prevention for diabetics. To lower blood sugar is not enough].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fibrinolytic Agents; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Vasodilator Agents | 2001 |
An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis.
Topics: Adult; Aged; Colitis, Ulcerative; Colonoscopy; Female; Humans; Ligands; Male; Middle Aged; Prospective Studies; Receptors, Cytoplasmic and Nuclear; Remission Induction; Rosiglitazone; Severity of Illness Index; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
15-deoxy-delta12,14-prostaglandin J2-induced apoptosis in amnion-like WISH cells.
Topics: Amino Acid Chloromethyl Ketones; Amnion; Apoptosis; Caspase Inhibitors; Caspases; Cell Survival; Cells, Cultured; Cysteine Proteinase Inhibitors; Enzyme Activation; Humans; Hypoglycemic Agents; Immunologic Factors; Ligands; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors | 2001 |
PPARgamma is not a critical mediator of primary monocyte differentiation or foam cell formation.
Topics: ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; CD36 Antigens; Cell Differentiation; Cells, Cultured; DNA-Binding Proteins; Dose-Response Relationship, Drug; Flow Cytometry; Foam Cells; Humans; Interleukin-6; Ligands; Light; Lipoproteins, LDL; Liver X Receptors; Macrophages; Matrix Metalloproteinase 9; Monocytes; Nicotinic Acids; Oligonucleotides, Antisense; Orphan Nuclear Receptors; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Scattering, Radiation; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy.
Topics: Adipocytes; Cell Differentiation; Cells, Cultured; Connective Tissue; Fibroblasts; Flow Cytometry; Graves Disease; Humans; Immunohistochemistry; Orbit; Phenotype; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Thy-1 Antigens; Transcription Factors | 2002 |
Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Chromans; DNA Fragmentation; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured | 2001 |
In vitro metabolite identification using fast gradient high performance liquid chromatography combined with tandem mass spectrometry.
Topics: Animals; Biotransformation; Chromatography, High Pressure Liquid; Dealkylation; Haplorhini; Hydrolysis; Hypoglycemic Agents; In Vitro Techniques; Mass Spectrometry; Microsomes, Liver; Pharmaceutical Preparations; Rats; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein.
Topics: Base Sequence; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; DNA Primers; Enzyme Induction; Humans; Immunohistochemistry; Isoenzymes; Lipoproteins, LDL; Membrane Proteins; Monocytes; Nitrobenzenes; Oxidation-Reduction; Phospholipids; Prostaglandin-Endoperoxide Synthases; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sulfonamides; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure.
Topics: Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
Topics: Animals; Blood Glucose; Carbazoles; Cholesterol; Cholesterol, Dietary; Crystallography, X-Ray; Drug Evaluation, Preclinical; Glucose Tolerance Test; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Models, Molecular; Nuclear Proteins; Phenylpropionates; Pioglitazone; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2002 |
[Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Approval; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Peroxisome proliferator-activated receptor gamma activators inhibit MMP-1 production in human synovial fibroblasts likely by reducing the binding of the activator protein 1.
Topics: Aged; Blotting, Northern; Cells, Cultured; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Gene Expression; Humans; Interleukin-1; Matrix Metalloproteinase 1; Promoter Regions, Genetic; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Synovial Membrane; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic | 2002 |
Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists.
Topics: Adipocytes; Adult; Aged; Cell Differentiation; Female; Gene Expression; Humans; Hypoglycemic Agents; Ligands; Male; Middle Aged; Nicotinic Acids; Omentum; Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Skin; Stem Cells; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.
Topics: Adipocytes; Adipose Tissue; Blood Glucose; Body Composition; Calorimetry, Indirect; Diabetes Mellitus, Type 2; Fatty Acids; Glucose Clamp Technique; Glycated Hemoglobin; Glycerol; Humans; Hyperinsulinism; Insulin; Kinetics; Lipids; Lipolysis; Liver; Magnetic Resonance Spectroscopy; Microdialysis; Middle Aged; Muscle, Skeletal; Oxidation-Reduction; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2002 |
[A case report. Rosiglitazone treatment was highly effective yet had to be terminated].
Topics: Administration, Oral; Contraindications; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Rosiglitazone treatment of patients with extreme insulin resistance and diabetes mellitus due to insulin receptor mutations has no effects on glucose and lipid metabolism.
Topics: Adolescent; Adult; Apolipoproteins B; Body Mass Index; Diabetes Complications; Diabetes Mellitus; Fatty Acids, Nonesterified; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mutation; Plasminogen Activator Inhibitor 1; Receptor, Insulin; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2001 |
Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.
Topics: Actins; Angiotensin II; Animals; Atrial Natriuretic Factor; Body Weight; Cardiomegaly; Cell Size; Cells, Cultured; Chromans; Disease Models, Animal; Gene Expression; Heart; Heterozygote; Hypoglycemic Agents; Ligands; Mice; Mice, Knockout; Myocardium; Organ Size; Pioglitazone; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
Mechanisms regulating adipocyte expression of resistin.
Topics: Adipocytes; Animals; Base Sequence; Binding Sites; Blotting, Northern; CCAAT-Enhancer-Binding Protein-alpha; Cell Line; Chromatin; CREB-Binding Protein; Dose-Response Relationship, Drug; Down-Regulation; E1A-Associated p300 Protein; Fibrinolytic Agents; Gene Expression Regulation; Genetic Vectors; Histones; Hormones, Ectopic; Humans; Intercellular Signaling Peptides and Proteins; Introns; Kinetics; Ligands; Mice; Molecular Sequence Data; Nerve Growth Factor; Nuclear Proteins; Precipitin Tests; Promoter Regions, Genetic; Protein Binding; Proteins; Resistin; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Trans-Activators; Transcription, Genetic; Transfection | 2002 |
Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor.
Topics: Adult; Aged; Arginine; Cardiovascular Diseases; Cross-Sectional Studies; Enzyme Inhibitors; Female; Humans; Hypertension; Hypoglycemic Agents; Lipoproteins; Male; Metabolic Diseases; Metabolic Syndrome; Middle Aged; Nitric Oxide Synthase; Regression Analysis; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Vasodilator Agents | 2002 |
Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation.
Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Animals; Blotting, Northern; Cell Differentiation; Cell Line; DNA Primers; Enzymes; Gene Expression Profiling; Gene Expression Regulation; Humans; Hypoglycemic Agents; Insulin; Kidney; Liver; Mice; Muscle, Skeletal; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Proteins; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic | 2002 |
A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Dose-Response Relationship, Drug; Energy Intake; Energy Metabolism; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Mice; Mice, Mutant Strains; Organic Chemicals; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Heart; Heart Rate; Hypoglycemic Agents; Insulin Resistance; Myocardial Ischemia; Myocardial Reperfusion; Obesity; Organ Size; Perfusion; Rats; Rats, Zucker; Reference Values; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors | 2002 |
[Type 2 diabetes. How can the infarction risk be reduced?].
Topics: Acarbose; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Pioglitazone; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Vasodilator Agents | 2002 |
PPAR-gamma decreases endometrial stromal cell transcription and translation of RANTES in vitro.
Topics: Adult; Cells, Cultured; Chemokine CCL5; Endometrium; Female; Humans; Ligands; Protein Biosynthesis; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Stromal Cells; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic | 2002 |
PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.
Topics: Anti-Inflammatory Agents; Arteriosclerosis; CD4-Positive T-Lymphocytes; Cells, Cultured; Fenofibrate; Graft Survival; Heart Transplantation; Humans; Interferon-gamma; Interleukin-2; Lymphocyte Activation; Peroxisome Proliferators; Pioglitazone; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha | 2002 |
Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Sample Size; Thiazoles; Thiazolidinediones | 2002 |
Cbl, IRS-1, and IRS-2 mediate effects of rosiglitazone on PI3K, PKC-lambda, and glucose transport in 3T3/L1 adipocytes.
Topics: 3T3 Cells; Adipocytes; Animals; Antimetabolites; Biological Transport, Active; Blotting, Western; Deoxyglucose; Enzyme Activation; Glucose; Insulin; Insulin Receptor Substrate Proteins; Intracellular Signaling Peptides and Proteins; Isoenzymes; Mice; Phosphatidylinositol 3-Kinases; Phosphoproteins; Protein Kinase C; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones | 2002 |
Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro.
Topics: Adipocytes; Adipose Tissue; Adult; Dose-Response Relationship, Drug; Drug Synergism; Female; Glycerol; Humans; Hypoglycemic Agents; In Vitro Techniques; Insulin; Lipolysis; Lipoprotein Lipase; Middle Aged; Norepinephrine; Rosiglitazone; Sterol Esterase; Sympathomimetics; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2002 |
Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury.
Topics: Animals; Cardiotonic Agents; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glucose Transporter Type 4; Hypoglycemic Agents; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Lactic Acid; Male; Mitogen-Activated Protein Kinases; Monosaccharide Transport Proteins; Muscle Proteins; Myocardial Reperfusion Injury; Myocardium; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Differential gene regulation by PPARgamma agonist and constitutively active PPARgamma2.
Topics: 3T3 Cells; Adipocytes; Animals; Cell Differentiation; Gene Expression Regulation; Herpes Simplex Virus Protein Vmw65; Hormones, Ectopic; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Mice; Nerve Growth Factor; Proteins; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Resistin; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic | 2002 |
Rosiglitazone monotherapy and type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Pregnancy; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.
Topics: AMP-Activated Protein Kinases; Animals; Catalysis; Enzyme Activation; Hypoglycemic Agents; Metformin; Mice; Mice, Transgenic; Multienzyme Complexes; Phosphorylation; Protein Serine-Threonine Kinases; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones | 2002 |
Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts.
Topics: Adipocytes; Cell Differentiation; Cell Division; Cells, Cultured; Fibroblasts; Graves Disease; Humans; Orbit; Receptors, Cytoplasmic and Nuclear; Receptors, Thyrotropin; RNA, Messenger; Rosiglitazone; Stem Cells; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Induction of adipocyte differentiation by a thiazolidinedione in cultured, subepidermal, fibroblast-like cells of an infant with congenital generalized lipodystrophy.
Topics: Adipocytes; Cell Differentiation; Cells, Cultured; Epidermis; Fibroblasts; Gene Expression; Humans; Infant, Newborn; Leptin; Lipids; Lipodystrophy; Male; Rosiglitazone; Stem Cells; Thiazoles; Thiazolidinediones | 2002 |
Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Blood Vessels; Body Weight; Cell Cycle Proteins; Cell Division; Collagen; DNA; Drug Administration Schedule; Endothelium, Vascular; In Vitro Techniques; Inflammation; Injections, Subcutaneous; Lipids; Male; NF-kappa B; Pioglitazone; Platelet Endothelial Cell Adhesion Molecule-1; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Receptors, Cytoplasmic and Nuclear; Renin; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Vascular Cell Adhesion Molecule-1; Vasoconstrictor Agents; Vasodilator Agents | 2002 |
The gene encoding the Acyl-CoA-binding protein is activated by peroxisome proliferator-activated receptor gamma through an intronic response element functionally conserved between humans and rodents.
Topics: 3T3 Cells; Adipocytes; Animals; Base Sequence; Blotting, Northern; Blotting, Western; Cell Differentiation; Cell Nucleus; Chromatin; Cross-Linking Reagents; Diazepam Binding Inhibitor; Fibrinolytic Agents; Gene Expression Regulation; Genes, Reporter; Humans; Introns; Ligands; Liver; Mice; Mice, Inbred C57BL; Molecular Sequence Data; Plasmids; Polymerase Chain Reaction; Precipitin Tests; Rats; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors | 2002 |
Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists.
Topics: 3T3 Cells; Adipocytes; Algorithms; Animals; beta Catenin; Blotting, Western; Cell Differentiation; Cells, Cultured; Cytoskeletal Proteins; Gene Expression Regulation; Hypoglycemic Agents; In Situ Hybridization; Lipid Metabolism; Mice; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Oligonucleotide Probes; Phenotype; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Trans-Activators; Transcription Factors | 2002 |
Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells.
Topics: Animals; Cell Division; Cell Transformation, Neoplastic; Cyclooxygenase 2; Enzyme Induction; Epoprostenol; Genes, ras; Intestinal Mucosa; Intestines; Isoenzymes; Mitogen-Activated Protein Kinases; Prostaglandin-Endoperoxide Synthases; Protein Isoforms; ras Proteins; Rats; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster.
Topics: Animal Nutritional Physiological Phenomena; Animals; Apolipoproteins B; Cricetinae; Fructose; Hepatocytes; Hypoglycemic Agents; Immunoblotting; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Lipoproteins, VLDL; Liver; Male; Mesocricetus; Microsomes, Liver; Perfusion; Phosphoproteins; Phosphorylation; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides | 2002 |
Prostaglandin D2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of I kappa B alpha degradation using a peroxisome proliferator-activated receptor-gamma-independent mechanism.
Topics: Apoptosis; Binding Sites; Caspases; Cell Death; Cells, Cultured; Dinoprost; DNA-Binding Proteins; Enzyme Activation; Eosinophils; Granulocytes; Humans; Hydrolysis; I-kappa B Proteins; Neutrophils; NF-kappa B; NF-KappaB Inhibitor alpha; Peroxisomes; Prostaglandin D2; Protein Biosynthesis; Receptors, Cytoplasmic and Nuclear; Receptors, Immunologic; Receptors, Prostaglandin; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.
Topics: Animals; Benzhydryl Compounds; Bile Ducts; Carbon Tetrachloride; Cell Division; Cells, Cultured; Collagen; Dimethylnitrosamine; DNA; Epoxy Compounds; Fibronectins; Hypoglycemic Agents; Ligation; Liver; Liver Cirrhosis; Male; Phenols; Pioglitazone; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival.
Topics: Animals; Cell Death; Cell Survival; Cells, Cultured; Humans; Hypoglycemic Agents; Interleukin-3; Lymphocyte Activation; Membrane Potentials; Mice; Mice, Inbred C57BL; Mitochondria; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; T-Lymphocytes; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection; Up-Regulation | 2002 |
Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes.
Topics: Adipocytes; Adult; Aged; Body Mass Index; Cell Differentiation; Female; Glycerol; Humans; Hypoglycemic Agents; Leptin; Lipolysis; Male; Middle Aged; Norepinephrine; Obesity; Omentum; RNA, Messenger; Rosiglitazone; Skin; Thiazoles; Thiazolidinediones; Transcription, Genetic; Tumor Necrosis Factor-alpha | 2002 |
Normalization of skeletal muscle glycogen synthesis and glycolysis in rosiglitazone-treated Zucker fatty rats: an in vivo nuclear magnetic resonance study.
Topics: Animals; Disease Models, Animal; Gluconeogenesis; Glycolysis; Kinetics; Magnetic Resonance Spectroscopy; Models, Biological; Muscle, Skeletal; Obesity; Rats; Rats, Zucker; Reference Values; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.
Topics: Adult; Animals; Cardiotonic Agents; Cell Adhesion Molecules; Cell Line; Cells, Cultured; Chemokine CCL2; Clofibrate; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; Ligands; Male; Membrane Proteins; Myocardial Infarction; Myocardial Reperfusion Injury; Pioglitazone; Prostaglandin D2; Prostaglandins A; Protein Isoforms; Pyrimidines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
LC determination of rosiglitazone in bulk and pharmaceutical formulation.
Topics: Chromatography, Liquid; Hypoglycemic Agents; Pharmaceutical Preparations; Reference Standards; Reproducibility of Results; Rosiglitazone; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Thiazoles; Thiazolidinediones | 2002 |
Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes.
Topics: Adult; Aged; Body Mass Index; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Edema; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Activation of peroxisome proliferator-activated receptor gamma inhibits the growth of human pancreatic cancer.
Topics: Antineoplastic Agents; Cell Division; Chromans; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Humans; Pancreatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Cells, Cultured | 2001 |
Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone.
Topics: Alkaline Phosphatase; Chemical and Drug Induced Liver Injury; Cholestasis; Chromans; Female; Humans; Hypoglycemic Agents; Liver Function Tests; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Transaminases; Troglitazone | 2002 |
Potentiation of insulin signaling in tissues of Zucker obese rats after acute and long-term treatment with PPARgamma agonists.
Topics: Adipose Tissue; Animals; Fatty Acids, Nonesterified; Female; Insulin; Insulin Receptor Substrate Proteins; Kinetics; Liver; Muscle, Skeletal; Obesity; Phosphoproteins; Phosphorylation; Phosphoserine; Phosphotyrosine; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Zucker; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor gamma.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line; Cell Separation; Enzyme Inhibitors; Fibrinolytic Agents; Flow Cytometry; Humans; Inflammation; Interleukin 1 Receptor Antagonist Protein; Interleukin-1; Interleukin-6; Ligands; Monocytes; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Sialoglycoproteins; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Tretinoin; Tumor Necrosis Factor-alpha; Up-Regulation; Vitamin D | 2002 |
Efficient gene regulation by PPAR gamma and thiazolidinediones in skeletal muscle and heart.
Topics: Animals; Female; Gene Expression Regulation; Genes, Reporter; Heart; Humans; Kinetics; Luciferases; Male; Mice; Mice, Inbred C57BL; Mice, SCID; Muscle, Skeletal; Myocardium; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Rosiglitazone--useful drug but has side effects.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lipids; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Gain | 2002 |
Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy.
Topics: Animals; Arterial Occlusive Diseases; CD36 Antigens; Cell Line; Cells, Cultured; Cyclooxygenase 2; Drug Delivery Systems; Isoenzymes; Ligands; Male; Muscle, Smooth, Vascular; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tunica Intima; Tunica Media | 2002 |
Glitazones regulate glutamine metabolism by inducing a cellular acidosis in MDCK cells.
Topics: Acidosis; Alanine Transaminase; Animals; Cell Line; Chromans; Epithelial Cells; Glutamine; Hydrogen-Ion Concentration; Hypoglycemic Agents; Kidney; L-Lactate Dehydrogenase; Nitrogen; Nitrogen Isotopes; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; Chromans; Dose-Response Relationship, Drug; Fibrinolytic Agents; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Melanoma; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Skin Neoplasms; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Cells, Cultured | 2002 |
Effect of rosiglitazone on the differential expression of diabetes-associated proteins in pancreatic islets of C57Bl/6 lep/lep mice.
Topics: Animals; Electrophoresis, Gel, Two-Dimensional; Female; Glucose; Glucose Tolerance Test; Hypoglycemic Agents; Islets of Langerhans; Mice; Mice, Inbred C57BL; Mice, Obese; Phenotype; Protein Array Analysis; Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Rosiglitazone in the management of older patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Hemoglobins; Humans; Hypoglycemic Agents; Male; Middle Aged; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Stimulation of peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cell Line; Chromans; Fenofibrate; HIV-1; Humans; Leukocytes, Mononuclear; Macrophages, Alveolar; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone; Tumor Necrosis Factor-alpha; Virus Replication | 2002 |
[Severe electrolyte imbalance and edema in therapy with rosiglitazone].
Topics: Chemical and Drug Induced Liver Injury; Contraindications; Diabetes Mellitus, Type 2; Edema; Humans; Hypoglycemic Agents; Liver Diseases, Alcoholic; Liver Function Tests; Male; Middle Aged; Rosiglitazone; Thiazoles; Thiazolidinediones; Water-Electrolyte Imbalance | 2002 |
Lipopolysaccharide increases resistin gene expression in vivo and in vitro.
Topics: 3T3 Cells; Animals; Base Sequence; DNA Primers; Gene Expression Regulation; Hormones, Ectopic; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Lipopolysaccharides; Male; Mice; Nerve Growth Factor; Proteins; Rats; Rats, Wistar; Resistin; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors.
Topics: Adenosine Triphosphate; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Chemical and Drug Induced Liver Injury; Chromans; Coloring Agents; Female; Formazans; Glutathione; Hepatocytes; Humans; Hypoglycemic Agents; Infant; Liver Diseases; Male; Middle Aged; Neutral Red; Oxazines; Rosiglitazone; Sex Factors; Smoking; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Troglitazone; Xanthenes | 2002 |
Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Type 2; Gene Expression; Heart; Lipid Metabolism; Lipids; Liver; Male; Mice; Mice, Obese; Myocardium; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Weight Gain | 2002 |
A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity.
Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Adipose Tissue, Brown; Aged; Animals; Anti-Obesity Agents; Cell Differentiation; Epididymis; HeLa Cells; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Mice; Mice, Knockout; Molecular Structure; Organophosphorus Compounds; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Rosiglitazone and retinoic acid induce uncoupling protein-1 (UCP-1) in a p38 mitogen-activated protein kinase-dependent manner in fetal primary brown adipocytes.
Topics: Adipocytes; Adipose Tissue, Brown; Animals; Carrier Proteins; Cells, Cultured; Culture Media, Serum-Free; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Enzyme Activation; Enzyme Inhibitors; Fetus; Gene Expression Regulation; Genes, Reporter; Glutathione; Imidazoles; Ion Channels; Membrane Proteins; Mitochondrial Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Promoter Regions, Genetic; Rats; Rats, Wistar; Recombinant Fusion Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Tretinoin; Uncoupling Agents; Uncoupling Protein 1 | 2003 |
[Glinides and glitazones in diabetes treatment. Are they really effective?].
Topics: Carbamates; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones; Treatment Outcome | 2002 |
Rosiglitazone fails to improve hypertriglyceridemia and glucose tolerance in CD36-deficient BN.SHR4 congenic rat strain.
Topics: Adipocytes; Adipose Tissue; Administration, Oral; Animals; Body Composition; CD36 Antigens; Diet; Dietary Sucrose; Glucose Intolerance; Glucose Tolerance Test; Hypertriglyceridemia; Hypoglycemic Agents; Insulin; Male; Rats; Rats, Inbred BN; Rats, Inbred SHR; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
[Meta-analysis shows: insulin sensitizer is safe for the liver].
Topics: Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Retrospective Studies; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Triglycerides | 2002 |
Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter.
Topics: Animals; Anticholesteremic Agents; Base Sequence; Catalase; Dimerization; Free Radical Scavengers; Gene Deletion; Gene Expression; Molecular Sequence Data; Mutagenesis; Organic Chemicals; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Repetitive Sequences, Nucleic Acid; Response Elements; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection | 2002 |
Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone.
Topics: Adipocytes; Adiponectin; Adult; Aged; Aged, 80 and over; Body Mass Index; Cells, Cultured; Humans; Hypoglycemic Agents; Insulin; Intercellular Signaling Peptides and Proteins; Middle Aged; Omentum; Proteins; Rosiglitazone; Subcutaneous Tissue; Thiazoles; Thiazolidinediones | 2002 |
Peroxisome proliferator-activated receptor gamma and transforming growth factor-beta pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22.
Topics: Animals; Blotting, Northern; Blotting, Western; Cell Differentiation; Cell Division; Cell Line; COS Cells; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA; DNA, Complementary; Dose-Response Relationship, Drug; Epithelial Cells; Genes, Dominant; Genetic Vectors; Humans; In Situ Hybridization; Intermediate Filament Proteins; Intestines; Keratin-20; Ligands; Mutation; Oligonucleotide Array Sequence Analysis; Precipitin Tests; Protein Structure, Tertiary; Receptors, Cytoplasmic and Nuclear; Repressor Proteins; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Transcription, Genetic; Transfection; Transforming Growth Factor beta | 2003 |
Rosiglitazone treatment restores renal dopamine receptor function in obese Zucker rats.
Topics: Animals; Benzazepines; Binding, Competitive; Blood Glucose; Blood Pressure; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Down-Regulation; Epithelial Cells; Glucose; Hyperinsulinism; Hypoglycemic Agents; Insulin; Kidney; Kidney Tubules, Proximal; Male; Obesity; Rats; Rats, Zucker; Receptors, Dopamine D1; Rosiglitazone; Sodium-Potassium-Exchanging ATPase; Thiazoles; Thiazolidinediones | 2002 |
Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats.
Topics: Animals; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Eating; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glycated Hemoglobin; Glycogen; Hypoglycemic Agents; Insulin Resistance; Islets of Langerhans; Liver; Male; Oxazines; Phenylpropionates; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis.
Topics: Acute Disease; Animals; Antibody Formation; Antioxidants; Chromans; Colitis; Cytokines; Disease Models, Animal; Hypoglycemic Agents; Ligands; Mice; Mice, Inbred C57BL; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Th2 Cells; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2002 |
The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation.
Topics: 3T3 Cells; Adipocytes; Animals; Cell Differentiation; Gene Expression Regulation, Enzymologic; Genes, Reporter; Histone Deacetylases; Lipoprotein Lipase; Macromolecular Substances; Mice; Phosphorylation; Protein Binding; Protein Structure, Tertiary; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Retinoblastoma Protein; RNA, Messenger; Rosiglitazone; Signal Transduction; Stem Cells; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Differential regulation of lipogenesis and leptin production by independent signaling pathways and rosiglitazone during human adipocyte differentiation.
Topics: Adipocytes; Androstadienes; Cell Differentiation; Cell Survival; Cells, Cultured; Enzyme Inhibitors; Flavonoids; Humans; Imidazoles; Leptin; Lipid Metabolism; Lipids; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Pyridines; Rosiglitazone; Signal Transduction; Sirolimus; Stem Cells; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha; Wortmannin | 2003 |
Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats.
Topics: Adipose Tissue; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 2; Insulin Resistance; Lipid Metabolism; Liver; Longitudinal Studies; Magnetic Resonance Spectroscopy; Male; Muscle, Skeletal; Obesity; Organ Size; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators.
Topics: Base Sequence; Cell Differentiation; Cells, Cultured; Gene Expression Regulation; Hormones, Ectopic; Humans; Intercellular Signaling Peptides and Proteins; Macrophages; Monocytes; Polymerase Chain Reaction; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; Resistin; Response Elements; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Tissue Distribution; Transcription Factors; Up-Regulation | 2003 |
Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells.
Topics: Animals; Biological Transport; Cell Differentiation; Cells, Cultured; Culture Media, Serum-Free; Deoxyglucose; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Mice; Muscle, Skeletal; Myoblasts; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Pioglitazone; Receptor, Insulin; Rosiglitazone; Thiazoles; Thiazolidinediones; Tyrosine | 2003 |
Rosiglitazone improves insulin resistance, lipid profile and promotes adiposity in a genetic model of metabolic syndrome X.
Topics: Adipose Tissue; Animals; Disease Models, Animal; Glucose; Glucose Tolerance Test; Glycogen; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Metabolic Syndrome; Rats; Rats, Inbred Strains; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension.
Topics: Animals; Blood Pressure; Body Weight; Endothelin-1; Endothelins; Extracellular Matrix; Fenofibrate; Hypertension; In Vitro Techniques; Male; Mesenteric Arteries; Oxygen; Protein Precursors; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tunica Media; Vascular Resistance; Vasodilator Agents | 2003 |
Did this drug cause my patient's hepatitis?
Topics: Chemical and Drug Induced Liver Injury; Chromans; Humans; Pioglitazone; Product Surveillance, Postmarketing; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation.
Topics: Adipocytes; Animals; Blood Vessels; CCAAT-Enhancer-Binding Protein-beta; Cell Differentiation; Diet; Disease Models, Animal; Gene Expression Regulation, Enzymologic; Hypoglycemic Agents; Male; Matrix Metalloproteinase 12; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Matrix Metalloproteinases, Membrane-Associated; Matrix Metalloproteinases, Secreted; Metalloendopeptidases; Mice; Mice, Inbred AKR; Mice, Inbred C57BL; Mice, Obese; Mitosis; Obesity; Phenylalanine; Protease Inhibitors; RNA, Messenger; Rosiglitazone; Stromal Cells; Thiazoles; Thiazolidinediones; Thiophenes; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-3 | 2003 |
Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone.
Topics: 3T3 Cells; Adipocytes; Animals; Cell Differentiation; Insulin; Mice; Microscopy, Electron; Mitochondria; Mitochondrial Proteins; Oxygen Consumption; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Is programming of glucocorticoid receptor expression by prenatal dexamethasone in the rat secondary to metabolic derangement in adulthood?
Topics: Animals; Appetite; Body Weight; Corticosterone; Dexamethasone; Female; Gene Expression; Glucocorticoids; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Organ Size; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Receptors, Glucocorticoid; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model.
Topics: Animals; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Fibrinolytic Agents; Male; Mice; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2003 |
Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma.
Topics: Adipocytes; Dimerization; Enhancer Elements, Genetic; Fibrinolytic Agents; Gene Expression; Humans; Ligands; Liposarcoma; Luciferases; Mutagenesis; Promoter Regions, Genetic; Receptors, Cell Surface; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Receptors, Retinoic Acid; Response Elements; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured | 2003 |
PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly.
Topics: Animals; Dietary Fats; Fatty Liver; Glucose; Glucose Clamp Technique; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Muscle, Skeletal; Oxazines; Phenylpropionates; Pyrimidines; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice.
Topics: Animals; Antineoplastic Agents; Azoxymethane; Carcinogens; Chromans; Colon; Colonic Neoplasms; Female; Immunohistochemistry; Ligands; Mice; Mice, Inbred BALB C; Pioglitazone; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2003 |
A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs.
Topics: Aequorin; Animals; Calcium; Cell Line; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Genes, Reporter; Humans; Hypoglycemic Agents; Islets of Langerhans; Mice; Palmitic Acids; Receptors, Cell Surface; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Tissue Distribution | 2003 |
Diminished production of nitric oxide synthase cofactor tetrahydrobiopterin by rosiglitazone in adipocytes.
Topics: 3T3 Cells; Adipocytes; Animals; Biopterins; Hypoglycemic Agents; Mice; Nitric Oxide; Nitric Oxide Synthase; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia.
Topics: Animals; Anti-Inflammatory Agents; Astrocytes; Carrier Proteins; DNA-Binding Proteins; Gene Expression Regulation; Inflammation; Janus Kinase 1; Janus Kinase 2; Neuroglia; Phosphorylation; Prostaglandin D2; Protein Biosynthesis; Protein-Tyrosine Kinases; Proteins; Proto-Oncogene Proteins; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Repressor Proteins; Rosiglitazone; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Thiazoles; Thiazolidinediones; Trans-Activators; Transcription Factors | 2003 |
Regulation of uncoupling protein-2 mRNA in L6 myotubules: I: Thiazolidinediones stimulate uncoupling protein-2 gene expression by a mechanism requiring ongoing protein synthesis and an active mitogen-activated protein kinase.
Topics: Animals; Cell Line; Chromans; Ion Channels; Membrane Transport Proteins; Mitochondrial Proteins; Mitogen-Activated Protein Kinases; Muscle Fibers, Skeletal; Proteins; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone; Uncoupling Protein 2 | 2002 |
Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Chromans; Cyclin A; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; G1 Phase; Humans; Liver Neoplasms; Protein Serine-Threonine Kinases; Rats; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2003 |
Improvement of acquired partial lipodystrophy with rosiglitazone despite ongoing complement activation.
Topics: Adult; Anthropometry; Complement Activation; Female; Follow-Up Studies; Humans; Lipodystrophy; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Initial management of glycemia in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study.
Topics: Animals; Blood Glucose; Insulin; Lipid Metabolism; Lipids; Magnetic Resonance Spectroscopy; Muscle Fibers, Skeletal; Muscle, Skeletal; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides; Weight Gain | 2003 |
Reduced production rates of testosterone and dihydrotestosterone in healthy men treated with rosiglitazone.
Topics: Adult; Dihydrotestosterone; Humans; Hydrocortisone; Male; Random Allocation; Reference Values; Rosiglitazone; Steroids; Testosterone; Thiazoles; Thiazolidinediones | 2003 |
Amphipathic 3-phenyl-7-propylbenzisoxazoles; human pPaR gamma, delta and alpha agonists.
Topics: Administration, Oral; Animals; Biological Availability; COS Cells; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Isoxazoles; Mice; Mice, Mutant Strains; Nuclear Proteins; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.
Topics: Animals; Blood Glucose; Fatty Acids, Nonesterified; Fatty Liver; Hyperglycemia; Insulin Resistance; Leptin; Lipoprotein Lipase; Lipoproteins, VLDL; Liver; Mice; Mice, Inbred C57BL; Mice, Obese; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Receptors, Leptin; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2003 |
Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.
Topics: 3T3 Cells; Adipose Tissue; Animals; Binding Sites; Biological Transport; Carrier Proteins; Diabetes Mellitus; Disease Models, Animal; Fatty Acid-Binding Proteins; Fish Proteins; Glucokinase; Humans; Hypoglycemic Agents; Ion Channels; Liver; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mitochondrial Proteins; Oxadiazoles; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Trypsin; Tumor Cells, Cultured; Uncoupling Protein 1 | 2003 |
Effects of rosiglitazone and oleic acid on UCP-3 expression in L6 myotubes.
Topics: Animals; Carrier Proteins; Cells, Cultured; Drug Combinations; Hypoglycemic Agents; Ion Channels; Mitochondrial Proteins; Muscle Fibers, Skeletal; Oleic Acid; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Uncoupling Protein 3 | 2003 |
Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells.
Topics: Adipocytes; Adrenergic beta-Agonists; Animals; Cells, Cultured; Cyclic AMP; Enzyme Activation; Esterification; Fatty Acids; Female; Gene Expression; Glycerol; Glycerol Kinase; Homeostasis; Hypoglycemic Agents; Isoproterenol; Lipid Metabolism; Lipolysis; Phosphoenolpyruvate Carboxykinase (GTP); Pioglitazone; Pyruvic Acid; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Viscera | 2003 |
Phenylacetic acid derivatives as hPPAR agonists.
Topics: Animals; Blood Glucose; Dose-Response Relationship, Drug; Drug Design; Hypoglycemic Agents; Insulin Resistance; Male; Mice; Phenylacetates; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2003 |
Troglitazone stimulates IGF-binding protein-1 by a PPAR gamma-independent mechanism.
Topics: Carcinoma, Hepatocellular; Chromans; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor Binding Protein 1; Kinetics; Liver Neoplasms; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone; Tumor Cells, Cultured | 2003 |
Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.
Topics: Abdomen; Adipose Tissue; Adult; Body Composition; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Fatty Acids, Nonesterified; Fatty Liver; Female; Gene Expression; Humans; Hyperlipidemias; Insulin Resistance; Kinetics; Liver; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Middle Aged; Mutation; Neoplasm Proteins; Phenotype; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Tumor Suppressor Proteins | 2003 |
[Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Topics: 1-Deoxynojirimycin; Acarbose; Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Glucosamine; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Resistance; Insulin Secretion; Metformin; Obesity; Pioglitazone; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Time Factors | 2003 |
PPAR gamma-dependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNF alpha secretion is not mediated by PTEN regulation.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chromones; Enzyme Activation; Enzyme Inhibitors; Humans; In Vitro Techniques; Monocytes; Morpholines; Oxazoles; Phosphoinositide-3 Kinase Inhibitors; Phosphoric Monoester Hydrolases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha; Tumor Suppressor Proteins; Tyrosine | 2003 |
[When HbA1c cannot be pushed down under 7. Don't hesitate to use a 2d antidiabetic agent].
Topics: Diabetes Mellitus; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects.
Topics: Adult; CD36 Antigens; Cells, Cultured; Chromans; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Acids, Nonesterified; Female; Gene Expression; Humans; Insulin Resistance; Male; Membrane Glycoproteins; Middle Aged; Muscle, Skeletal; Organic Anion Transporters; Oxidation-Reduction; Palmitic Acid; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
A peroxisome proliferator-activated receptor-gamma agonist and the p53 rescue drug CP-31398 inhibit the spontaneous immortalization of breast epithelial cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Breast; Cell Transformation, Neoplastic; DNA Damage; Dose-Response Relationship, Drug; Epithelial Cells; Humans; Li-Fraumeni Syndrome; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Telomere; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
c-Fos-driven transcriptional activation of transforming growth factor beta-1: inhibition of high glucose-induced promoter activity by thiazolidinediones.
Topics: Animals; Cells, Cultured; Chromans; Glucose; Hydrogen Peroxide; Mice; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fos; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Swine; Tetradecanoylphorbol Acetate; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Transforming Growth Factor beta; Transforming Growth Factor beta1; Troglitazone | 2003 |
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Lipids; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic.
Topics: 3T3 Cells; Adipocytes; Animals; Binding Sites; Carrier Proteins; Cyclic AMP Response Element-Binding Protein; Histone Acetyltransferases; Hypoglycemic Agents; Mediator Complex Subunit 1; Mice; Nuclear Receptor Coactivator 1; Pyridines; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors | 2003 |
Peroxisome proliferator-activated receptor gamma inhibits the migration of dendritic cells: consequences for the immune response.
Topics: Animals; Cell Migration Inhibition; Cell Movement; Cells, Cultured; Cytokines; Dendritic Cells; Dermatitis, Contact; Epidermis; Female; Fluorescein-5-isothiocyanate; Haptens; Immunosuppressive Agents; Langerhans Cells; Lung; Lymph Nodes; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Mice, Transgenic; Ovalbumin; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Thorax; Transcription Factors; Transcriptional Activation; Tumor Necrosis Factor-alpha | 2003 |
Rosiglitazone reverses insulin secretion altered by chronic exposure to free fatty acid via IRS-2-associated phosphatidylinositol 3-kinase pathway.
Topics: Animals; Cells, Cultured; Fatty Acids; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Secretion; Intracellular Signaling Peptides and Proteins; Islets of Langerhans; Male; Phosphatidylinositol 3-Kinases; Phosphoproteins; Rats; Rats, Sprague-Dawley; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones | 2003 |
Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation.
Topics: Becaplermin; Cell Count; Cell Cycle; Cell Division; Cells, Cultured; Chromans; Dose-Response Relationship, Drug; Humans; Hypoglycemic Agents; Insulin; Ligands; Mammary Arteries; Mitogens; Muscle, Smooth, Vascular; Phosphorylation; Pioglitazone; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Radial Artery; Receptors, Cytoplasmic and Nuclear; Retinoblastoma Protein; Rosiglitazone; Saphenous Vein; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2003 |
Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo-Asian patients.
Topics: Adult; Aged; Asia; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Placebos; Rosiglitazone; Sensitivity and Specificity; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
Hepatic scavenger receptor class B, type I is stimulated by peroxisome proliferator-activated receptor gamma and hepatocyte nuclear factor 4alpha.
Topics: Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Binding Sites; CD36 Antigens; COS Cells; DNA Mutational Analysis; DNA-Binding Proteins; Hepatocyte Nuclear Factor 4; Hepatocytes; Humans; Kinetics; Kupffer Cells; Liver; Membrane Proteins; Mice; Phosphoproteins; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; Receptors, Immunologic; Receptors, Lipoprotein; Receptors, Retinoic Acid; Receptors, Scavenger; Response Elements; Retinoid X Receptors; Rosiglitazone; Scavenger Receptors, Class B; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured | 2003 |
Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice.
Topics: Adipocytes; Adipose Tissue; Animals; Blood Glucose; Body Weight; Female; Glucose Clamp Technique; Hypoglycemic Agents; Insulin; Insulin Resistance; Liver; Male; Mice; Mice, Mutant Strains; Muscle, Skeletal; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells.
Topics: Adenocarcinoma; Cell Division; Gene Expression Regulation, Neoplastic; Humans; Male; Phenotype; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Tumor Cells, Cultured | 2003 |
Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect.
Topics: Adipocytes; Animals; CHO Cells; Cricetinae; Dimerization; Fibroblasts; Gene Expression Regulation; Genetic Complementation Test; Glucose Transporter Type 4; Humans; Hypoglycemic Agents; Immunologic Factors; Mice; Monosaccharide Transport Proteins; Muscle Proteins; Promoter Regions, Genetic; Prostaglandin D2; Protein Structure, Tertiary; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Suppression, Genetic; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic | 2003 |
Rapid reversal of hepatic steatosis, and reduction of muscle triglyceride, by rosiglitazone: MRI/S studies in Zucker fatty rats.
Topics: Animals; Fatty Liver; Hepatomegaly; Hypoglycemic Agents; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Muscle, Skeletal; Obesity; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2003 |
Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.
Topics: Adipose Tissue; Animals; Blotting, Southern; Blotting, Western; Female; Hypoglycemia; Insulin Resistance; Lipid Metabolism; Liver; Liver Diseases; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Receptors, Cytoplasmic and Nuclear; Recombination, Genetic; RNA; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Triglycerides | 2003 |
Human invasive trophoblasts transformed with simian virus 40 provide a new tool to study the role of PPARgamma in cell invasion process.
Topics: Antigens, Polyomavirus Transforming; Cell Division; Cell Transformation, Viral; Cells, Cultured; DNA Primers; Dose-Response Relationship, Drug; Humans; Immunoblotting; Nuclear Proteins; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Simian virus 40; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection; Trophoblasts | 2003 |
Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells.
Topics: Adenocarcinoma; Antigens, Differentiation; Antigens, Neoplasm; Breast Neoplasms; Caveolin 1; Caveolin 2; Caveolins; Cell Differentiation; Cell Line; Chromans; Colonic Neoplasms; Dimerization; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, Dominant; Humans; Kidney; Ligands; Macromolecular Substances; Membrane Microdomains; Neoplasm Proteins; Phenotype; Phenylacetates; Prostaglandin D2; Protein Structure, Tertiary; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; RNA, Neoplasm; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone; Tumor Cells, Cultured | 2003 |
[Preventing infarct in the diabetic patient. Lowering blood glucose and HbA1c are not enough].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Infarction; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Effects of rosiglitazone and linoleic acid on human preadipocyte differentiation.
Topics: Adipocytes; Adipose Tissue; Adult; Aged; Cell Differentiation; Female; Humans; Hypoglycemic Agents; Linoleic Acid; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
PPARgamma controls cell proliferation and apoptosis in an RB-dependent manner.
Topics: 3T3 Cells; Adipocytes; Animals; Apoptosis; Blotting, Northern; Blotting, Western; Bromodeoxyuridine; Cell Cycle; Cell Division; Cell Nucleus; Flow Cytometry; G1 Phase; G2 Phase; Gene Expression Regulation; Histone Deacetylases; In Situ Nick-End Labeling; Luciferases; Mice; Microscopy, Fluorescence; Mitosis; Neoplasms; Plasmids; Precipitin Tests; Receptors, Cytoplasmic and Nuclear; Retinoblastoma Protein; RNA, Small Interfering; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transfection | 2003 |
Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.
Topics: Carbamates; Cohort Studies; Decision Trees; Diabetes Mellitus, Type 2; Direct Service Costs; Drug Costs; Drug Therapy, Combination; Glipizide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Managed Care Programs; Markov Chains; Metformin; Models, Economic; Piperidines; Rosiglitazone; Thiazoles; Thiazolidinediones; United States | 2003 |
Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Desoxycorticosterone; Endothelin-1; Endothelins; Fenofibrate; Fibrosis; Heart; Heart Ventricles; Hypertension; Myocardium; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Ventricular Remodeling | 2003 |
Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Binding Sites; Blotting, Northern; Caspase Inhibitors; Cell Division; Cells, Cultured; Chromans; Cysteine Proteinase Inhibitors; DNA Damage; DNA-Binding Proteins; Dose-Response Relationship, Drug; GADD45 Proteins; Gene Expression Regulation; Host Cell Factor C1; Humans; Intracellular Signaling Peptides and Proteins; Luciferases; Muscle, Smooth, Vascular; Mutation; Octamer Transcription Factor-1; Promoter Regions, Genetic; Protein Binding; Proteins; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone | 2003 |
PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist.
Topics: Animals; Apoptosis; Arachidonic Acid; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Indomethacin; Isoenzymes; Ligands; Models, Biological; Muscle, Smooth, Vascular; Phospholipases A; Phospholipases A2; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Rats; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation | 2003 |
A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential.
Topics: 3T3 Cells; Adipocytes; Adipose Tissue; Animals; Blood Glucose; Cells, Cultured; Diabetes Mellitus; Dose-Response Relationship, Drug; Glycogen; Humans; Hypoglycemic Agents; Insulin; Mice; Mice, Inbred C57BL; Mice, Obese; Radioligand Assay; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation; Transfection | 2003 |
Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice.
Topics: Animals; Blood Glucose; Body Weight; Cholesterol; Diet; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glucose Tolerance Test; Heart; Hypoglycemic Agents; Insulin Resistance; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Myocardium; Rosiglitazone; Thiazoles; Thiazolidinediones; Triglycerides | 2003 |
Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation.
Topics: Anilides; Animals; Asthma; Chemotaxis; Disease Models, Animal; DNA-Binding Proteins; Down-Regulation; Eosinophils; GATA3 Transcription Factor; Humans; Inflammation; Lung; Mice; Mice, Inbred BALB C; Mice, Knockout; Rats; Receptors, Cytoplasmic and Nuclear; Respiratory Hypersensitivity; Rosiglitazone; Thiazoles; Thiazolidinediones; Trans-Activators; Transcription Factors | 2003 |
Peroxisome proliferator-activated receptor-gamma ligand inhibition of RANTES production by human endometriotic stromal cells is mediated through an upstream promoter element.
Topics: Base Sequence; Cells, Cultured; Chemokine CCL5; Endometriosis; Female; Humans; Ligands; Mutagenesis, Site-Directed; Promoter Regions, Genetic; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Response Elements; Rosiglitazone; Stromal Cells; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection | 2003 |
Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation.
Topics: 3T3 Cells; Animals; Breast; Breast Neoplasms; CCAAT-Enhancer-Binding Protein-alpha; CCAAT-Enhancer-Binding Protein-beta; Cyclin D1; Ecdysterone; Epithelial Cells; Fatty Liver; Female; Gene Expression Regulation; Humans; Mice; Mice, Mutant Strains; Mice, Transgenic; Models, Molecular; Mutation; Protein Conformation; Receptors, Cytoplasmic and Nuclear; Reference Values; Repressor Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation | 2003 |
Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes.
Topics: Animals; Animals, Newborn; Base Sequence; Cell Size; Cells, Cultured; Fenofibrate; Gene Expression; Heart Ventricles; Hypertrophy; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Molecular Sequence Data; Mutagenesis, Site-Directed; Myocytes, Cardiac; Natriuretic Peptide, Brain; Peroxisome Proliferators; Pyrimidines; Rats; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Sarcomeres; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line.
Topics: BRCA1 Protein; Breast Neoplasms; Female; Genetic Predisposition to Disease; Humans; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2003 |
Glitazones and heart failure: critical appraisal for the clinician.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Diuretics; Edema; Heart Failure; Humans; Hypoglycemic Agents; Insulin; Pioglitazone; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
Topics: Adipose Tissue; Animals; Basal Metabolism; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fatty Acids; Fenofibrate; Glycogen; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Islets of Langerhans; Male; Muscle, Skeletal; Obesity; Rats; Rats, Inbred OLETF; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Viscera | 2003 |
Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells.
Topics: Blotting, Northern; Bronchi; Bronchitis; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Humans; Hypoglycemic Agents; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Respiratory Mucosa; Rosiglitazone; Thiazoles; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-1; Transcription Factors | 2003 |
Selective activation of PPARgamma inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator.
Topics: Chromans; Humans; Integrins; Matrix Metalloproteinase Inhibitors; Neoplasm Invasiveness; Pancreatic Neoplasms; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Tissue Plasminogen Activator; Transcription Factors; Troglitazone; Tumor Cells, Cultured | 2003 |
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.
Topics: Alkenes; Animals; Benzene Derivatives; Caprylates; Cell Line; Chlorocebus aethiops; Dose-Response Relationship, Drug; Drug Design; Drug Synergism; Hypoglycemic Agents; Male; Mice; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Retinoic Acid; Retinoid X Receptors; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Thyroxine; Transcription Factors; Transfection; Triglycerides | 2003 |
Ascochlorin derivatives as ligands for nuclear hormone receptors.
Topics: Alkenes; Animals; Cell Differentiation; Cells, Cultured; Fibroblasts; Furans; Genes, Reporter; Genetic Vectors; Glycolates; Humans; Inhibitory Concentration 50; Ligands; Mice; Models, Molecular; Osteosarcoma; Phenols; Plasmids; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection | 2003 |
Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes.
Topics: Animals; Blood Glucose; Carotid Arteries; Carotid Artery Injuries; Cells, Cultured; Diabetes Mellitus, Type 2; Diet; Disease Models, Animal; Female; Homozygote; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Lipids; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Rosiglitazone; Thiazoles; Thiazolidinediones; Tunica Intima | 2003 |
Novel PPARgamma-dependent and independent effects for thiazolidinediones.
Topics: Animals; Bezafibrate; Body Weight; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Proteins; Mice; Monocytes; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Pregnancy Proteins; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone; Tumor Necrosis Factor-alpha | 2003 |
[Blood sugar inspite of maximal metformin dosage. New fixed combination forces HbA1c down].
Topics: Body Mass Index; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Patient Compliance; Placebos; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors | 2003 |
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Cell Differentiation; Cells, Cultured; Chlorocebus aethiops; Drug Evaluation, Preclinical; Gene Expression Regulation; Imidazoles; Insulin; Irbesartan; Losartan; Male; Mice; Models, Molecular; Myoblasts; Protein Conformation; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Structure-Activity Relationship; Telmisartan; Tetrazoles; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors; Triglycerides; Valine; Valsartan; Weight Gain | 2004 |
Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
Topics: Alkanesulfonates; Binding Sites; Cinnamates; Computational Biology; Humans; Ligands; Oxazines; Oxazoles; Phenylpropionates; PPAR gamma; Protein Binding; Protein Conformation; Protein Interaction Mapping; Protein Structure, Tertiary; Rosiglitazone; Solvents; Thiazoles; Thiazolidinediones; Thiazolidines; Tyrosine | 2005 |
Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drinking; Drug Therapy, Combination; Drug Tolerance; Eating; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Islets of Langerhans; Male; Obesity; Pentanoic Acids; Rats; Rats, Zucker; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Time Factors | 2005 |
Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.
Topics: Anilides; Benzhydryl Compounds; Butyrates; DNA-Binding Proteins; Epoxy Compounds; Genes, Reporter; HeLa Cells; Humans; Inhibitory Concentration 50; Ligands; Luciferases; Peroxisome Proliferator-Activated Receptors; Phenylurea Compounds; PPAR alpha; PPAR delta; PPAR gamma; Rosiglitazone; Saccharomyces cerevisiae Proteins; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection | 2005 |
Activation of PPARgamma is not involved in butyrate-induced epithelial cell differentiation.
Topics: Alkaline Phosphatase; Apoptosis; Butyrates; Caco-2 Cells; Cell Cycle Proteins; Cell Differentiation; Cell Proliferation; Colonic Neoplasms; Epithelial Cells; Humans; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones | 2005 |
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.
Topics: Adipocytes; Animals; Bone Density; Bone Marrow Cells; Cell Culture Techniques; Cell Differentiation; Cell Line; Culture Media; Dose-Response Relationship, Drug; Gene Expression Regulation; Genetic Markers; Ligands; Male; Mice; Mice, Inbred C57BL; Osteoblasts; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazoles; Thiazolidinediones; Tomography, X-Ray Computed | 2006 |
Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment.
Topics: Adenosine Triphosphate; Animals; Cell Death; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Induction; Fibrinolytic Agents; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ion Channels; Membrane Transport Proteins; Mitochondrial Proteins; Muscle Fibers, Skeletal; Muscular Diseases; Myoblasts, Skeletal; Peroxisome Proliferator-Activated Receptors; Pyrimidines; Rats; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Uncoupling Protein 2 | 2005 |
Thiazolidinediones inhibit albumin uptake by proximal tubular cells through a mechanism independent of peroxisome proliferator activated receptor gamma.
Topics: Albumins; Anilides; Animals; Cells, Cultured; Cholesterol; Chromans; Farnesol; Kidney Tubules, Proximal; Ligands; Mevalonic Acid; Opossums; Polyisoprenyl Phosphates; PPAR gamma; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone | 2006 |
Letter to the editor in reference to article titled: Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2007 |
Activation of PPARdelta inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts.
Topics: Animals; Animals, Newborn; Cell Differentiation; Cell Proliferation; Cells, Cultured; Collagen; Fibroblasts; Fibrosis; Humans; Immunohistochemistry; Ligands; Myocytes, Cardiac; Peroxisome Proliferators; PPAR alpha; PPAR delta; PPAR gamma; Pyrimidines; Rats; Rats, Inbred Lew; Rosiglitazone; Thiazoles; Thiazolidinediones; Transduction, Genetic | 2007 |
Response to Pokharna and Kanna: initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Topics: Confounding Factors, Epidemiologic; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2008 |
A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.
Topics: Alkyl and Aryl Transferases; Animals; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Enzyme Induction; Glioma; Lipid Metabolism; Mice; Myelin Sheath; Oligodendroglia; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; PPAR-beta; Pyrimidines; Rats; Receptor Cross-Talk; RNA Interference; RNA, Small Interfering; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription, Genetic; Transfection | 2008 |
Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice.
Topics: Animals; Antidepressive Agents; Cyclic AMP-Dependent Protein Kinases; Cyclin-Dependent Kinase 5; Enzyme Inhibitors; Female; Glycogen Synthase Kinase 3; Male; Mice; Mitogen-Activated Protein Kinases; Motor Activity; PPAR gamma; Rosiglitazone; Swimming; Thiazoles; Thiazolidinediones; Urea | 2008 |
Effects of rosiglitazone on the proliferation of vascular smooth muscle cell induced by high glucose.
Topics: Animals; Aorta, Thoracic; Cattle; Cell Count; Cell Proliferation; Cells, Cultured; Dimethyl Sulfoxide; Dose-Response Relationship, Drug; Flow Cytometry; Glucose; Hypoglycemic Agents; Male; Mannose; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Muscle, Smooth, Vascular; Proliferating Cell Nuclear Antigen; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; S Phase; Skin; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Trypan Blue; Wound Healing | 2008 |
[Avandia and avandamet in the treatment of patients with diabetes mellitus type 2: effects on secretion of some fat tissue hormones].
Topics: Adiponectin; Adipose Tissue; Diabetes Mellitus, Type 2; Drug Combinations; Female; Fibrinolytic Agents; Ghrelin; Humans; Hypoglycemic Agents; Insulin; Leptin; Male; Metformin; Middle Aged; Resistin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2008 |
PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle.
Topics: Animals; Cells, Cultured; Cytokines; Down-Regulation; Humans; Hypoglycemic Agents; Inflammation Mediators; Male; Mice; Middle Aged; Muscle, Skeletal; NF-kappa B; PPAR gamma; Pyrimidines; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcriptional Activation | 2009 |
Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel.
Topics: Anilides; Animals; Benzamides; Biological Transport; Cell Survival; CHO Cells; Chromans; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Epithelial Sodium Channels; Hypoglycemic Agents; Insulin; Membrane Potentials; Pioglitazone; PPAR gamma; Pyridines; Rosiglitazone; Sodium; Tetrazolium Salts; Thiazoles; Thiazolidinediones; Troglitazone | 2009 |
Spectrophotometric and HPLC determinations of anti-diabetic drugs, rosiglitazone maleate and metformin hydrochloride, in pure form and in pharmaceutical preparations.
Topics: Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Combinations; Hypoglycemic Agents; Metformin; Molecular Structure; Rosiglitazone; Spectrophotometry; Tablets; Thiazoles; Thiazolidinediones | 2009 |
Modulation of nutrient sensing nuclear hormone receptors promotes weight loss through appetite suppression in mice.
Topics: Animals; Appetite Depressants; Appetite Regulation; Energy Metabolism; Insulin Resistance; Lipid Peroxidation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; PPAR alpha; PPAR delta; PPAR gamma; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Loss | 2010 |
A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling.
Topics: Aldosterone; Animals; Cell Proliferation; Cells, Cultured; Cyclin A; Cyclin D1; ErbB Receptors; Mesangial Cells; Mice; Mineralocorticoid Receptor Antagonists; Nitro Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; PPAR gamma; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones | 2011 |
Effect of synthetic ligands of PPAR α, β/δ, γ, RAR, RXR and LXR on the fatty acid composition of phospholipids in mice.
Topics: Acetyltransferases; Animals; Benzoates; Butyrates; Fatty Acid Elongases; Fatty Acids; Female; Gene Expression; Hydrocarbons, Fluorinated; Liver; Liver X Receptors; Mice; Mice, Inbred C57BL; Organic Chemicals; Orphan Nuclear Receptors; Peroxisome Proliferator-Activated Receptors; Phenylurea Compounds; Phospholipids; Receptors, Retinoic Acid; Rosiglitazone; Stearoyl-CoA Desaturase; Sulfonamides; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones | 2011 |
Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico.
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Drug Combinations; Edema; Female; Follow-Up Studies; Glyburide; Humans; Hypoglycemic Agents; Male; Medication Adherence; Metformin; Mexico; Middle Aged; Pharmacovigilance; Prospective Studies; Rosiglitazone; Thiazoles; Thiazolidinediones; Weight Gain | 2012 |
GSK fights compensation claims from UK patients who took rosiglitazone.
Topics: Compensation and Redress; Drug Combinations; Drug Industry; Humans; Hypoglycemic Agents; Metformin; Rosiglitazone; Safety-Based Drug Withdrawals; Thiazoles; Thiazolidinediones; United Kingdom | 2013 |
Differential sensitivities of the vascular K(ATP) channel to various PPAR activators.
Topics: Adenosine Triphosphate; Gene Expression; HEK293 Cells; Humans; KATP Channels; Membrane Potentials; Patch-Clamp Techniques; PPAR alpha; PPAR delta; PPAR gamma; PPAR-beta; Rosiglitazone; Signal Transduction; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Vasodilator Agents | 2013 |
Evaluation of peroxisome proliferator-activated receptor agonists on interleukin-5-induced eosinophil differentiation.
Topics: Adolescent; Adult; Aged; Butyrates; Cell Differentiation; Dose-Response Relationship, Drug; Eosinophils; Female; Humans; Interleukin-5; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; Phenylurea Compounds; Rosiglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Young Adult | 2014 |
Notch activation drives adipocyte dedifferentiation and tumorigenic transformation in mice.
Topics: Adipocytes; Animals; Biomarkers, Tumor; Cell Dedifferentiation; Cell Differentiation; Cell Lineage; Cell Proliferation; Cell Transformation, Neoplastic; Diabetes Mellitus, Experimental; Diamines; Dibenzazepines; Gene Deletion; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Ligands; Lipid Metabolism; Liposarcoma; Metabolic Syndrome; Mice, Inbred C57BL; PPAR gamma; Precancerous Conditions; PTEN Phosphohydrolase; Receptors, Notch; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Xenograft Model Antitumor Assays | 2016 |
Characterization of the Mouse and Human Monoacylglycerol O-Acyltransferase 1 (Mogat1) Promoter in Human Kidney Proximal Tubule and Rat Liver Cells.
Topics: Acyltransferases; Anilides; Animals; Blotting, Northern; Caco-2 Cells; Cell Line; Cell Line, Tumor; Chromatin Immunoprecipitation; Computational Biology; HT29 Cells; Humans; Kidney Tubules, Proximal; Liver; Mice; Oxazoles; PPAR alpha; Promoter Regions, Genetic; Pyrimidines; Rats; Real-Time Polymerase Chain Reaction; Rosiglitazone; Sulfones; Thiazoles; Thiazolidinediones; Thiophenes; Tyrosine | 2016 |
Enhancing insulin sensitivity by dual PPARγ partial agonist, β-catenin inhibitor: Design, synthesis of new αphthalimido-o-toluoyl2-aminothiazole hybrids.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adiponectin; Animals; beta Catenin; Cell Differentiation; Diabetes Mellitus, Type 2; Gene Expression; Glucose; Insulin; Insulin Resistance; Mice; Molecular Docking Simulation; Phthalimides; PPAR gamma; Rosiglitazone; Thiazoles; Thiazolidinediones | 2020 |
Comparison of PPAR Ligands as Modulators of Resolution of Inflammation, via Their Influence on Cytokines and Oxylipins Release in Astrocytes.
Topics: Anilides; Animals; Anti-Inflammatory Agents; Astrocytes; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Fenofibrate; Interleukin-10; Lipopolysaccharides; MAP Kinase Kinase 4; Oxazoles; Oxylipins; p38 Mitogen-Activated Protein Kinases; PPAR gamma; PPAR-beta; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Tumor Necrosis Factor-alpha; Tyrosine | 2020 |